Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW® 2018

AGA Institute
4930 Del Ray Avenue
Bethesda, MD 20814

301.654.2055 (National Office)
301.654.3978 (Fax)

www.gastro.org

* Information contained in this report is current as of May 21, 2018.
AGA Oral Presentations
1. INTERPLAY BETWEEN CHREBP AND SREBP-1C COORDINATES... (2*)||(4)

2. GPBAR1 (TGR5) AGONISM REVERSES ENDOTHELIAL DYSFUNCTION... (4*)

3. BARIATRIC SURGERY IS SAFE IN PATIENTS... (5*)

4. EFFECT OF METABOLIC TRAITS ON THE... (6*)

5. BENEFICIAL EFFECT OF RESOLVINS IN ETHANOL... (2*)

6. WHILE ALCOHOLIC LIVER DISEASE HAS RISEN... (5*)

7. THE MAIN EFFECT OF ERADICATION OF DYSPLASIA... (5*)

8. ERADICATION OF DYSPLASIA ONLY WITHOUT ERADICATING... (5*)

9. BARRETT’S ESOPHAGUS INTERNATIONAL CONSORTIUM STUDY: DETECTION... (5*)

10. PREDICTION IN SURVEILLANCE OF BARRETT’S ESOPHAGUS... (5*)

11. CLINICAL AND ENDOSCOPI... (5*)

12. VACCINATION PRACTICES DURING THE FIRST YEAR... (5*)

13. VACCINE-PREVENTABLE DISEASES IN HOSPITALIZED PATIENTS... (5*)

14. CHRONIC OPIOID USE AMONG INFLAMMATORY BOWEL... (5*)

15. HEALTH CARE USE, WORK LOSS, AND... (2*)

16. A NOVEL PATIENT REPORTED QUALITY OF... (6*)|(2)

17. IMPROVED QUALITY OF CARE AND QUALITY... (2*)

18. IN VITRO STUDIES OF HTERT... (4*)|(5)

19. GATA4 INHIBITS EXPRESSION OF P63 AND... (2*)|(4)

20. YAP1-DEPENDENT INDUCTION OF IGF2BP3 REPROG... (5*)|(2)

21. IN VIVO DAMAGE PRIMES BILIARY ORGANOIDs... (2*)|(7)

22. 42. FUNCTIONAL DYSPEPSIA HAS DOUBLED OVER TWO... (4*)

23. HUMAN COLONOID REGENERATION IS GUIDED BY... (2*)

24. A NOVEL ROUTE TO CONTROLLING CLOSTRIDIODES... (4*)

25. MICROBIOME AND METABOLIC MARKERS OF CLOSTRIDIUM... (4*)||(7)

26. FUSOBACTERIUM NUCLEATUM BOLSTERS CLOSTRIDIUM DIFFICILE BIOFILMS... (2*)

27. LONGITUDINAL SUSTAINED MICROBIOME CHANGES WITH FECAL... (5*)

28. FECAL MICROBIOTA TRANSPLANT VERSUS ANTIBIOTICS FOR... (4*)

29. METABOLIC PLASTICITY OF CLOSTRIDIUM DIFFICILE RIBOTYPE... (2*)|(4)

30. ESTROGEN REGULATES DUODENAL CALCIUM ABSORPTION THROUGH... (2*)

31. TAMOXIFEN-INDUCIBLE SLC5A6 CONDITIONAL (INTESTINAL-SPECIFIC) KNOCKOUT (ISMV-T-KO)... (2*)

32. MECHANISM OF REGULATION OF NA-GLUTAMINE CO-TRANSPORT... (2*)

33. CONNECTION BETWEEN LIPID ABSORPTION AND THE... (2*)|(4)

34. NA-K-ATPASE MEDIATED REGULATION OF GLUCOSE AND... (2*)

35. ANION SECRETION IS QUANTITATIVELY RATHER THAN... (2*)

36. ESOPHAGEAL MOTILITY DISORDERS: NEW PERSPECTIVES FROM... (5*)

37. PHARMACOLOGIC INTERROGATION OF IDIOPATHIC VERSUS OPIOID... (5*)|(1)

38. ESOPHAGOGASTRIC JUNCTION DISTENSIBILITY INDEX ON FUNCTIONAL... (2*)|(5)|(NIH R01 DK079902)

39. MANOMETRIC PARAMETERS OF DEGLUTITIVE UPPER ESOPHAGEAL... (2*)

40. ESOPHAGEAL MOTILITY DIAGNOSES CAN BE ESTABLISHED... (2*)

41. BOTULINUM TOXIN INJECTIONS FOR THE TREATMENT... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
63. . . . LOSS OF COLONIC FOXO3 TRANSCRIPTION FUNCTION... (2*)
64. . . . TFF1 SUPPRESSES IL-6 MEDIATED STAT3 ACTIVATION... (2*)
65. . . . ROLE OF DOUBLECORTIN-LIKE KINASE 1 (DCLK1)... (2*)[4]
79. . . . EXPOSURE-BASED COGNITIVE BEHAVIORAL THERAPY DELIVERED VIA... (2*)[1]
80. . . . MICROBIAL MULTI-OMICS DIFFERENTIATES CHILDREN WITH IRRITABLE... (2*)
81. . . . RNA BINDING PROTEIN HUR PROTECTS INTESTINAL... (2*)
82. . . . ACTIVATION OF PH-SENSING RECEPTOR OGR1 (GPR68)... (2*)
83. . . . FECAL MICROBIOTA TRANSPLANTATION ALters THE GUT... (4*)[1](Hong Kong Society of Gastroenterology Faculty of Medicine, the Chinese University of Hong Kong)
84. . . . PARVIMONAS MICRA 512 PROMOTES INTESTINAL... (2*)
85. . . . SER-287, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, INDUCES... (3*)[Seres Therapeutics, Inc.]
86. . . . A HUMAN-ASSOCIATED SAMP1/YITFC (SAMP) FECAL TRANSPLANTATION... (2*)[4]
87. . . . ENTERIC FUNGI COMPOSITIONAL AND ECOLOGICAL DYSBIOSIS... (2*)
88. . . . DOES THE DONOR MATTER? MICROBIOME SEQUENCING... (5*)
89. . . . PERSISTENT OPIOID USE AND HEALTHCARE UTILIZATION... (2*)
90. . . . NEW PERSISTENT OPIOID USE OCCURS IN... (4*)
91. . . . OVER 30% OF ACTIVE FLARES IN... (3*) Biomerieux)
92. . . . ASSESSING THE COST-EFFECTIVENESS OF EPSTEIN-BARR VIRUS... (5*)
93. . . . LONG TERM USE OF CIPROFLOXACIN AND... (6*)
94. . . . DAILY ASPIRIN USE DOES NOT IMPACT... (5*)
95. . . . OVER-UTILIZATION OF REPEAT UPPER ENDOSCOPY IN... (4*)
96. . . . HIGH RISK ADENOMAS AT BASELINE COLONOSCOPY... (2*)
97. . . . PATTERNS AND YIELD OF REPEAT FECAL... (2*)
98. . . . TIME TO COLONOSCOPY ASSOCIATED WITH THE... (2*)
99. . . . POTENTIALLY MODIFIABLE FACTORS IN THE SCREENING... (2*)
100. . . . TIME TRENDS IN POST-COLONOSCOPY INCIDENT AND...(2*)
101. . . . MIST1+ SECRETORY PROGENITOR CELLS CAN GIVE... (2*)
102. . . . WNT SIGNALING PROMOTES MOUSE AND HUMAN... (6*)[2]
103. . . . CONDITIONAL KNOCKOUT OF CDC42/RAC NUCLEOTIDE EXCHANGE... (5*)
104. . . . PANCREATIC STELLATE CELLS INDUCE BASEMENT MEMBRANE... (2*)
105. . . . TTPAL PROMOTES COLORECTAL TUMORIGENESIS BY ACTIVATING... (2*)
106. . . . CROSSTALK BETWEEN EGFR AND WNT SIGNALING... (2*)
125. . . . EFFECTS OF FECAL MICROBIOTA TRANSPLANTATION ON... (2*)
126. . . . SOUTH ASIAN ETHNICITY DRIVES DIFFERENCES IN... (5*)
127. . . . ESTABLISHMENT OF A MURINE BEHAVIORAL MODEL... (2*)[6]
128. . . . FACIALIBACTERIUM PRASUNITZII PRODUCEs BUTYRACE TO MAINTAIN... (4*)
129. . . . ORAL DELIVERY OF HUMAN BETA-DEFENSIN 2... (7*)
130. . . . IN FECAL MICROBIOTA TRANSPLANTATION FOR... (6*)[4]
131. . . . DOES THE RETROVIEW COLONOSCOPE ENHANCE POLYP... (3*)[PENTAX medical]
132. . . . AUTOMATIC POLYP DETECTION IN COLONOSCOPY PROCEDURE... (3*) Magnetiq Eye LTD)
133. . . . COMPUTER-ASSISTED POLYP DETECTION IDENTIFIES ALL POLYPS... (5*)
134. . . . PREPLESS CRC SCREENING IS FEASIBLE WITH... (3*)[Check-Cap LTD.]
135. . . . THE DIAGNOSTIC YIELD OF CHROMOENDOSCOPY-GUIDED PROBE-BASED... (5*)
136. . . . IMPACT OF EPITHELIAL BARRIER DISRUPTION ON... (2*)
137. . . . PROTECTIVE EFFECT OF SLC26A3 (DRA) ON... (2*)
138. . . . KNOCKOUT OF CLC-2 REVEALS CRITICAL FUNCTIONS... (2*)
139. . . . MECHANISM OF MMP-9 ACTIVATION OF MYOSIN... (2*)[7]
140. . . . CHRONIC PROTON PUMP INHIBITORS (PPI) ADMINISTRATION... (4*)[2]
141. . . . DIURNAL VARIATION OF INTESTINAL PERMEABILITY IS... (2*)
142. . . . MECHANISMS REGULATING GASTRIC MUSCULARIS MACROPHAGE ACTIVATION... (2*)[7]
143. . . . GASTRIC EMPTYING CHANGES OVER TIME IN... (2*)
144. . . . REAL-TIME EVALUATION OF A NOVEL GASTRIC... (2*)
145. . . . DISTURBANCES OF GASTRIC EMPTYING AND INTESTINAL... (2*)
146. . . . DUODENAL MUCOSA-ASSOCIATED MICROBIOTA (MAM) AND GASTRIC... (2*)
147. . . . CELL THERAPY USING CO-INJECTION OF NEURAL-PROGENITOR... (4*)
148. . . . FUNCTIONAL INVESTIGATION OF A NOVEL ONCOGENIC... (2*)
149. . . . GASTROINTESTINAL MICROBES ENHANCE THE ACCUMULATION OF... (2*)[4]
150. . . . ALTERATIONS OF THE ENTERIC VIROME IN... (2*)
151. . . . COLONIC BACTERIA AND THE TUMOR IMMUNE... (6*)[2](Resphera Biosciences)
152. . . . FUSOBACTERIUM NCELEATUM INFECTION CORRELATES WITH TWO... (2*)[4]
153. . . . IS LONG TERM SURVEILLANCE BEYOND 5... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
154. CLINICAL AND ECONOMIC OUTCOMES OF PATIENTS... (7*)

155. A REVISED MODEL OF CLONAL EVOLUTION... (2*)[(4)]

156. A LARGE SINGLE CENTER EXPERIENCE USING... (7*)

157. THE UTILITY OF INTRACYSTIC GLUCOSE LEVELS... (5*)

158. THE INCIDENCE, RISK FACTORS AND CHARACTERISTICS... (5*)

159. CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF... (3*)[(6)](Merck Sharp & Dohme, Abbvie, Pfizer, Napp)

160. ANTI-TNF INHIBITORS ARE NOT ASSOCIATED WITH... (4*)

161. RISK FACTORS FOR POOR WOUND HEALING... (6*)

162. LONG-TERM RISK OF ADVANCED NEOPLASIA AFTER... (5*)

163. META-ANALYSIS OF RANDOMIZED AND NON-RANDOMIZED CONTROL... (5*)

164. VEDOLIZUMAB THERAPY INDUCES A REDISTRIBUTION OF... (4*)

165. EGGERTHELLA LENTA MODULATES GUT MICROBIAL PHYSIOLOGY... (2*)

166. SERT DEFICIENCY CAUSES DYBSISOS AND CHANGES... (2*)

167. COMPETITIVE HYDROGEN GAS UTILIZATION BY METHANE... (4*)

168. PROSPECTIVE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL... (7*)

169. NEEDLE BASED CONFOCAL LASER ENDOMICROSCOPY: THE... [3*](Mauna Kea Technologies)

170. A SYSTEMATIC REVIEW AND META-ANALYSIS: COMPARISON... (5*)

171. LEARNING CURVE OF EU-S-GUIDED BILIARY DRAINAGE... (5*)

172. OPTICAL COHERENCE TOMOGRAPHY OF THE PANCREATIC... (5*)

173. THE "HUMANIZED" CHICKEN EMBRYO CHORIOALLANTOIC MEMBRANE... (4*)

174. LOSS OF TFF1 DECREASES MIR-143-3P EXPRESSION... (2*)

175. CDK1 IS A NOVEL MEDIATOR OF... (2*)

176. GAMMA: SELECTIVE ERADICATION OF CANCER CELLS... (3*)

177. AXL PROMOTES EPIRUBICIN RESISTANCE THROUGH REGULATION... (2*)

178. SPECIFIC INHIBITION OF BONE MORPHOGENETIC PROTEIN4... (2*)

179. MENOPAUSAL AND REPRODUCTIVE FACTORS AND RISK... (5*)

180. CONVOLUTIONAL NEURAL NETWORKS IMAGE ANALYSIS OF... (4*)[(6)]

181. COMPARISON OF ABILITY OF ELEVATED FECAL... (2*)

182. EFFICACY AND SAFETY OF TRAM-34 OVER... (5*)

183. ORAL DELIVERY OF PEPTIDES WITH DUAL... (3*)Protagonist Therapeutics)

184. INVESTIGATION OF SMALL INTESTINAL BACTERIAL OVERGROWTH... (5*)

185. THE EFFECTS OF DIET-INDUCED OBESITY ON... (2*)

186. GLIAL CONNEXIN-43 REGULATES NEURO-IMMUNE INTERACTIONS IN... (2*)[(6)]

187. HYPOXIA-INDUCIBLE FACTOR 1 ALPHA (HIF1A) STIMULATES... (2*)[(4)]

188. GUT MICROBIAL PRODUCTS AND SATURATED FATTY... (2*)

189. ROLE OF INTERSTITIAL CELLS OF CAJAL... (5*)

190. THE ROLE OF ENTERIC GLIAL CELLS... (4*)

191. A PRAGMATIC, RANDOMIZED TRIAL OF FIT... (2*)

192. A COMPARISON OF OUTREACH INTERVENTIONS TO... (4*)

193. EFFECTIVENESS OF VOLUNTEER-DELIVERED TELEPHONE REMINDERS ON... (6*)[We acknowledge the funding support from the Hong Kong Jockey Club Charities Trust.]

194. A SYSTEMATIC REVIEW AND META-ANALYSIS: COMPARISON... (5*)

195. PLACEBO CONTROLLED STUDY OF THE ACUTE... (2*)

196. NATIONAL ESTIMATES OF 30-DAY READMISSIONS AMONG... (5*)

197. COST-EFFECTIVENESS ANALYSIS OF A COMBINED PATIENT... (2*)[(6)]

198. EFFECTIVENESS OF WHATSAPP REMINDER ON COMPLIANCE... (5*)

199. HEPATOKINES, METALLOPROTEASES AND THEIR TISSUE INHIBITORS... (4*)

200. DYSLIPIDEMIA TREATMENT AND ADVANCED FIBROSIS IN... (5*)

201. SUSTAINED LONG-TERM CLINICAL AND COGNITIVE IMPROVEMENT... (2*)

202. LOW INFliximab LEVELS AND ANTI-INFliximab ANTIBODIES... (4*)[(3)](Prometheus Inc.)

203. EPIGENETIC PATTERNING OF THE HUMAN GASTROINTESTINAL... (2*)[(4)]

204. THE RELATIONSHIP OF LARYNGOPHARYNGEAL REFLUX AND... (5*)

205. ESOPHAGEAL MOTILITY IS AUGMENTED AND GASTROESOPHAGEAL... (5*)

206. IMPLEMENTATION OF A STANDARDIZED APPROACH TO... (5*)

207. PLACEBO CONTROLLED STUDY OF THE ACUTE... (2*)

208. PERIPHERAL MECHANISM OF NARCOTIC BOWEL SYNDROME... (2*)

209. TYPE-1 CANNABINOID RECEPTOR EFFECT ON HUMAN... (4*)

210. NATIONAL ESTIMATES OF 30-DAY READMISSIONS AMONG... (5*)

211. PELVIC FLOOR SYMPTOM RELATED DISTRESS IN... (5*)

212. OUTLET DYSFUNCTION IS PREVALENT IN SEVERE... (5*)

213. TARGETING THE STRESS POLARITY SIGNALING (SPS) PATHWAY... (2*)[(4)]

214. TOWPHYLQUINONE-MEDIATED ACTIVATION OF ARYL HYDROCARBON RECEPTOR... (2*)

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA AASLD, etc.)
265. Resolvin... 266. H19 Long Noncoding RNA plays an... 267. Rho GTPase inhibition contributes to enteropathy... 268. Histone methylation regulates chronic stress-induced, interleukin... 269. A novel model of human enteroids... 270. H. pylori infection of the human... 271. Two dimensional human gastric organoid model... 272. Novel intestinal differentiation approach from human... 273. Nuclear receptor LRH-1 mitigates intestinal inflammatory... 274. Gut microbiota metabolites modulate the amplitude... 275. The national experience with vedolizumab... 276. Risk factors and outcomes associated with... 277. Comparative safety profile of vedolizumab and... 278. Sialic Acid: a possible antigenic epitope... 279. Randomized trial evaluating the immunogenicity of... 280. Risk of venous thromboembolic events in... 281. Global increasing incidence of colorectal cancer... 282. Disparities in trends of colorectal cancer... 283. Obesity is associated with an increased... 284. Potential impact of family history based... 285. Colorectal cancer screening initiation at age... 286. Prevalence and characteristics of gastrointestinal manifestations... 287. Exploring an antihistamine combination therapy for... 288. Food intolerance in IBS is due... 289. The efficacy and safety of immediate... 290. Prevalence and risk factors for new... 291. Sarcopenia is a common complication of... 292. Pancreatic cancer associated mortality is low... 293. BM-derived cells recruited to the pancreas... 294. D52 mediated membrane trafficking is critical... 295. Pressure-induced pancreatitis is associated with aberrant... 296. Prolongation of esosinophilic esophagitis treatment with... 297. Maintenance treatment of esosinophilic esophagitis with... 298. Esophageal distensibility in response to treatment... 299. Both fibrotic and inflammatory endoscopic alterations... 300. Sub-classification and oncogenic network analysis of... 301. Efficacy of cytosponge directed food elimination... 302. Maintenance treatment of esosinophilic esophagitis with... 303. Esophageal distensibility in response to treatment... 304. Both fibrotic and inflammatory endoscopic alterations... 305. Sub-classification and oncogenic network analysis of... 306. Efficacy of online aftercare programs following... 307. Comparison of pharmacotherapy, argon plasma coagulation... 308. Analysis of volume adjustment impact and... 309. Comparative effectiveness of vedolizumab and tumor... 310. Combination therapy of cyclosporine and vedolizumab... 311. Disparate effects of BMP4 signaling in... 312. Reflux-induced epithelial mesenchymal transition: a potential... 313. Differential effects of PPI therapy on... 314. Development of T cell-pancreatic cancer organoid... 315. FGFR signaling pathway plays an important... 316. Deficient unfolded protein response (UPR) in... 317. Interest in the addition of azathioprine... 

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
346. IN ANTI-TNF NAIVE CROHN’S DISEASE PATIENTS... (5*)

347. IMPACT OF DRUG LEVELS, ANTI-DRUG ANTIBODIES... (4*)

348. LACK OF IMPROVEMENT OF IMPAIRED CHEMICAL... (5*)

349. THE TRANSPHINCTERIC PRESSURE INDEX (TPJ) DURING... (5*)

350. CONTRACTILE SEGMENT IMPEDANCE (CSI) DURING HIGH-RESOLUTION... (5*)

351. ASSESSMENT OF AGREEMENT FOR IMPEDANCE-PH MONITORING... (5*)

352. GENETIC VARIATION WITHIN GNβ3 AND ADRB2... (2*)

353. A NOVEL NON-INVASIVE CIRCULATING MiRNA SIGNATURE... (5*)

354. DETECTION OF ESOPHAGEAL CANCER BY ASSAY... (4*) (3) [(Exact Sciences Development Company, Madison WI)]

355. IDENTIFICATION OF NOVEL FUSION GENE, PUM1-TRAF3,... (5*)

356. MiR-133A IS A PREDICTIVE OF ITOPRIDE IN... (3*) [(Shire Pharmaceuticals funded this collaborative research.)]

357. EVALUATING WHY AND WHEN PATIENTS DISCONTINUE... (5*)

358. PROSPECTIVE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL... (7*)

359. ENDOGENOUS GASTRIN COLLABORATES WITH MUTANT KRAS... (2*)

360. A NEW TREATMENT FOR PANCREATIC CANCER:... (4*) (2) [Nanjing Personal Oncology Biotechnology Co. Ltd, Nanjing, China]

361. CIRCULATING EXTRACELLULAR VESICLE ENCAPSULATED LONG NON-CODING... (2*)

362. PANCREATIC CANCER IS ASSOCIATED WITH A... (6*)

363. MULTI-SITE GASTROINTESTINAL CANCER DETECTION BY STOOL... (4*) (3) [(Exact Sciences (Madison WI)]

364. COMBINED IN VIVO/IN VITRO IDENTIFICATION OF... (2*)

365. EPITHELIAL-SECRETED WNT LIGANDS ARE ESSENTIAL DRIVERS... (2*)

366. METASTASIS-ASSOCIATED MiRNAs AS BLOOD-BASED PROGNOSTIC BIOMARKERS... (4*)

367. CRITICAL ROLE OF TOB1 IN CONTROLLING... (2*)

368. GENOMIC CORRELATES OF REDUCED NEUTROPHIL GRANULOCYTE-MACROPHAGE... (2*)

369. STAT2 CONTROLS COLITIS DEVELOPMENT AND MUCOSAL... (2*)

370. IL-23 CONFRS MOLECULAR RESISTANCE TO ANTI-TNF... (5*)

371. IL-3 EXERTS PROTECTIVE EFFECTS IN EXPERIMENTAL... (4*)

372. THE THERAPEUTIC OUTCOME OF ITOPRIDE IN... (4*)

373. ROLE OF PROKINETICS IN SYMPTOM IMPROVEMENT... (5*)

374. NALOXEGOL COMPARED WITH PEG 3350 IN... (3*) [(AstraZeneca)]

375. NON-INTERVENTIONAL COHORT STUDY OF THE RELATIVE... (3*) [(Shire Pharmaceuticals funded this collaborative research.)]

376. EVALUATING WHY AND WHEN PATIENTS DISCONTINUE... (5*)

377. THE ROLE OF PROKINETICS IN SYMPTOM IMPROVEMENT... (5*)

378. STAT2 CONTROLS COLITIS DEVELOPMENT AND MUCOSAL... (2*)

379. MIR-133A IS A PREDICTIVE OF ITOPRIDE IN... (3*) [(Shire Pharmaceuticals funded this collaborative research.)]

380. AUTOMATED DIGITAL CALCULATION OF ENDOSCOPIC INFLAMMATION... (3*) [(Panx Medical)]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds

(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCF, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
458. LACK OF DEVELOPMENT OF OPPORTUNISTIC INFECTIONS... (3*)
(Salix Pharmaceuticals, Bridgewater, NJ, USA)

459. EFFICACY AND SAFETY OF NOVEL 5-HT4... (3*)
(Funding support: This study was funded by Sumitomo Dainippon Pharma Co., Ltd.)

460. INFLAMMATORY CYTOKINES DIMINISH NOTCH SIGNALING TO...

461. PRE-TREATMENT DIFFERENTIAL CORRELATION OF GENE EXPRESSION...

462. SINGLE-CELL RNA-SEQUENCING REVEALS DISTINCT ESOPHAGEAL EPITHELIAL...

463. RAPAMYCIN-MEDIATED AUTOPHAGY ACTIVATION AMELIORATES EOE-ASSOCIATED ALTERATIONS...

464. GENOME-WIDE EPIGENETIC SCAN OF EOSINOPHILIC ESOPHAGITIS...

465. COMPARISON OF DIAGNOSTIC YIELD OF TWO...

466. REGIONAL AND TEMPORAL PREFERENCES FOR COLONOSCOPY...

467. ADENOMA DETECTION RATES IN COLONOSCOPIES FOR...

468. A NOVEL FECAL BACTERIAL MARKER FOR...

469. STATIN USE AND POST-COLONOSCOPY INTERVAL CANCER...

470. RANDOMIZED PLACEBO-CONTROLLED TRIAL OF DIFLUOROMETHYLORNITHINE (DFMO)...

471. NO INCREASE IN IMMUNOMODULATOR USE IN...

472. NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYEOSUPPRESSION...

473. IMPACT OF CONTINUING 5-AMINOSALICYLATES IN PATIENTS...

474. EXPLORING STOMA RATES IN CROHN'S DISEASE...

475. CLINICAL PREDICTORS OF RECURRENCE AFTER END...

476. EFFECT OF ACUPUNCTURE AND MOXIBUSTION TREATMENT...

477. POSITIVE CELIAC SEROLOGY AND PERMISSIVE GENOTYPE...

478. EXPANDING IMMUNE REACTIVITY AGAINST GLIADIN AND...

479. GENDER-BASED DIFFERENCES IN SCREENED POPULATIONS IN...

480. FROM SELF-REPORTED WHEAT INTOLERANCE TO NON...

481. NEAR INFRARED PHOTOIMMUNOTHERAPY USING DIFFUSER FOR...

482. LOSS OF HUMAN EPIDIDYMIS PROTEIN 4...

483. SELUMETINIB, A MEK INHIBITOR, SUPPRESSES ACTIVE...

484. CXC CHEMOKINE RECEPTOR 2 (CXCR2) DEFICIENCY...

485. A NOVEL, METHYLATION-BASED NOMOGRAM PREDICTS RECURRENCE...

486. AMELIORATION OF METASTASIS AND RE-EMERGENCE OF...

487. WHOLE EXOME SEQUENCING OF OVER 1000...

488. PREDICTING RISK OF POST-OPERATIVE DISEASE RECURRENCE...

489. THE TREATMENT NAIVE RECTAL TRANSCRIPTOME IDENTIFIES...

490. HLA-DQA1 CONtributes TO THE DEVELOPMENT OF...

491. VALIDATED NOVEL GENETIC RISK VARIANTS CAN...

492. GENDER-STRATIFIED ANALYSES IDENTIFIES SEX-SPECIFIC IBD ASSOCIATIONS...

493. LIMITING THE TOXICITY OF CHEMOTHERAPY BY...

494. 5-HYDROXYMETHYLCYTOSINE AND OPEN CHROMATIN PROFILING REVEAL...

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
595. MTGR1 restricts the intestinal stem cell... (2*)
596. Krüppel-like factor 5 is critical for... (2*)
597. Notch ligand Delta-like 1 promotes epithelial... (2*)
598. Single-cell level analysis of organoids derived... (5*)
599. Comprehensive video capsule endoscopy-based monitoring predicts... (6*)
600. Endoscopy based therapeutic management in postoperative... (5*)
601. Natural history of Crohn's disease postoperative... (5*)
602. Follow-up ileocolonoscopy is underused in Crohn's... (3*) (5) [MSD Merck Sharp & Dohme AG (Switzerland)]
603. Histological healing is associated with decreased... (2*)
604. Consecutive negative findings on colonoscopy during... (5*)
615. A VA cooperative, randomized trial of... (2*)
616. AMG 714 (anti-IL-15 mab) halts the... (3*) (Celimmune LLC)
617. Fecal microbiota transplantation in irritable bowel... (1*)
618. AMG 714 (anti-IL-15 mab) ameliorates the... (3*) (Celimmune LLC)
619. Determination of gluten grams ingested and... (4*) (3) Biomedal S.L.
626. Selective deletion of MyD88 signaling in... (2*) (6)
627. Enteric glia share characteristics with antigen... (2*)
628. Direct signaling of TL1A-DR3 on fibroblasts... (2*)
629. Creeping-fat derived free fatty acids induce... (2*)

630. Increased matrix metalloproteinase mediated cleavage of... (2*)
631. BCL2 regulates differentiation of intestinal fibroblasts... (2*) (3) (AbbVie BioResearch Center, AbbVie Worcester, MA, USA)
632. Immunoglobulin A-coated bacteria represent a unique... (2*)
633. The BBD candidate gene, PTPN2, restricts... (2*) (6)
634. Gut microbial factors implicated in disease... (2*)
635. Intestinal microbiota direct an epithelial epigenetic... (2*) (7)
636. Convergence toward donor microbial and metabolicomic... (2*)
637. Single-cell sequencing of creeping fat in... (4*)
638. Microglia in the central nucleus of... (4*)
639. Lactobacillus reuteri ingestion attenuates lumen distention-associated... (2*)
640. Estrogen and serotonin drive enhanced pre-natal... (2*) (4)
641. Conventionalisation of germ free mice with... (2*)
642. SCN10A SNP rs6795970 (G>A) associated with... (6*)
643. Reversal of visceral hypersensitivity in rat... (3*) (6) [Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany]
685. Machine learning model to predict recurrent... (2*)
686. Risk of both upper and lower... (3*) (Bayer AG provided funding for this study)
687. The safety of pantoprazole versus famotidine... (4*)
688. Outpatient telephonic transitional care after hospital... (5*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
707. . . . PROTON PUMP INHIBITORS ARE UNDER-PRESCRIBED IN... (POSTER PRESENTATION) . . . (5*)
708. . . . INTERVAL COLORECTAL CANCER IN INFLAMMATORY BOWEL... (POSTER PRESENTATION) . . . (5*)
709. . . . MORBIDITY AND MORTALITY CONFERENCES IN THE... (5*)
710. . . . UTILIZING THE ELECTRONIC HEALTH RECORD TO... (POSTER PRESENTATION) . . . (5*)
711. . . . QUALITY GAPS IN THE MANAGEMENT OF... (POSTER PRESENTATION) . . . (5*)
712. . . . IMPLEMENTATION OF AN AUTOMATED EPIC HAND-OFF... (POSTER PRESENTATION) . . . (5*)
713. . . . A NEW INTESTINE-CHIP MODEL TO STUDY... (3*)|Emulate Inc.)
714. . . . EXTRACELLULAR MATRIX HYDROGEL DOWNREGULATES NEOPLASTIC ESOPHAGEAL... (4*)
715. . . . HUMAN INTESTINAL ORGANOID IN VIVO Responds... (7*)|(2)
716. . . . GLYCOSYLTRANSFERASE ST6GAL-I ASSOCIATES WITH WNT SIGNALLING... (2*)
717. . . . DEVELOPMENT OF A COLON-CHIP TO STUDY... (3*)|Emulate Inc.)
718. . . . EPIGENOMIC LANDSCAPE, SPATIAL CONFORMATION AND FUNCTION... (2*)|(4)
719. . . . SENSORY SYNAPTIC TRANSDUCTION FROM GUT TO... (2*)|(4)
720. . . . RET SIGNALING IN THE INTESTINAL EPITHELIUM... (2*)|(3) |(Research agreement from GlaxoSmithKline)
721. . . . REGULATION OF PANETH CELL FUNCTION BY... (2*)|(4)
722. . . . MOLECULAR AND FUNCTIONAL DEFECT IN ABGC2... (2*)
723. . . . CLINICAL AND MOLECULAR FEATURES OF MISSED-INTERVAL... (7*)
724. . . . THE LONG NONCODING RNA PVT1A... (2*)
725. . . . HISTONE DEMETHYLASE JMID2P PROMOTES COLORECTAL CANCER... (5*)
730. . . . THE LONG NONCODING RNA PVT1A... (2*)
731. . . . HISTONE DEMETHYLASE JMID2P PROMOTES COLORECTAL CANCER... (5*)
732. . . . NOVEL MARMELIN ANALOG MRL16 TARGETS NOTCH... (2*)
734. . . . LIFESTYLE FACTORS AND RISK OF SERRATED... (2*)
735. . . . DISEASE-SPECIFIC ANTIBODIES AND PROTEOMIC MARKERS ALLOW... (3*)
736. . . . MICROBIOTA METABOLITES SHORT-CHAIN FATTY ACIDS INHIBIT... (2*)
737. . . . RANDOMIZED ADAPTIVE TRIAL OF DIGITAL BEHAVIORAL... (4*)|UPMC has a financial interest in Thrive Network, Inc which develops and commercializes the Lantern products and services. As part of that minority ownership, UPMC provides advice and oversight to the Lantern team on product, market, and clinical issues.)
738. . . . INHIBITION OF TYROSINE KINASE 2 SIGNALLING... (3*)|GlaxoSmithKline
740. . . . AGE-OF-ONSET DEPENDENT ILEAL IMMUNE MATURATION AND... (6*)
741. . . . PROGRESSION OF ALPHA-SYNUCLEIN TRANSPORT IN THE... (2*)|(4)
742. . . . A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF... (2*)|(4) |(OpenBiome provided the FMT and placebo capsules for this study without charge to the investigators. Finch Therapeutics conducted the microbiome analyses for this study without charge to the investigators. No other financial support was received from industr)
743. . . . PHYSIOLOGICAL EFFECTS OF REGULATION OF ANO1... (2*)
744. . . . MEDIUM-TERM EFFICACY AND LONG-TERM SAFETY OF... (3*)|EA Pharma Co., Ltd., Tokyo, Japan, Mochida Pharmaceutical Co., Ltd., Tokyo, Japan
746. . . . MICROBIOME CHANGES ASSOCIATED WITH TOTAL PARENTERAL... (5*)
747. . . . GAVAGE OF FECAL MICROBIOTA FROM TMAO... (2*)
748. . . . DIETARY INTERVENTIONS MAY MODIFY INTESTINAL INFLAMMATION... (6*)
749. . . . ERADICATION OF BREATH METHANE USING ANTIBIOTICS... (7*)|(2)
750. . . . CARBOHYDRATE METABOLIC PATHWAYS IN RESIDENT INTESTINAL... (4*)|(6)
751. . . . DYNAMIC CHANGES IN GUT MICROBIAL DERIVED... (4*)|(2)
752. . . . EFFICACY AND SAFETY OF TAK-954 IN... (3*)|(Clinical trial was conducted and sponsored by Theravance Biopharma. Takeda Pharmaceutical Company Ltd was involved in data analysis/interpretation for this study. Medical writing assistance was provided by Oxford Pharmagenesis and was supported by Takeda)
753. . . . CATHETER-RELATED BLOODSTREAM INFECTIONS IN PATIENTS WITH... (5*)
754. . . . SURVIVAL OF PATIENTS WITH SHORT BOWEL... (3*)|(3) |(Canadian Nutrition Society Ontario Medical Supply Baxter Healthcare Corporation)
755. . . . EFFECTS OF SHORT-TERM TREATMENT WITH GLEPAGLUTIDE,... (3*) |(This trial was sponsored by Zealand Pharma.)
756. . . . ENTEROHEMORRHAGIC E.COLI (EHEC) SECRETED SERINE PROTEASE... (2*)
758. . . . HELICOBACTER HEPATICUS INFECTION INCREASES COLONIZATION OF... (2*)
759. . . . DISSECTION OF THE CONTRIBUTIONS OF ENTEROPATHOGENIC... (2*)
760. . . . INTESTINAL EPITHELIAL HMGB1 PREVENTS CHRONIC ENTERIC... (2*)
761. . . . CIRCADIAN RHYTHMS OF INTESTINAL EPITHELIAL CELL... (2*)
781. . . . CLINICAL IMPACT OF RECOMBINANT SOLUBLE THROMBOMODULIN... (5*)
782. . . . NATURAL HISTORY OF PATIENTS DIAGNOSED WITH... (5*)
783. . . . WEB-BASED CLINICAL RISK SCORE TO PREDICT... (5*)
784. . . . TARGETED DELETION OF THE INTESTINAL LYSOPHOSPHATIDYCHOLINE... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
785. . . . NATURAL HISTORY OF POTENTIAL CELIAC DISEASE... (5*)
786. . . . A RANDOMIZED CONTROLLED TRIAL COMPARING SIX-FOOD... (5*)
787. . . . NADPH OXIDASE AND AQUAPORIN-3 DEPENDENT REDOX... (2*)
788. . . . CHOLERA TOXIN (CTX)/Forskolin (FSK) STIMULATE... (2*)
789. . . . ENTERIC PATHOGENS INDUCE M CELL TRANSCYTOSIS... (2*)
790. . . . ALDOSTERONE DOWN-REGULATES COLONIC AQUAPORIN-3 (AQP3) EXPRESSION:... (2*)
791. . . . GASTROINTESTINAL BACTERIAL PATHOGEN COLONIZATION AND RISK... (7*])[(2)
792. . . . GLEPAGLUTIDE, A LONG-ACTING GLUCAGON-LIKE PEPTIDE-2 ANALOG,... (3*)[(This trial was sponsored by Zealand Pharma.)
793. . . . RACIAL AND ETHNIC DISPARITIES IN HEPATOCELLULAR... (4*)
794. . . . ETHNIC MINORITIES AND PATIENTS WITH NONALCOHOLIC... (5*)
795. . . . TFF2 DRIVES CALCIUM MOBILIZATION AND EPITHELIAL... (2*)[(2)
796. . . . HEDGEHOG SIGNALING DIRECTLY REGULATES METABOLISM AND... (2*)[(4)
797. . . . EPITHELIAL-SPECIFIC P85α KO ENHANCES CRYPT RESILIENCE... (2*)
798. . . . HEAT SHOCK PROTEIN GP96 IS ESSENTIAL... (2*)
799. . . . PLASMINOGEN ACTIVATOR INHIBITOR-1 IS A THERAPEUTIC... (2*)
800. . . . ENDOGENOUS GLUCAGON-LIKE PEPTIDE -1 AND 2... (5*)
801. . . . APremilast for Active Ulcerative Colitis: A... (3*)[(This study is sponsored by Celgene Corporation.)
802. . . . Phase III Randomized Controlled Trial To... (3*)[(CELLTRION INC.)
803. . . . Long-Term Efficacy and Safety of CT-P13... (2*)
804. . . . Oral Once Daily Budesonide Granules Induce... (3*)[(The study was sponsored by Dr. Falk Pharma GmbH, Freiburg, Germany)
805. . . . Topical Administration of A GATA-3 Specific... (5*)
806. . . . Tacrolimus Suppositories as Induction Therapy For... (2*)
807. . . . Dysregulation of the Enulfement Pathway In... (2*)[(4)
808. . . . Intestinal Epithelial MHCII Expression Modulates the... (2*)[(6)
809. . . . Intestinal Epithelial Par Polarity Proteins Are... (2*)
810. . . . Differential Requirements for Epithelial Mitochondrial Respiration... (2*)
811. . . . Pept1 Facilitates Bacterial Peptide Transport Into... (2*)
812. . . . Inflammation-Induced Alterations in Colonic Epithelial Mitochondria... (2*)
813. . . . Transient Receptor Potential Vanilloid 4 (TRPV4)- Induced... (2*)[(Supported by Grants from JSPS KAKENHI to Mihara H, No. 26870214.)
814. . . . TNFaip8 Deficiency Protects Against Intestinal Injury... (2*)
815. . . . Epithelial Ikkβ Signaling Controls Esophageal Apoptosis... (2*)[(4)
816. . . . Corticotropin Releasing Factor Receptor 2 Activation... (2*)[(4)
817. . . . Secondary Bile Acids Are Responsible For... (2*)
818. . . . Epithelial-Stromal Signaling in Fibrolamellar Hepatocellular Carcinoma... (6*)[(4)
819. . . . The RNA-Binding Protein Tristetraprolin Controls Intestinal... (4*)
820. . . . Tyrosyl Phosphorylation of Kras Disrupts the... (2*)
821. . . . Epigenetic Silencing of Mir-490-3p by H... (2*)
822. . . . Density and Distribution of Tumour-Infiltrating CD4+Foxp3+... (4*)
823. . . . Absence of Slc26a9 Results in Chronic... (2*)
824. . . . Iw-3718, a Novel Gastric-Retentive Bile Acid... (3*)[(Ironwood Pharmaceuticals, Inc.)
825. . . . Sustained Long-Term Efficacy and Safety of... (3*)[(This study is sponsored by Celgene Corporation.)
826. . . . α4β7 Integrin Is Dynamically Expressed in... (3*)[(Funded in part by Exact Sciences)
827. . . . Upregulation of Acid-Sensing Ion Channels 1... (2*)
828. . . . Expression of Capza1, a Negative Regulator... (2*)[(4)
829. . . . An Enteroid Model of Congenital Tufting... (2*)
830. . . . Human Breast Milk Promotes Microbial Proliferation... (2*)[(4) |(BioGaia AB)
831. . . . Double Blind Randomised Controlled Trial Of... (4*)
832. . . . Low Fodmap Diet Improves Functional-Like Gastrointestinal... (6*)
833. . . . A Randomized Controlled Trial of Telemedicine... (2*)
834. . . . Tofacitinib for the Treatment of Ulcerative... (3*)[(AbbVie Inc.)
835. . . . Efficacy and Safety of Tofacitinib Treatment... (3*)[(Pfizer Inc)
836. . . . Efficacy and Safety of Upadacitinib Maintenance... (3*)[(AbiVie Inc.)
837. . . . Targeting a Novel Er Chaperone Erdj4/DnaJb9... (7*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
909. . . . MUCOSAL STEM CELL HETEROGENEITY IN PEDIATRIC... (2*)|] [4]
910. . . . IRE1β IS A NEGATIVE REGULATOR OF... (2*)|] [4]
911. . . . THE P21-ACTIVATED KINASE (PAK) 1 AND... (2*)
912. . . . SCHLAFEN 12 PROMOTES HUMAN INTESTINAL EPITHELIAL... (2*)
913. . . . AGE-RELATED CHANGES IN GUT MICROBIOTA ALTER... (2*)
914. . . . FECAL MICROBIOTA TRANSPLANTATION ALTERS GUT MICROBIOTA... (6*)|] [1]
915. . . . INTESTINAL MICROBIOTA PREDICT RESPONSE TO COGNITIVE... (4*)|] [2]
916. . . . GUT MICROBIOTA-DIET INTERACTIONS IN A HUMANIZED... (2*)
917. . . . BUTYRATE-PRODUCING SYNBIONTS REDUCE VISCERAL HYPERALGESIA AND... (2*)
918. . . . CORRELATION OF GUT MICROBIOTA-DERIVED TRYPTOPHAN METABOLITES... (2*)
984. . . . H19 LONG NON-CODING RNA IS AN... (2*)
985. . . . HUMAN LONG NON-CODING RNA (LncRNA) CCAT1... (2*)|] [6]
986. . . . MICE FED A HIGH FAT DIET... (4*)] [1UMC statutory grant: K/ZDS/007161]
993. . . . WIRELESS ANAL SPHINCTER EMG RECORDING TO... (5*)
994. . . . SIX-WEEK INTERNET SELF-HELP INTERVENTION REDUCES SYMPTOM... (2*)
995. . . . BRAIN FUNCTIONAL MRI REVEALS ALTERATIONS IN... (1*)
996. . . . PHARMACOLOGICAL MODULATION OF RECTAL COMPLIANCE IN... (2*)
997. . . . LONG TERM RESTORATION OF FECAL CONTINENCE... (2*)
998. . . . FECOBIONICS: NOVEL DEFECATORY FUNCTION TESTING IN... (4*)
999. . . . AGREEMENT OF IBDOC® AND QUANTON CAL®... (3*)|] [4] [Janssen R&D]
1000. . . . CHRONIC FATIGUE IS NOT ASSOCIATED WITH... (4*)
1001. . . . RADIOLOGIC PREDICTORS OF SHORT-TERM CLINICAL REMISSION... (5*)
1002. . . . PREDICTIVE SEROLOGICAL MARKERS OF RESPONSE TO... (5*)
1003. . . . NEW FAECAL CALPROTECTIN CUT-OFF POINTS FOR... (6*)|] [3] [Abbvie Pharmaceuticals sponsored the TrueColours UC pilot through an unrestricted research grant Buhlmann laboratories provided all IBDoc faecal calprotectin kits for their TrueColours pilot]
1004. . . . SERUM ALBUMIN AND C-REACTIVE PROTEIN WEEK... (5*)
1005. . . . TISSUE RESIDENT MEMORY T CELLS CRITICALLY... (2*)
1006. . . . MESENTERIC ADIPOCYTES COULD PROMOTE LYMPHOID NEOGENESIS... (6*)] [MsD Avenir]
1007. . . . ILC3-INDEPENDENT SPONTANEOUS INNATE IMMUNE COLITIS ... (6*)
1009. . . . IMMUNOPHENOTYPING OF PERIPHERAL WHOLE BLOOD FROM... (3*)|] [4] [Janssen R&D]
1010. . . . SCALING ACCESS TO FECAL MICROBIOTA TRANSPLANTATION... (5*)
1011. . . . REDUCING COST AND SCHEDULING COMPLEXITY OF... (5*)
1012. . . . COST-EFFECTIVENESS ANALYSIS OF MULTIPLE STRATEGIES FOR... (5*)
1013. . . . THE MICROBIOTA-BASED DRUG RBX2660 IS EFFICACIOUS... (3*)] [This analysis was funded by Rebiotix Inc., Roseville, MN]
1014. . . . MICROBIOTA COMPOSITION, METABOLIC PROFILES AND INFLAMMATORY... (4*)
1015. . . . NOVEL LONG NONCODING RNA UC230 ENHANCES... (2*)
1016. . . . MICE WITH INTESTINE-SPECIFIC DELETION OF KRÜPPEL-LIKE... (2*)
1017. . . . GUANYLATE CYCLASE 2C ACTIVATION RESCUES THE... (2*)
1018. . . . MICROBIOTA FROM IBS-D PATIENTS INDUCES DYSREGULATION... (2*)
1019. . . . THE INFLUENCE OF VITAMIN D ON... (2*)|] [1]
1020. . . . INDUCIBLE NITRIC OXIDE MEDIATES THE INHIBITION... (2*)
1021. . . . INVESTIGATION OF THE MECHANISM OF ACTION... (3*)] [Ironwood/Forest Pharmaceuticals]
1022. . . . SERINE PROTEASES AS LUMINAL MEDIATORS OF... (2*)|] [4]
1023. . . . CYTOKINE PROFILES BEFORE AND AFTER RIFAXIMIN... (3*)] [Salix Pharmaceuticals]
1024. . . . EXPRESSION OF AQUAPORIN CHANNELS IN MUCOSAL... (2*)
1025. . . . LONG-TERM EFFECT OF MOXIBUSTION ON IRRITABLE... (2*)
1026. . . . AMELIORATING EFFECTS AND MECHANISMS OF SACRAL... (5*)
1027. . . . MIR-144-3P/451A AS A NOVEL BIOMARKER FOR... (5*)
1028. . . . ENDOSCOPIC RESECTION OF DUODENAL CARCINOID TUMORS... (5*)
1029. . . . IS IT POSSIBLE TO PREDICT THE... (5*)
1030. . . . PREDICTORS OF ANTIPROLIFERATIVE EFFECT OF LANREOTIDE... (5*)
1048. . . . CENTRALLY MEDIATED VAGAL EFFERENT PATHWAY INVOLVED... (2*)
1049. . . . A LOW FODMAP (FERMENTABLE CARBOHYDRATE) DIET... (2*)
1050. . . . WHEAT AMYLASE/TRYPsin INHIBITORS AGGRAVATE ORAL ANTIGEN... (2*)
1051. . . . M480, AN ORAL FXR AGONIST, IS... (3*)] [Metacrine, Inc.]
1052. . . . GENETIC DELETION OF FIBROBLAST GROWTH FACTOR-INDUCIBLE... (2*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCF, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds

(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
AGA Poster Presentations
Sa1102. . . . BARRETT’S EPITHELIUM DISPLAYS INCREASED EXPRESSION OF... (4*)
Sa1103. . . . NON-OBSENE NON-ALCOHOLIC FATTY LIVER DISEASE IS... (5*)
Sa1104. . . . P-AKT/AKT PATHWAYS IN THE CRURAL DIAPHRAGM... (2*)
Sa1105. . . . P-AKT/AKT PATHWAYS IN THE CRURAL DIAPHRAGM... (2*)
Sa1106. . . . ABDOMINAL OBESITY, METABOLIC SYNDROME, AND INSULIN... (2*)
Sa1107. . . . PROTON PUMP INHIBITOR TREATMENT MAY REVERSE... (4*)
Sa1108. . . . ISOKETAL PROTEIN ADDUCTS, WHICH ARE FORMED... (2*)
Sa1109. . . . RELATIONSHIP BETWEEN ESOPHAGEAL MUCOSAL INNERVATION AND... (4*)
Sa1110. . . . LONG-TERM MAINTENANCE THERAPY WITH THE LOWEST... (5*)
Sa1111. . . . MARKERS OF ESOPHAGEAL EPITHELIAL-MESENCHYMAL TRANSITION (EMT)... (3*) This study is sponsored by Celgene Corporation.
Sa1112. . . . ENDOSCOPIC FEATURES ARE SIGNIFICANTLY ASSOCIATED WITH... (3*) (Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT02379052. Medical writing/editorial assistance provided by Jennifer Port of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.)
Sa1113. . . . CORRELATION BETWEEN ESOPHAGEAL DISTENSIBILITY AND OBJECTIVE... (3*) (Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT02379052. Medical writing/editorial assistance provided by Jennifer Port, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.)
Sa1114. . . . EFFICACY AND SAFETY OF RPC4046, AN... (3*) (This study is sponsored by Celgene Corporation.)
Sa1115. . . . BIOPSY ALONE DOES NOT RELIABLY ASSESS... (5*)
Sa1116. . . . DEMOGRAPHIC FEATURES OF EOSINOPHILIC GASTRITIS, ENTERITIS... (2*)[6]
Sa1117. . . . TREATMENT PATTERNS FOR EOSINOPHILIC GASTRITIS, ENTERITIS... (2*)[6]
Sa1118. . . . EOSINOPHILIC ESOPHAGITIS-LIKE DISEASE WITH LACK OF... (5*)
Sa1119. . . . THE NATURAL COURSE AND LONG-TERM CONSEQUENCES... (5*)
Sa1120. . . . VEDOLIZUMAB MAY REDUCE STEROID BURDEN WHILE... (2*)
Sa1121. . . . SEASONAL EXACERBATION OF EOSINOPHILIC ESOPHAGITIS HISTOLOGIC... (2*)
Sa1122. . . . OUTCOMES OF COMBINED TREATMENT WITH FOOD... (2*)
Sa1123. . . . HISTOLOGIC CHARACTERIZATION OF A MULTI-CENTER RETROSPECTIVE... (2*)
Sa1124. . . . ESOPHAGOgaSTRIC JUNCTION DISTENSIBILITY IS DECREASED IN... (4*)
Sa1125. . . . NEW INSIGHTS INTO THE PATHOPHYSIOLOGY OF... (5*)
Sa1126. . . . FEASIBILITY, SAFETY, AND UTILITY OF A... (2*)[4]
Sa1127. . . . THE RISE OF EOSINOPHILIC ESOPHAGITIS AND... (5*)
Sa1128. . . . SEASONAL AND CLIMATE VARIATION IN ADMISSIONS... (5*)
Sa1129. . . . SUBEPITHELIAL FIBROSIS RESOLVES AFTER TOPICAL STEROID... (2*)
Sa1130. . . . THE DISTAL ESOPHAGUS IS THE MOST... (2*)
Sa1131. . . . ADAPTING AN ESTABLISHED MEDICAL ALGORITHM TO... (6*)
Sa1132. . . . FAECAL CALPROTECTIN AS A BIOMARKER OF...
Sa1133. . . . SOCIOECONOMIC FACTORS PREDICT TREATMENT CHOICE IN... (6*)
Sa1134. . . . DIFFERENCES IN QUALITY OF LIFE IN... (6*)
Sa1135. . . . BASELINE IMPEDANCE ON HIGH-RESOLUTION IMPEDANCE MANOMETRY... (5*)
Sa1136. . . . EFFICACY OF AND PREDICTORS FOR PROTON... (5*)
Sa1137. . . . HOW DO GASTROENTEROLOGISTS MANAGE EOSINOPHILIC ESOPHAGITIS?... (5*)
Sa1138. . . . PATIENTS WITH LIKELY EOSINOPHILIC ESOPHAGITIS ARE... (5*)
Sa1139. . . . MUCOSAL IMPEDANCE PATTERN DIFFERENTIATES ESOPHAGEAL INFLAMMATORY... (5*)
Sa1140. . . . ESOPHAGEAL EOSINOPHIL INFILTRATES WITH AND WITHOUT... (5*)
Sa1141. . . . LYMPHOCYTIC ESOPHAGITIS: A DESCRIPTIVE ANALYSIS OF...
Sa1142. . . . ABSOLUTE PERIPHERAL EOSINOPHIL COUNT INDEPENDENTLY DISTINGUISHES... (5*)
Sa1143. . . . SHORT- AND LONG-TERM THERAPEUTIC GOALS OF... (2*)
Sa1144. . . . TREATMENT PREFERENCES OF ADULT EOSINOPHILIC ESOPHAGITIS... (2*)
Sa1145. . . . PREDICTORS FOR EARLY VERSUS DELAYED RESPONSE... (3*) (The study was sponsored by Dr Falk Pharma GmbH, Freiburg, Germany.)
Sa1146. . . . ASSESSMENT OF TOXIC METALS MEASURED IN...
Sa1147. . . . QUALITY OF LIFE IS LOWER ON...
Sa1148. . . . ETHNIC VARIATIONS IN PREVALENCE AND DISPARITIES... (5*)
Sa1149. . . . EFFICACY OF TOPICAL CORTICOSTEROIDS IN DIFFERENT...
Sa1150. . . . LONG-TERM CONTINUED PPI USE IS COMMON...
Sa1151. . . . BASELINE CHARACTERISTICS AND CORRELATION BETWEEN DYSPHAGIA... (3*) (Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT02379052. Medical writing/editorial assistance provided by Jennifer Port, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.)
Sa1152. . . . CALPAIN-14 IMPAIRS ESOPHAGEAL EPITHELIAL BARRIER INTEGRITY... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1153. . . . ESOPHALGEAL SQUAMOUS CELLS FROM EOSINOPHILIC ESOPHAGITIS... (2*)

funded by a research grant of the Flemish Government (FWO project Number G028615N)

Sa1154. . . . AN ALLERGEN-SPECIFIC IMMUNE SIGNATURE IDENTIFIES FOOD... (4*)][2]

Sa1155. . . . A NOVEL ALLERGEN-SPECIFIC IMMUNE SIGNATURE-DIRECTED APPROACH... (4*)][2]

Sa1156. . . . THE ESOPHALGEAL MICROBIOME DIFFERES IN ADULTS... (2*)

Sa1157. . . . SALIVARY MICROBIOME IS ALTERED IN CHILDREN... (2*)

Sa1158. . . . GPX3 IS REDUCED IN Eosinophilic Esophagitis... (4*)

Sa1159. . . . ASSOCIATION OF MAST EOSINOPHILIC ESOPHAGITIS... ALTERED IN CHILDREN...

Sa1160. . . . PATIENTS WITH EOSINOPHILIC ESOPHAGITIS HAVE A SPECIFIC IMMUNE SIGNATURE- A NOVEL ALLERGEN-DIRECTED APPROACH...

Sa1161. . . . TGF-β1 MEDIATED UPREGULATION OF A TRANSCRIPTION... (4*)

Sa1162. . . . NONINVASIVE BIOMARKERS ACCURATELY IDENTIFY EOSINOPHILIC ESOPHAGITIS... (6*)][4]

Sa1163. . . . LAMINA PROPRIA FIBROSIS AND EOSINOPHILIC COUNT... (7*)][2]

Sa1164. . . . PATIENTS WITH EOSINOPHILIC ESOPHAGITIS HAVE A... (6*)][2]

Sa1165. . . . A GENE EXPRESSION ARRAY AS A... (4*)

Sa1166. . . . GASTRIC DERIVED DOPAMINE REGULATES DUODENAL EPITHELIUM... (2*)

Sa1167. . . . ROLE OF INFLAMMASOME IN 5-FU INDUCED... (5*)

Sa1168. . . . DUAL ANTIPLATELET THERAPY DOES NOT AFFECT... (7*)

Sa1169. . . . DEFICIENCY OF CCR7 IS RESPONSIBLE FOR... (5*)

Sa1170. . . . MIR-874-3P SUPPRESSES ATG16L1 IN VITRO DURING... (2*)

Sa1171. . . . THE STABLE GLP-2 ANALOG TEDUGLUTIDE ACUTELY... (3*)][2][Shire grant]

Sa1172. . . . EFFECTS OF THE NON-SELECTIVE PROTEASE INHIBITOR... (4*)][2][This project was partially

Sa1173. . . . DOPAMINERGIC RESPONSES IN ENTERIC NEURONAL PLEXUSES... (2*)

Sa1174. . . . SEROLOGICAL ASSESSMENT OF WOUND HEALING IN... (3*)][4][The Danish Science Foundation]

Sa1175. . . . IMPACT OF INTESTINAL RESECTION ON INTESTINAL... (4*)

Sa1176. . . . A NOVEL METHOD FOR MEASURING BILE... (4*)

Sa1177. . . . UNIQUE REGULATION OF SODIUM-GLUCOSE CO-TRANSPORT BY... (2*)

Sa1178. . . . ACTIVATION OF THE VACUOLAR H+-ATPASE... (4*)

Sa1179. . . . ALTERED PHOSPHORYLATION OF THE ALPHA-1 SUBUNIT... (2*)

Sa1180. . . . ACTIVATION OF THE CALCIUM SENSING RECEPTOR... (4*)

Sa1181. . . . ZINC ACETATE INHIBITS METFORMIN-STIMULATED H+ ATPASE-DEPENDENT GASTRIC... (4*)

Sa1182. . . . DO ALL SERRATED POLYPS, INCLUDING HYPERPLASTIC... (4*)

Sa1183. . . . LARAZOTIDE STIMULATES RECOVERY OF ISCHEMIC-INJURED INTESTINE... (3*)][4][Innovate Biopharmaceuticals Inc]

Sa1184. . . . THE EFFECT OF ESTRADIOL ON THE... (4*)

Sa1185. . . . THE DISTRIBUTION OF ENTERIC INFECTIONS IN... (5*)

Sa1186. . . . HUMAN NOROVIRUS INDUCES A TYPE III... (2*)

Sa1187. . . . ALTERNATION OF INTESTINAL EPITHELIAL STEM CELLS... (2*)

Sa1188. . . . EARLY READMISSION PREDICTS INCREASED MORTALITY IN... (5*)

Sa1189. . . . FAILURE OF FECAL MICROBIOTA TRANSPLANT FOR... (5*)

Sa1190. . . . HEALING TWO WOUNDS WITH ONE KISS... (3*)][4][Tsumura & Co. 2-17-11 Akasaka, Minato-ku, Tokyo 107-8521, JAPAN +813-6361-7137 http://www.tsumura.co.jp/english/]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1582. OUTCOMES OF SURGICAL INTERVENTION FOR REFRACTORY...
(5*)
Sa1583. AN EVALUATION OF THE RELATIONSHIP BETWEEN...
(5*)
Sa1584. G-POEM IMPROVES CLINICAL SYMPTOMS AND GASTRIC...
(5*)
Sa1585. MOTILITY DEFECTS IN CHRONIC INTESTINAL PSEUDO-
OBSTRUCTION ... (4*)
Sa1586. TOWARD CLOSED-LOOP GASTROINTESTINAL STIMULATION ...
(2*)
Sa1587. MODULATING GASTROINTESTINAL (GI) MOTILITY THROUGH A...
(2*)
Sa1588. PREVALENCE AND PREDICTORS OF GASTROINTESTINAL DYSMOTILITY...
(5*)
Sa1589. VOLUME VS. CALORIC STIMULATION OF SMALL...
(2*)|(4)
Sa1590. INVESTIGATING DISEASES ASSOCIATED WITH GASTROPARESIS IN...
(5*)
Sa1591. OVERLAP BETWEEN ESOPHAGEAL AND GASTRIC DYSMOTILITY...
(5*)
Sa1592. ANTIBIOTICS TREATMENT PROLONGS GASTROINTESTINAL TRANSIT TIME...
(5*)
Sa1593. ANTIBIOTICS IMPAIR GASTRIC EMPTING 6 WEEKS...
(6*)
Sa1594. PATIENTS WITH IBS AND SIBO HAVE...
(7*)|(Medtronic R&D Pilot Award from the American Gastroenterology Association (AGA)
Sa1595. DIFFERENCES BETWEEN FRUCTOSE AND LACTOSE METABOLISM...
(4*)
Sa1596. DIETARY FODMAPS SUCH AS FRUCTO-OLIGOSACCHARIDES CAN...
(2*)
Sa1597. UPREGULATION OF MAST CELL RELATED GENES...
(2*)
Sa1598. DNA METHYLATION AGE ACCELERATION IS ASSOCIATED...
(2*)
Sa1599. CHOLINERGIC STATUS, A PRO INFLAMMATORY FACTOR,...
(4*)|(7)
Sa1600. TENAPANOR ATTENUATES INCREASED MACROMOLECULE PERMEABILITY IN...
(3*)|Ardelyx, Inc.)
Sa1601. THE IMMEDIATE EFFECT OF IBS SYMPTOMS...
(5*)
Sa1602. A SOMATIZATION BRAIN NETWORK IN IRRITABLE...
(4*)
Sa1603. COGNITIVE BEHAVIORAL THERAPY IS ASSOCIATED WITH...
(2*)
Sa1604. CYTOKINE PROFILE AND IGE-MEDIATED SEROLOGICAL FOOD...
(4*)
Sa1605. EFFECTS OF CORTICOTROPIN-RELEASING HORMONE RECEPTOR 1...
(2*)
Sa1606. FECAL FKBP-TYPE PEPTIDYLPROLYL CIS-TRANS ISOMERASES ARE...
(2*)|3)(This study was supported by Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan and by Research Grant from Miyarisan Pharmaceutical Co., Ltd., Tokyo, Japan.)
Sa1607. LONG-TERM EFFECTS OF H. PYLORI ERADICATION...
(5*)
Sa1608. COMPREHENSIVE BIOINFORMATIC ANALYSIS OF ABERRANTLY EXPRESSED...
(2*)
Sa1609. EVALUATION OF MUCOSAL LINEAGE CHANGES IN...
(2*)|(4)
Sa1610. EXPRESSION OF DCLK1 ISOFORMS REGULATE EPITHELIAL...
(5*)
Sa1611. REPRIMO EXPRESSION IN GASTRIC CANCER AND...
(2*)|4)
Sa1612. LOSS OF RAB25 AGGRAVATES LESIONS OF...
(5*)
Sa1613. EXPRESSION OF LRIG1, A NEGATIVE REGULATOR...
(5*)
Sa1614. AN IBD ASSOCIATED VARIANT IN PTEN...
(2*)
Sa1615. INCREASED COLONIC LGR5 EXPRESSION IS ASSOCIATED...
(2*)
Sa1616. IMPACT OF GENETIC VARIATION ON GENE...
(3*)|(Janssen Research & Development, LLC, funded this study.)
Sa1617. DISCOVERY AND VALIDATION OF POTENTIAL FIELD...
(2*)|6)
Sa1618. SOX2 EXPRESSION IS DOWN-REGULATED THROUGH...
(2*)|4)
Sa1619. EXPRESSION OF ENDOCRINE-RELATED GENES IN GIRELIN-ENCRIRED... (2*)
Sa1620. MITOCHONDRIAL 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE 2 (HMGC2) IS...
(2*)
Sa1621. EZH2 REGULATES SFRP4 EXPRESSION WITHOUT AFFECTING...
(2*)|(Wuhan applied basic research projects 2015061701011642)
Sa1622. ROLE OF COX-2 GENE PROMOTER METHYLATION...
(2*)
Sa1623. SIRT2 PROMOTES THE MIGRATION AND INVASION...
(4*)
Sa1624. NGF AND VEGF SIGNALING ARE CRITICAL...
(4*)
Sa1625. FLUID FLOW STRESS MODULATES GASTRIC CARCINOMA...
(5*)
Sa1626. TGF-β1 INHIBITS COLON TUMOR CELL APOPTOSIS...
(5*)
Sa1627. SIRT2 PROTEIN CONTRIBUTES TO INTESTINAL CELL...
(2*)
Sa1628. STIMULATION OF THE BILE ACID RECEPTOR...
(5*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1629. . . . TESTOSTERONE-DEPENDENT DIFFERENTIAL EXPRESSION OF EGFR IN... (2*)|(4)
Sa1630. . . . RISK OF COLORECTAL CANCER AFTER CHOLECYSTECTOMY... (2*)
Sa1631. . . . INCREASING RATES OF SURGERY FOR NON-MALIGNANT... (2*)
Sa1632. . . . METFORMIN IS ASSOCIATED WITH REDUCED RISK... (2*)
Sa1633. . . . HIGHER DEGREES OF DYSPLASIA ARE ASSOCIATED... (7*)
Sa1634. . . . DESPITE THE SUCCESS OF... (5*)
Sa1635. . . . INCIDENCE OF COLORECTAL CANCER IN YOUNG... (5*)
Sa1636. . . . LONG-TERM CANCER RISK IN MICROSCOPIC COLITIS... (5*)
Sa1637. . . . COLONIC ADENOMA RISK IN HIV PATIENTS... (5*)
Sa1638. . . . ADDRESSING GASTRIC CANCER RISKS VIA GENERAL... (4*)
Sa1639. . . . KYOTO CLASSIFICATION OF GASTRITIS IS USEFUL... (5*)
Sa1640. . . . EVALUATION OF THE GASTRIC CANCER RISK... (5*)
Sa1641. . . . COMPARING SPLIT-DOSE VERSUS SINGLE-DOSE BOWEL PREP... (5*)
Sa1642. . . . DURATION OF RETROFLEXION SIGNIFICANTLY INFLUENCES ADENOMA... (5*)
Sa1643. . . . FEASIBILITY OF THE IMPLEMENTATION OF CYTOSPONGE... (6*)
Sa1644. . . . HIGH PREVALENCE OF AUTOIMMUNE GASTROPATHY, CLINICAL... (5*)
Sa1645. . . . COMPARISON OF THE FUKUOKA CONSENSUS GUIDELINES... (2*)|(7)
Sa1646. . . . EFFECT OF BARRETT’S ESOPHAGUS ON SCREENING... (5*)
Sa1647. . . . TERMINAL ILEUM INTUBATION DOES NOT IMPROVE... (5*)
Sa1648. . . . DETECTION OF BARRETT’S ESOPHAGUS USING A... (3*)|(Medtronic)
Sa1649. . . . THE DIAGNOSTIC VALUE OF A CHANGE... (4*)
Sa1650. . . . RISK OF METACHRONOUS ADVANCED NEOPLASTIC LESIONS... (5*)
Sa1651. . . . THE NEW JERSEY BOWEL PREPARATION SCALE... (5*)
Sa1652. . . . ROLE OF NRF2 IN ESOPHAGEAL PREMALIGNANT... (2*)
Sa1653. . . . SHOULD ELDERLY PATIENTS UNDERGO ADDITIONAL TREATMENTS... (5*)
Sa1654. . . . GDF15 MRNA EXPRESSION IS ENRICHED... (5*)
Sa1655. . . . FORKHEAD BOX F1 (FOXF1) CAN NOT... (4*)|(7)
Sa1656. . . . IDENTIFICATION OF FOUR DISTINCT BIOLOGICAL SUBTYPES... (4*)
Sa1657. . . . INCREASED NOTCH SIGNALING AND LOSS OF... (2*)
Sa1658. . . . MICRORNA NANOTHERAPEUTICS FOR ESOPHAGEAL ADENOCARCINOMA... (4*)
Sa1659. . . . PATHOLOGICAL FEATURES ASSOCIATED WITH METASTATIC SPREAD... (5*)
Sa1660. . . . ESOPHAGEAL ADENOCARCINOMA (EAC) EXOSOMES INDUCE FEATURES... (2*)
Sa1661. . . . HANGESHASHINTO (TJ-14) PREVENTS PROSTAGLANDIN E2 PRODUCTION... (5*)
Sa1662. . . . SUPPRESSION OF MURINE TUMOR GROWING THROUGH... (5*)
Sa1663. . . . DIRECT INTERACTION OF CD24 WITH BTB/CAMTA2... (4*)
Sa1664. . . . THE LIN28B-IMP1 AXIS DIRECTS A POST-TRANSCRIPTIONAL... (2*)|(6)
Sa1665. . . . GP87 COLONIC EXPRESSION EXPLAINS SOME OBSERVED... (2*)
Sa1666. . . . DARPP-32 PROMOTES ACTIVATION OF STAT3 THROUGH... (2*)
Sa1667. . . . PROFILING OF RNA EXPRESSION IN COLITIS... (6*)|(1)
Sa1668. . . . EPITHELIAL CELL DERIVED CCL11 PLAYS A... (2*)
Sa1669. . . . THE SYNTHETIC FLAVAGLINE FL3 PROTECTS AGAINST... (4*)
Sa1670. . . . EXPRESSION OF PATTERN RECOGNITION RECEPTOR PATHWAY... (2*)|(6)
Sa1671. . . . LONG-TERM REDUCTION OF NHE3 EXPRESSION IN... (2*)
Sa1672. . . . APC GENE REGULATION BY MIR-135A AND... (2*)
Sa1673. . . . EPICALLOTECHIN-3-GALLATE FROM GREEN TEA AS A... (5*)
Sa1674. . . . DYNAMIC NETWORK OF SERUM CIRCULAR RNA... (2*)|(National Natural Science Foundation of China)
Sa1675. . . . PERIOSTIN ATTENUATES TUMOR GROWTH BY INDUCING... (2*)
Sa1676. . . . PROGNOSTIC VALUE OF COX-2 EXPRESSION FOR... (5*)
Sa1677. . . . POST-OPERATIVE OUTCOMES IN PATIENTS WITH INTESTINAL... (5*)
Sa1678. . . . METASTASIS OF GASTROINTESTINAL STROMAL TUMOR (GIST)... (5*)
Sa1679. . . . NUDT15 VARIANT CAN PREDICT THE DEVELOPMENT... (5*)
Sa1680. . . . A NOVEL SCORING SYSTEM TO PREDICT... (5*)
Sa1681. . . . ANTI-TNFα EXPOSURE DURING PREGNANCY IS NOT... (1*)
Sa1682. . . . AN OVERVIEW OF AUTOIMMUNE COMPLICATIONS INDUCED... (5*)
Sa1683. . . . ACUTE INFUSION REACTIONS ASSOCIATED WITH INFlixIMAB... (5*)
Sa1684. . . . NO SIGNS OF SYMPTOMATIC HYPOPHOSPHATEMIA OR... (3*)|(Pharmacosmos A/S Denmark)
Sa1685. . . . THE IMPACT OF CORTICOSTEROIDS, IMMUNOMODULATOR AND... (5*)
Sa1686. . . . PREDICTION OF POSTOPERATIVE OUTCOME OF COLECTOMY/PROCTOCOLECTOMY... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFCA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1687. . . . PREMEDICATION USE IN THE PREVENTION OF... (3*)
(Coram/CVS Specialty Infusion Services)

Sa1688. . . . CHARACTERIZATION OF MEGAPOUCH IN PATIENTS WITH... (5*)

Sa1689. . . . THE SURVEILLANCE OF ADVERSE EVENTS AND... (5*)

Sa1690. . . . THE RISK OF SERIOUS INFECTIONS IN... (5*)

Sa1691. . . . MONITORING OF LABORATORY PARAMETERS DURING THIOPURINE... (4*)

Sa1692. . . . VEDOLIZUMAB AND EARLY POSTOPERATIVE COMPLICATIONS IN... (5*)

Sa1693. . . . HIGH RELAPSE RATES WITH THIOPURINE MONOTHERAPY... (5*)

Sa1694. . . . UTILITY OF CHECKING VITAL SIGNS DURING... (5*)

Sa1695. . . . SUPERIORITY OF INTERFERON-GAMMA RELEASE ASSAY OVER... (4*)

Sa1696. . . . VEDOLIZUMAB INDUCES DE NOVO EXTRAINTESTINAL MANIFESTATIONS... (5*)

Sa1697. . . . OUTCOME OF PREGNANCIES IN VEDOLIZUMAB TREATED... (5*)

Sa1698. . . . IMPACT OF ANTI-TNFA EXPOSURE DURING PREGNANCY... (1*)

Sa1699. . . . SAFETY OF VEDOLIZUMAB IN PATIENTS NAÏVE... (3*) (Clinical trials were conducted and sponsored by Takeda Pharmaceutical Company Ltd. Medical writing assistance was provided by Oxford Pharmagenesis and was supported by Takeda Pharmaceutical Company, Ltd.)

Sa1700. . . . INCIDENCE OF COLORECTAL CANCER, NON-MELANOMA SKIN... (3*) (Takeda Pharmaceutical Company Limited, Tokyo, Japan)

Sa1701. . . . A MULTICENTER COHORT STUDY TO ASSESS... (5*)

Sa1702. . . . NOVEL INSIGHTS ON THIOPURINE INDUCED LEUKOPENIA... (2*) (4)

Sa1703. . . . POST-MARKETING SAFETY EXPERIENCE OF VEDOLIZUMAB IN... (3*) (This study is supported by Takeda Pharmaceutical Company, Ltd. Medical writing assistance was provided by Oxford Pharmagenesis and was supported by Takeda Pharmaceutical Company, Ltd.)

Sa1704. . . . INFliximab AND VEDOLIZUMAB SHOW A DIFFERENT... (5*)

Sa1705. . . . RECURRENCE OF NON-MELANOMA SKIN CANCER (NMSC)... (3*) (Pfizer Pharmaceuticals)

Sa1706. . . . CURRENT STATUS OF HOME INFUSIONS FOR... (5*)

Sa1707. . . . PATIENTS WITH RESOLVED HBV INFECTION (ANTI-HBC... (5*)

Sa1708. . . . THE EFFECT OF IBD BIOLOGIC DRUGS... (3*) (Funded in part by an investigator initiated research grant from Takeda)

Sa1709. . . . ELDERLY AGE IS A RISK FACTOR... (5*)

Sa1710. . . . RISK OF POSTOPERATIVE SURGICAL SITE INFECTIONS... (2*)

Sa1711. . . . REAL WORLD COMPARATIVE RISK OF SERIOUS... (3*) (Financial support for the study was provided by AbbVie.)

Sa1712. . . . HEPATITIS B VIRUS REACTIVATION IN HEPATITIS... (5*)

Sa1713. . . . STOPPING AZATHIOPRINE IN MONOTHERAPY AFTER VERY... (5*)

Sa1714. . . . INCIDENCE AND PREDICTORS OF LFT ABNORMALITIES... (5*)

Sa1715. . . . SARCOPENIA AS PREDICTOR FOR POOR OUTCOMES... (5*)

Sa1716. . . . HIGH ANTI-TNF DRUGS TROUGH LEVELS ARE... (5*)

Sa1717. . . . VERY HIGH RATE OF TUBERCULOSIS COMPLICATING... (5*)

Sa1718. . . . SAFETY OF TUMOR NECROSIS FACTOR INHIBITOR... (5*)

Sa1719. . . . PREDICTORS OF ACUTE AND DELAYED VEDOLIZUMAB... (5*)

Sa1720. . . . THE IMPACT OF INTESTINAL COMPLICATIONS ON... (3*) (Financial support for the study was provided by AbbVie. All authors participated in and approved the interpretation of data, review, and abstract development and content.)

Sa1721. . . . NON-CLASSICAL MONOCYTE HOMING TO THE GUT... (6*) (Support provided by Takeda.)

Sa1722. . . . RATES OF NEWBORN ANEMIA EXPOSED TO... (7*) (6)

Sa1723. . . . COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND TUMOR... (3*) (Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals U.S.A., Inc.)

Sa1724. . . . EXPANDED ALLOGENEIC ADIPOSE DERIVED MESENCHYMAL STEM... (3*) (Tigenix, S.A.U.)

Sa1725. . . . VEDOLIZUMAB COMPARED WITH INFLIXIMAB FOR PERIANAL... (5*)

Sa1726. . . . IMPACT OF CONCOMITANT IMMUNOMODULATOR USE ON... (3*) (Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals U.S.A., Inc.)

Sa1727. . . . CHROMOENDOSCOPY VERSUS HIGH DEFINITION WHITE LIGHT... (5*)

Sa1728. . . . EARLY USE OF VEDOLIZUMAB VERSUS INFliximab... (3*) (Funding was provided by Takeda Pharmaceutical Company Ltd.)

Sa1729. . . . COMPARISON OF GASTROINTESTINAL PATHOGEN PANEL AND... (7*)

Sa1730. . . . TREATMENT DISCONTINUATION, FLARES, AND HOSPITALIZATIONS AMONG... (3*) (Funding was provided by Takeda Pharmaceutical Company Ltd.)

Sa1731. . . . LONGER DURATION OF VANCOMYCIN PREVENTS RECURRENCE... (2*) (Short Term Training Health Professional Students grant T35 DK062719)

Sa1732. . . . THE EFFECTS AND ADHERENCE OF ASCACOL®... (3*) (Daewoong cooperation)

Sa1733. . . . HIGHER ADDED SUGAR AND LOWER MONO-UNSATURATED... (2*)

Sa1734. . . . IMPACT OF PRIOR SURGICAL HISTORY ON... (3*) (Janssen Research & Development, LLC, Spring House, PA; Janssen Scientific Affairs, LLC, Horsham, PA, US)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1735. . . . ANTI-TNF AND IMMUNOMODULATOR THERAPY MODIFY THE... (5*)
Sa1736. . . . STEROID THERAPY AND SEVERE ACTIVE CROHN'S... (5*)
Sa1737. . . . COST PER RESPONDER AND COST PER... (3*)| (Janssen Scientific Affairs, LLC; Janssen Pharmaceuticals, Inc.)
Sa1738. . . . THIOPURINES VERSUS ANTI-TNFα FOR THE PREVENTION... (5*)
Sa1739. . . . BIOLOGICS FOR THE TREATMENT OF PERIANAL... (5*)
Sa1740. . . . TOFACITINIB FOR THE INDUCTION AND MAINTENANCE... (5*)
Sa1741. . . . RATES OF USTEKINUMAB DEEP REMISSION: A... (5*)
Sa1742. . . . EFFICACY AND SAFETY OF AN ADDITIONAL... (3*)| (Pfizer Inc)
Sa1743. . . . REDUCED RATES OF CROHN'S- RELATED SURGERIES,... (3*) | (Janssen Scientific Affairs, LLC; Horsham, PA, US; Janssen Research & Development, LLC, Spring House, PA, US.)
Sa1744. . . . CANNABIS INDUCES CLINICAL AND ENDOSCOPIC IMPROVEMENT... (5*)
Sa1745. . . . BIOLOGICAL INTERVENTIONS FOR INDUCTION AND MAINTENANCE... (5*)
Sa1746. . . . LONG-TERM SAFETY AND EFFICACY OF THE... (3*) | (The OPERA II study was funded by Pfizer. Medical writing support was provided by Katie Pillidge PhD of PharmaGenesis London, London, UK, with funding from Shire.)
Sa1747. . . . AN ANTI-INFLAMMATORY DIET PREVENTS SUBCLINICAL INFLAMMATION... (4*)
Sa1748. . . . HERPES ZOSTER INFECTION IN PATIENTS WITH... (3*) | (Pfizer Inc)
Sa1749. . . . INDIGO NATURALIS IS EFFECTIVE IN TREATMENT-REFRACTORY... (4*) | (This study was funded by Development Programs for Medical Innovation and Keio Fukuzawa Memorial Fund.)
Sa1750. . . . THE EFFECT OF TOFACITINIB ON SERUM... (3*) | (Pfizer Inc)
Sa1751. . . . A PHASE 3 STUDY OF VEDOLIZUMAB... (3*)| (Takeda Pharmaceutical Company Limited)
Sa1752. . . . OZANIMOD INDUCES DOSE-RESPONSIVE HISTOLOGICAL IMPROVEMENT WITH... (3*) | (This study is sponsored by Celgene Corporation.)
Sa1753. . . . TOFACITINIB ACHIEVES SYMPTOMATIC IMPROVEMENT WITHIN 3... (3*) | (Pfizer Inc)
Sa1754. . . . BIOLOGICAL INTERVENTIONS FOR INDUCTION AND MAINTENANCE... (5*)
Sa1755. . . . RAPIDITY OF CLINICAL AND LABORATORY IMPROVEMENTS... (3*) | (AbbVie Inc)
Sa1756. . . . PATIENT-REPORTED IMPROVEMENTS IN PAIN AND DISCHARGE... (3*) | (TiGenix S.A.U.)
Sa1757. . . . FILGOTINIB DECREASES SYSTEMIC AND MUCOSAL MARKERS... (3*) | (Supported by Galapagos NV and Gilead Sciences)
Sa1758. . . . UPADACITINIB IMPROVES STEROID-FREE CLINICAL AND ENDOSCOPIC... (3*) | (AbbVie Inc)
Sa1759. . . . NET REMISSION RATES WITH BIOLOGIC TREATMENT... (5*)
Sa1760. . . . NOVEL MICROSCOPIC COLITIS DISEASE ACTIVITY INDEX... (3*) | (Dr. Falk Pharma GmbH, Freiburg, Germany)
Sa1761. . . . EFFICACY AND SAFETY OF DOSE ESCALATION... (3*) | (Pfizer Inc)
Sa1762. . . . FIRST-IN-HUMAN STUDY OF THE NOVEL 5-HT2B... (5*)
Sa1763. . . . TOFACITINIB FOR THE TREATMENT OF ULCERATIVE... (3*) | (Pfizer Inc)
Sa1764. . . . UPADACITINIB EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY IN... (3*) | (AbbVie)
Sa1765. . . . CORRELATION OF LIPID LEVELS WITH REDUCTION... (3*) | (Pfizer Inc)
Sa1766. . . . VEDOLIZUMAB TREATMENT PERSISTENCE UP TO 3... (3*) | (Funding was provided by Takeda Pharmaceutical Company Ltd.)
Sa1767. . . . EB8018, A NOVEL FIMH BLOCKER IS... (3*)
Sa1768. . . . CLINICAL FACTORS ASSOCIATED WITH DISCONTINUATION OF... (5*)
Sa1769. . . . RANDOMIZED, CONTROLLED TRIAL TO COMPARE NOVEL... (3*) | (Niklcio, Germany)
Sa1770. . . . TOFACITINIB FOR THE TREATMENT OF ULCERATIVE... (3*) | (Pfizer Inc)
Sa1771. . . . DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL TO... (3*) | (Salix Pharmaceuticals)
Sa1772. . . . SUSTAINED CLINICAL REMISSION WITH VEDOLIZUMAB IN... (3*) | (Funding was provided by Takeda Pharmaceutical Company Ltd.)
Sa1773. . . . METHOTREXATE IS NOT SUPERIOR TO PLACEBO... (2*)
Sa1774. . . . INCIDENCE OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN... (3*) | (The five studies [NCT01276509; NCT01298492; NCT01387594; NCT01620255; NCT01771809] were funded by Pfizer. Medical writing support was provided by Katie Pillidge PhD of PharmaGenesis London, London, UK, with funding from Shire.)
Sa1775. . . . A NOVEL PHASE 1 TRIAL DESIGN... (3*) | (TopiVertPharma)
Sa1776. . . . SUSTAINED CORTICOSTEROID-FREE REMISSION WITH VEDOLIZUMAB IN... (3*) | (Funding was provided by Takeda Pharmaceutical Company Ltd.)
Sa1777. . . . COMBINED CLINICAL AND BIOLOGICAL RESPONSE (CONCOMITANT... (3*) | (Janssen Research & Development, LLC funded this study.)
Sa1778. . . . NUMBER NEEDED TO TREAT TO ACHIEVE... (3*) | (Janssen Scientific Affairs, LLC funded this study.)
Sa1779. . . . ARE LOWER LEVELS OF FECAL CALPROTECTIN... (5*)
Sa1780. . . . BOWEL ULTRASOUND IS ACCURATE IN ASSESSING... (5*)
Sa1781. . . . SEROLOGICAL MARKERS DEFINE NEWLY DIAGNOSED CROHN'S... (4*)
Sa1782. . . . SARCOPENIA IS A NOVEL PREDICTOR OF... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1783. . . . INTRA-CAVITARY CONTRAST-ENHANCED ULTRASOUND: A NOVEL RADIATION-FREE... (5*)

Sa1784. . . . UNAFFECTED FIRST-DEGREE RELATIVES OF PATIENTS WITH... (4*)

Sa1785. . . . THE ASSOCIATION OF SERUM 7A HYDROXY... (1*)[(Prometheus Laboratories Inc. Performed assays for 7C4 concentrations. The UCSD biobank is partially funded by Prometheus Inc.)

Sa1786. . . . PLASMA CYTOKINE PROFILES IN IBD PRIMARY... (5*)

Sa1787. . . . MOLECULAR ARCHETYPE HETEROGENEITY IN ULCERATIVE COLITIS... (2*)[(3) [Roche Molecular Systems, Hoffmann-La Roche Canada Ltd., the Roche Organ Transplant Research Foundation, Astellas, and (8)]]

Sa1788. . . . THE PRESENCE OF GRANULOMAS IN INTESTINAL... (5*)

Sa1789. . . . SERUM HEADSPACE METABOLOME ANALYSIS DISCRIMINATES CROHN’S... (4*)

Sa1790. . . . CIBERSORT TRANSCRIPTOME PROFILING OF INFLAMMATORY BOWEL... (4*)

Sa1791. . . . THE USE OF RAPID EVAPORATIVE IONISATION... (4*)

Sa1792. . . . RAID-IBS DIAGNOSIS: A NEW NON-INVASIVE METHOD... (2*)[(3)]

Sa1793. . . . DIAGNOSTIC YIELD OF UPPER ENDOSCOPY AND... (5*)

Sa1794. . . . UTILITY OF FAECAL CALPROTECTIN TO ASSESS... (5*)

Sa1795. . . . CLINICALLY SIGNIFICANT SMALL BOWEL CROHN’S DISEASE... (5*)

Sa1796. . . . 5-HYDROXYMETHYLCYTOSINE PROFILE FROM PLASMA OF ULCERATIVE... (2*)

Sa1797. . . . ENTERIC INFECTION IN PATIENTS WITH INFLAMMATORY... (5*)

Sa1798. . . . PLATELET ACTIVATION BY ACTIVATED VON WILLEBRAND... (3*) [The Danish Research Foundation]

Sa1799. . . . FECAL S100A12 LEVELS IN CHILDREN WITH... (4*)

Sa1800. . . . DIAGNOSTIC PERFORMANCE OF LOW HAEMOGLOBIN DENSITY... (5*)

Sa1801. . . . CLINICAL INDICES AND INFLAMMATORY MARKERS IN... (5*)

Sa1802. . . . EFFICACY OF ANTI-TNF THERAPY IN PATIENTS... (5*)

Sa1803. . . . A SELF-REPORTED MALNUTRITION TOOL PREDICTS HOSPITALIZATION... (5*)

Sa1804. . . . FECAL MICROBIOTA TRANSPLANTATION RESOLVES C. DIFFICILE... (5*)

Sa1805. . . . OUTCOMES AFTER JOINT REPLACEMENT SURGERY IN... (4*)

Sa1806. . . . VEDOZUMAB DOES NOT INCREASE PERIOPERATIVE SURGICAL... (5*)

Sa1807. . . . LONGITUDINAL INCIDENCE AND IMPACT OF CYTOMEGALOVIRUS... (5*)

Sa1808. . . . LONG-TERM EFFECTIVENESS AND SAFETY OF ADALIMUMAB... (3*)[Abbvie Inc.)

Sa1809. . . . CLINICAL, SEROLOGIC, AND GENETIC MARKERS ARE... (5*)

Sa1810. . . . GREAT AMOUNT OF PERIPOUCH FAT IN... (5*)[The authors declared no financial conflicts of interest.)

Sa1811. . . . OPIOID USE IN PATIENTS WITH INFLAMMATORY... (3*)

Sa1812. . . . DOES SURGICAL ANASTOMOSIS TYPE IMPACT RATES... (2*)

Sa1813. . . . FACTORS ASSOCIATED WITH IN-HOSPITAL COLITIS-RELATED COMPLICATIONS... (5*)

Sa1814. . . . COINFECTION WITH CLOSTRIDIUM DIFFICILE IN PATIENTS... (5*)

Sa1815. . . . COMPARISON BETWEEN DIFFERENT MALNUTRITION SCREENING TOOLS... (5*)

Sa1816. . . . RISK OF MALNUTRITION IN PATIENTS WITH... (5*)

Sa1817. . . . CLINICAL OUTCOME OF DYSPLASIA AND CANCER... (5*)

Sa1818. . . . PORTOMESENTERIC VENOUS THROMBOSIS IN MEDICALLY REFRACTORY... (5*)

Sa1819. . . . SURVEILLANCE-INDICATION FOR COLONOSCOPY IS ASSOCIATED WITH... (5*)

Sa1820. . . . PERIPOUCH FAT AREA MEASURED ON CT... (5*)

Sa1821. . . . CROHN’S DISEASE IS ASSOCIATED WITH INCREASED... (5*)

Sa1822. . . . STEROID AND OPIOID USE AMONG CROHN’S... (3*)[Janssen Scientific Affairs, LLC, Horsham PA, USA; Janssen Immunology, Horsham, PA, USA.)

Sa1823. . . . DIFFERENTIATING C. DIFFICILE DISEASE FROM COLONIZATION... (3*)[(Tech Lab]

Sa1824. . . . INFLAMMATORY BOWEL DISEASE AND RISK OF... (5*)

Sa1826. . . . SEROLOGICAL ASSESSMENT OF TYPE XVI COLLAGEN... (3*)[The Danish Research Foundation]

Sa1827. . . . RISK ESTRATIFICATION IN CROHN’S DISEASE... (5*)

Sa1828. . . . ENTEROPATHOGENS DETECTED ON STOOL CULTURE AND... (5*)

Sa1829. . . . VEDOZUMAB FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS... (5*)

Sa1830. . . . OBESITY IS ASSOCIATED WITH INCREASED RISK... (5*)

Sa1831. . . . INFLAMMATORY BOWEL DISEASE AND RISK OF... (5*)

Sa1832. . . . THE LARGE-NUCLEUS SUBTYPE OF “INDEFINITE FOR... (5*)

Sa1833. . . . ABDOMINAL PAIN IN INFLAMMATORY BOWEL DISEASE... (6*)

Sa1834. . . . BACTERIOCIN PRODUCTION BY MUCOSAL BACTERIA IN... (4*)

Sa1836. . . . FUSOBACTERIUM NUCLEATUM STATUS PREDICTS PROGNOSIS AND... (5*)

Sa1837. . . . ASSOCIATIONS BETWEEN LOW COLONIC SHORT CHAIN... (2*)

Sa1838. . . . THE CLINICAL AND CIRCULATING INFLAMMATORY CYTOKINES... (2*)

Sa1839. . . . ORALLY DELIVERED BETA-LACTAMASE PREVENTS GUT MICROBIOME... (3*) [Synthetic Biologics, Inc.]

Sa1840. . . . THE COLORECTAL CANCER MUCOSAL MICROBIOME IS... (4*)[(2)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1841. . . . THE IMPACT OF THE GUT MICROBIOME... (2*) (4)
Sa1842. . . . "LINKED MUTATIONS" WITHIN PATHOGENICITY LOCUS OF... (2*) (4)
Sa1843. . . . OPIOID USE IN CLOSTRIDIUM DIFFICILE INFECTION... (5*)
Sa1844. . . . FACTORS PREDICTING RELAPSE OF CLOSTRIDIUM DIFFICILE... (5*)
Sa1845. . . . MOOD AND PERSONALITY OUTCOMES BEFORE AND... (6*)
Sa1846. . . . LONG-TERM EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION... (5*)
Sa1847. . . . PREDICTORS OF FAILURE AFTER FECAL MICROBIOTA... (5*)
Sa1848. . . . EXACERBATION OF CLOSTRIDIUM DIFFICILE INFECTION... (5*)
Sa1849. . . . RESOLUTION RATES OF CLOSTRIDIUM DIFFICILE INFECTION... (5*)
Sa1850. . . . CLINICAL RESPONSE TO NITAZOXANIDE FOR PEDIATRIC... (5*)
Sa1851. . . . CLASSIFICATION OF CLOSTRIDIUM DIFFICILE INFECTION IN... (5*)
Sa1852. . . . MICROBIOTA PROFILE AND DYSBIOSIS ASSESSMENT IN... (5*)
Sa1853. . . . RECURRENT CLOSTRIDIUM DIFFICILE INFECTION OFTEN OCCURS... (4*)
Sa1854. . . . ORAL BACTERIOThERAPY IMPROVES GUT INFLAMMATION AND... (5*)
Sa1855. . . . MULTIPLE FECAL MICROBIOTA TRANSPLANTS FOR CLOSTRIDIUM... (5*)
Sa1856. . . . EVALUATING THE EFFICACY OF BEST PRACTICE... (5*)
Sa1857. . . . CLOSTRIDIUM DIFFICILE INFECTIONS IN IBD: EPIDEMIOLOGY... (5*)
Sa1858. . . . SUROTOMYCIN (A NOVEL ANTIBIOTIC) VS VANCOMYCIN... (5*)
Sa1859. . . . MINIMAL ASSOCIATION BETWEEN THE DUODENAL MUCOSA-ASSOCIATED... (2*)
Sa1860. . . . METABOLIC PHENOTYPING OF AFRICAN AND ALASKAN... (2*) (4)
Sa1861. . . . THE EPIDEMIOLOGY OF WHIPPLE’S DISEASE IN... (5*)
Sa1862. . . . MOXIBUSTION MODULATES THE GUT MICROBIOME AND... (2*) (4)
Sa1863. . . . PREVALENCE OF CLOSTRIDIUM DIFFICILE INFECTION: A... (5*)
Sa1864. . . . VEGETARIAN AND GLUTEN-FREE DIET IN PATIENTS... (2*)
Sa1865. . . . LONGITUDINAL ANALYSES OF THE GUT MICROBIOTA... (2*)
Sa1866. . . . METABOLIC ADAPTATIONS OF BILE ACIDS, FGF-19-... (4*)
Sa1867. . . . HYPOTHALAMIC NIBP/TRAPPC9 KNOCKOUT LEADS TO SPONTANEOUS... (2*)
Sa1868. . . . ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY (MR16-1) SUPPRESSED COLONIC... (4*) (5*)
Sa1869. . . . THE IMPACT OF BODY MASS INDEX... (5*)
Sa1870. . . . THE COST-EFFECTIVENESS OF PHARMACOTHERAPY IN OBESE... (5*)
Sa1871. . . . LIRAGLUTIDE ALTERS TASTE PREFERENCES AND REPORTED... (2*)
Sa1872. . . . FLUID-FILLED INTRAGASTRIC BALLOONS ARE SUPERIOR TO... (5*)
Sa1873. . . . GENETIC POLYMORPHISMS RELATED TO CHOLESTEROL METABOLISM... (3*) Funded by Pathway Genomics)
Sa1874. . . . MORBID OBESITY INCREASES RISK OF ADVERSE... (5*)
Sa1875. . . . THE EFFECTS OF LOSS OF SKELETAL... (5*)
Sa1876. . . . EFFICACY OF AEROBIC EXERCISE VS. RESISTANCE... (5*)
Sa1877. . . . LOCAL AND EXOGENOUS CYTOKINES CONTRIBUTE TO... (5*)
Sa1878. . . . ASSOCIATION BETWEEN BODY MASS INDEX, CLINICAL... (4*)
Sa1879. . . . ASSOCIATION BETWEEN BODY MASS INDEX... (5*)
Sa1880. . . . ACCURACY OF BROSELOW TAPE REVISED: A... (5*)
Sa1881. . . . BARIATRIC SURGERY IS ASSOCIATED WITH IMPROVED... (5*)
Sa1882. . . . SEX DIFFERENCES: EARLY LIFE ADVERSITY AND... (2*) (4)
Sa1883. . . . MULTIFACETED APPROACH TO WEIGHT LOSS... (5*) (1)
Sa1884. . . . OUTCOMES OF A BEHAVIORAL WEIGHT-MANAGEMENT PROGRAM... (5*)
Sa1885. . . . WEIGHT LOSS AND IMPROVEMENT IN HEPATIC... (5*)
Sa1886. . . . ASSOCIATION OF VARIOUS ANTI-HYPERTENSIVE AGENTS AND... (5*)
Sa1874. . . . DO CAUCASIANS YOUNGER THAN 50 YEARS... (5*)
Sa1895. . . . SURVIVAL ANALYSIS BASED ON RELATIONSHIP BETWEEN... (2*) (Government funding: Institute for Information & communications Technology Promotion(IITP) grant funded by the Korea government(MSIT) No.2017-0-01779)
Sa1896. . . . CD44 VARIANT 10-Aug EXPRESSION IN CANCER... (4*)
Sa1897. . . . NEW APPROACH TO PANCREATIC CANCER BIOMARKER... (5*)
Sa1898. . . . H.PYLORI-INDUCED MIR-135B-5P PROMOTES CISPLATIN RESISTANCE IN... (2*)
Sa1899. . . . SMAD4/FASCIN INDEX COULD PREDICT DISEASE-FREE AND... (4*)
Sa1900. . . . MICRORNA EXPRESSION PROFILE IN RECTAL CANCER... (2*)
Sa1901. . . . PROSPECTIVE CELL FREE DNA ASSESSMENT OF... (4*)
Sa1902. . . . A EUROPEAN MULTICENTER POST-AUTHORIZATION STUDY OF... (3*) (Ipsen)
Sa1903. . . . A PROSPECTIVE MULTICENTER REAL LIFE INTERNATIONAL VALIDATION... (5*)
Sa1904. . . . NEAR-INFRARED MOLECULAR IMAGING OF GASTROINTESTINAL STROMAL... (5*)
Sa1985. . . . NON-INVASIVE EVALUATION OF DISEASE ACTIVITY IN... (5*)
Sa1986. . . . DEVELOPMENT OF INNOVATIVE MAGNETIC RESONANCE IMAGING... (2*)[(6)
Sa1987. . . . SMALL INTESTINAL MRI PATHOLOGY INFLAMMATION SCORE... (2*)[(6)
Sa1988. . . . CROHN’S DISEASE PATIENTS HAVE AN INCREASED... (2*)
Sa1989. . . . THE PREDICTION OF ESOPHAGEAL VARICES USING... (5*)
Sa1990. . . . THE DANCING BOWEL MRI SEQUENCE IS SENSITIVE... (5*)
Sa1991. . . . RENAL EFFECTS OF CT ANGIOGRAM IN... (5*)
Sa1992. . . . FEASIBILITY, SAFETY, AND INITIAL EFFICACY OF... (2*)
Sa1993. . . . THE CLINICAL SIGNIFICANCE OF INCIDENTAL GI... (5*)
Sa1994. . . . FACTORS THAT PREDICT SUCCESSFUL PROVOCATIVE ANGIOGRAPHY... (5*)
Sa1995. . . . ESTABLISHED DAMAGE DETECTED AT MAGNETIC RESONANCE... (2*)
Sa1996. . . . ENDOSCOPIC SIGNS IN MICROSCOPIC DUODENITIS... (5*)[This study has not received any industry or commercial sources]
Sa1997. . . . MYOARCHITECTURE OF THE HUMAN AND PORCINE... (4*)
Sa1998. . . . THE SUTURE PULLEY COUNTERTRACTION METHOD REDUCES... (5*)
Sa1999. . . . USE OF TRANEXAMIC ACID TO DECREASE... (5*)
Sa2000. . . . THE PURE-VU COLON CLEANSING SYSTEM REDUCES... (3*)[Moton Gi Medical Technologies, Tirat Carmel, Israel]
Sa2001. . . . THE CLIP-OVER-LOOP METHOD: SAFE AND EFFICIENT... (5*)
Sa2002. . . . DUODENAL MUCOSAL IMPEDANCE IS ALTERED IN... (4*)[Vanderbilt co-owns the patent for mucosal impedance (MI) technology.]
Sa2003. . . . REDUCING FODMAP CONTENT IN THE BREASTFEEDING... (5*)
Sa2004. . . . UNDERSTANDING PHENOTYPIC DISTINCTIONS IN SUB-POPULATIONS OF... (2*)
Sa2005. . . . GENETICS OF EPCAM IN CONGENITAL TUFTING... (4*)
Sa2006. . . . THE GENETIC INFLUENCE ON THE DEVELOPING... (2*)
Sa2007. . . . INCIDENCE OF CELIAC DISEASE AUTOIMMUNITY AND... (2*)
Sa2008. . . . MUTATIONS IN STXBP3 CONTRIBUTE TO VERY... (2*)
Sa2009. . . . BIOAVAILABLE SERUM VITAMIN D AND RECTAL... (2*)
Sa2010. . . . INFLUENCE OF MATERNAL SSRI EXPOSURE ON... (6*)
Sa2011. . . . NOVEL CANDIDATE GENES IN ESOPHAGEAL ATRESIA/TRACHEOESOPHAGEAL... (2*)
Sa2012. . . . MULTICHANNEL INTRALUMINAL IMPEDANCE WITH PH TESTING... (4*)
Sa2013. . . . QUALITY OF LIFE IN CHILDREN WITH... (4*)
Sa2014. . . . GASTROESOPHAGEAL REFLUX AND FUNDOPICATION STATUS DO... (5*)
Sa2015. . . . THE TIMED BARIUM ESOPHAGROGRAM, A USEFUL... (4*)
Sa2016. . . . FECAL MICROBIOTA TRANSPLANTATION FOR CLOSTRIDIUM DIFFICILE... (6*)
Sa2017. . . . CREATING A DIFFERENTIAL GENE EXPRESSION PROFILE... (1*)
Sa2018. . . . RADIOMIC TEXTURE ANALYSIS SHOWS DIFFERENTIAL EXPRESSION... (4*)
Sa2019. . . . IMMUNOPHENOTYPING OF VERY EARLY ONSET INFLAMMATORY... (2*)
Sa2020. . . . ROLE OF GENETIC VARIANTS (PNPLA3 AND... (4*)
Sa2021. . . . VITAMIN D DEFICIENCY AND SUPPLEMENTATION IN... (5*)
Su1000. . . . INCREASING ECONOMIC BURDEN OF HEPATIC ENCEPHALOPATHY... (5*)
Su1001. . . . A HIDDEN COST OF COLONOSCOPY: USE... (5*)
Su1002. . . . COST-EFFECTIVENESS OF VEDOLIZUMAB, INFliximab, AND ADAHILUMAB... (4*)
Su1003. . . . COST-EFFECTIVENESS ANALYSIS OF FECAL CALPROTECTIN USED... (3*)[Janssen]
Su1004. . . . COMBINATION OF QUANTITATIVE FAECAL OCCULT BLOOD... (5*)
Su1005. . . . THE COST-EFFECTIVENESS OF DOPPLER PROBE EXAM... (5*)
Su1006. . . . EMERGENCY ROOM AND INPATIENT ADMISSION TRENDS... (5*)
Su1007. . . . COST-EFFECTIVENESS OF PANCREATIC CANCER SCREENING IN... (4*)
Su1008. . . . A COMPARISON OF MEDICATION ADHERENCE AND... (3*)[Acknowledgment: This study and medical writing assistance (by Stephanie Agbu, PhD, of inVentiv Medical Communications) were supported by Takeda Pharmaceuticals U.S.A., Inc.]
Su1009. . . . TRENDS AND FACTORS ASSOCIATED WITH HOSPITALIZATION... (2*)
Su1010. . . . USEFULNESS OF FOBT IN INPATIENT SETTING... (5*)
Su1011. . . . SIGNIFICANT COST SAVINGS THROUGH USE OF... (5*)
Su1012. . . . THE INCIDENCE, RISK FACTORS, CLINICAL AND... (5*)
Su1013. . . . COST-EFFECTIVENESS OF ADDING ENDOCUFF® TO COLONOSCOPY....(3*)[Funding for this study was provided by Olympus Corporation of the Americas]
Su1014. . . . DESPITE SHORTER LENGTH OF HOSPITAL STAYS,... (5*)
Su1015. . . . COST-UTILITY OF SCREENING FOR RENAL DYSFUNCTION... (5*)
Su1016. . . . COST-UTILITY ANALYSIS OF POTASSIUM-COMPETITIVE ACID BLOCKER-BASED... (3*)[Takeda Pharmaceutical Company Limited, Tokyo, Japan]
Su1017. . . . COSTS AND COST-DRIVING FACTORS FOR ACUTE... (5*)
Su1018. . . . DIRECT HEALTHCARE COST ANALYSIS OF INFLAMMATORY... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1019. . . . ADHERENCE AND PERSISTENCE WITH VEDOLIZUMAB AMONG... [3*]
Su1035. . . . POSSIBLE BIAS IN THE PERSISTENCE WITH VEDOLIZUMAB... [5*]
Su1041. . . . INTERNAL MEDICINE RESIDENTS REPORT LACK OF... [5*]
Su1042. . . . PERCEPTION OF PPI PRESCRIBING AMONGST RESIDENTS... [5*]
Su1043. . . . ENDOSCOPIC PART-TASK TRAINING BOX IMPROVE ENDOSCOPIC... [5*]
Su1044. . . . INCIDENCE AND PREDICTORS OF READMISSION WITH... [5*]
Su1045. . . . IS THERE GENDER EQUALITY IN ACADEMIC... [5*]
Su1046. . . . IMPORTANCE OF COMMUNICATION AND CONSULTATIVE PRACTICES... [5*]
Su1047. . . . DOES EDUCATION IMPROVE KNOWLEDGE OF ACG... [5*]
Su1048. . . . OPTIMIZING SURVEILLANCE COLONOSCOPY FOR COLITIC CANCER... [5*]
Su1049. . . . CASEQ: A MOBILE CASE-BASED APP FOR... [4*]
Su1050. . . . IMPLEMENTING RESOURCE STEWARDSHIP INTO UNDERGRADUATE MEDICAL... [5*]
Su1051. . . . THE PATIENT-CLINICIAN RELATIONSHIP ON TWITTER WITH... [5*]
Su1052. . . . THERAPEUTIC EFFECTS OF INHIBITORS OF THE... [4*][2]
Su1053. . . . BAR704, A POTENT AND SELECTIVE FXR... [4*]
Su1054. . . . IN BARRETT’S EPITHELIAL CELLS, URSODEOXYCHOLIC ACID... [2*]
Su1055. . . . GENE EXPRESSION PROFILING IDENTIFIES IFNG-AS1/NEST AS... [6*]
Su1056. . . . UNRAVELING POST-TRANSCRIPTIONAL REGULATION OF INTESTINAL RESPONSE... [2*][4]
Su1057. . . . SUBSTANCE P SIGNALING ALTERS MICROBIOTA IN... [2*]
Su1058. . . . A CASE FOR CANNABIS AND THE... [4*]
Su1059. . . . CONCURRENT NON-ACID REFLUX IS ASSOCIATED WITH... [5*]
Su1060. . . . BASELINE IMPEDANCE ON HIGH-RESOLUTION ESOPHAGEAL IMPEDANCE-MANOMETRY... [5*]
Su1061. . . . PRESENCE OF GASTROESOPHAGEAL REFLUX INDEPENDENTLY PREDICTS... [5*]
Su1062. . . . GASTROESOPHAGEAL REFLUX DISEASE IS ASSOCIATED WITH... [5*]
Su1063. . . . THE IMPACT OF GASTROESOPHAGEAL REFLUX ON... [5*]
Su1064. . . . CARDIOVASCULAR RESPONSES TO ACUTE AND CHRONIC... [2*]
Su1065. . . . A SINGLE COMBINED MANOMETRY AND PERFUSION... [2*]
Su1066. . . . CLINICAL AND PSYCHOLOGICAL CHARACTERISTICS IN REFLUX... [4*][4] [This study was supported by a grant, TCMM 104-02-01, from Hualien Tzu-Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan.]
Su1067. . . . CLINICAL AND IMPEDANCE-PH FACTORS ASSOCIATED TO... [5*]
Su1068. . . . SLEEP DISTURBANCE IS ASSOCIATED WITH INCREASED... [4*]
Su1069. . . . CHANGES IN CLOCK GENES EXPRESSION OF... [4*]
Su1070. . . . COMPREHENSIVE QUANTITATIVE ANALYSIS OF RELATIONSHIP BETWEEN... [4*]
Su1071. . . . SYMPTOMS CLASSICALLY ATTRIBUTED TO LARYNGOPHARYNGEAL REFLUX... [5*]
Su1072. . . . PREVALENCE OF UPPER GASTROINTESTINAL AND UPPER... [5*]
Su1073. . . . ASSESSMENT OF EXHALED BREATH CONDENSATE FOR... [2*]
Su1074. . . . ASSESSMENT OF IMPORTANT ANALYTICAL PARAMETERS OF... [2*]
Su1075. . . . HIGH RESOLUTION MANOMETRY CAN DISTINGUISH TRUE... [5*]
Su1076. . . . CLINICAL VALUE OF PROLONGED WIRELESS PH... [3*][This

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds     (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)     (3) = Industry or Commercial Entity     (4) = Institutional Funds
(5) = No Study funding     (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)     (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1185. NLRP3 INFLAMMASOMES CONTRIBUTE TO INFLAMMATION AND...
(5*)
Su1186. TREATMENT OUTCOMES OF SOLITARY RECTAL ULCE...
(5*)
Su1187. CLINICAL AND COST EFFECTIVENESS OF MINIMAL-
CONTACT... (2*)
Su1188. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL...
(3*)[RedHill Biopharma, Ltd 21 Ha'arba'a St Tel Aviv, Israel 6473921 (Israel)
Su1189. THE EFFECT OF ZESPRI™ SUNGOLD KIWIFRUIT...
(3*)[Zespri International provided funding for this study but had no input into the methodology, statistical methods, interpretation of the data or writing of abstracts or other outputs]
Su1190. CHARACTERIZATION OF LONG-TERM RIFAXIMIN RESPONDERS FROM...
(3*)[Salix Pharmaceuticals, Bridgewater, NJ, USA.]
Su1191. EFFICACY OF RIFAXIMIN ON BLOATING IN...
(3*) Salix Pharmaceuticals, Bridgewater, NJ, USA.]
Su1192. SAFETY, TOLERABILITY, AND EFFECTIVENESS OF PLECANATIDE...
(3*)[Synergy Pharmaceuticals Inc.]
Su1193. FOOD RELATED QUALITY OF LIFE RELATES...
(5*)
Su1194. EFFICACY OF RIFAXIMIN IN PATIENTS WITH...
(3*)[Fundied by Salix Pharmaceuticals.]
Su1195. RIFAXIMIN REPEAT TREATMENT FOR DIARRHEA-
PREDOMINANT IRRITABLE... (3*)[Salix Pharmaceuticals, Bridgewater, NJ, USA.]
Su1196. TRENDS IN IRRITABLE BOWEL SYMNDROME RELATED...
(5*)
Su1197. IBS PATIENTS AND THEIR RISK-TAKING BEHAVIOR...
(5*)
Su1198. COLONIC IMPAIRMENT OF INTESTINAL BARRIER INTEGRITY...
(4*)
Su1199. DESMOSOME ASSOCIATED GENES IMPROVE PREDICTABILITY OF...
(2*)
Su1200. ENVIRONMENTAL FACTORS (DIVORCE, JOB CHANGING, NIGHT...
(1*)[5]
Su1201. EFFECTS OF SYMBIOTIC BEVERAGE BASED ON...
(4*)
Su1202. ACUTE STRESS TRIGGERS IBS-LIKE MIRNA-MEDIATED REGULATION...
(2*)
Su1203. EFFECT OF THE BRANCHED CHAIN FATTY...
(2*)[4]
Su1204. NTR3 INTERACTS WITH NTR1 TO EXTEND...
(2*)
Su1205. FFAR4 AGONISTS STIMULATE NEUROTENSIN SECRETION...
(2*)
Su1206. KSR1 POSITIVELY REGULATES ERK1/2 SIGNALING AND...
(2*)
Su1207. THE BOMBESIN RECEPTOR SUBTYPE3 (BRS-3) AGONIST,...
(2*)
Su1208. IS THERE PERI-NEURONAL NET IN THE...
(2*)
Su1209. ADRENOMEDULLIN (ADM) REGULATES FEEDING BEHAVIOR,
ENERGY...
(2*)
Su1210. LOW RATES OF H. PYLORI ERADICATION...
(5*)
Su1211. EXPRESSION ANALYSIS OF BLOOD EXOSOME MIRNA...
(1*)
Su1212. DROPLET DIGITAL PCR DETECTS AN UNDERDIAGNOSED...
(2*)
Su1213. OPTIMIZATION OF C13-UREA BREATH TEST THRESHOLD...
(5*)
Su1214. EMERGENCE OF MAP-LIKE REDNESS IS A...
(5*)
Su1215. GASTRIC PATHOLOGY FOLLOW-UP STUDY IN CANADIAN...
(2*)
Su1216. ENDOSCOPIC, DEMOGRAPHIC AND CLINICAL FACTORS INFLUENCING...
(5*)
Su1217. ESTIMATION OF THE DEGREE OF GASTRIC...
(1*)
Su1218. DISPARITIES IN HELICOBACTER PYLORI PREVALENCE RATE...
(5*)
Su1219. PROSPECTIVE EVALUATION OF THE DIAGNOSTIC PERFORMANCE...
(3*) [The stool antigen kits and funding for the study was provided by the Coris BioConcept, Gembloux, Belgium]
Su1220. SEX DIFFERENCE BETWEEN HELICOBACTER PYLORI INFECTION...
(5*)
Su1221. THE BEST CHOICE FOR HELICOBACTER PYLORI...
(5*)
Su1222. DEVELOPMENT AND VALIDATION OF A SCORING...
(5*)
Su1223. PERFORMANCE OF 13C-UREA BREATH TEST TO...
(5*)
Su1224. HELICOBACTER PYLORI GASTRITIS: SEASONAL PERIODICITY...
(5*)
Su1225. HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE PATTERNS AMONG...
(5*)
Su1226. CAB39L ELICITED AN ANTI-WARBURG EFFECT VIA...
(2*)
Su1227. METFORMIN IS ASSOCIATED WITH A REDUCED...
(5*)
Su1228. FAMILIAL AGGREGATION OF GASTRIC CANCER: A...
(4*)
Su1229. DIAGNOSTIC ACCURACY AND CURATIVE SUCCESS OF...
(4*) [1.The 12th Six Talents Peak Project of Jiangsu Province (No. 2015-WSN-028); 2. The Research Project of Education Science in the 12th Five Year Plan of Nanjing Medical University (No. NY2222015030); 3. The Research Project of Chinese Medical Association]
Su1230. ENDOSCOPIC CHARACTERISTICS AND CORRELATION WITH HISTOPATHOLOGY...
(2*)[4][1.12th SixTalents Peak Project of Jiangsu Province (No.2015-WSN-028); 2. The Research Project of Chinese Medical Association and Chinese High Education Association (No.2016B-KC019)]
3. The project funded by the Priority Academic Program Development of
Su1231. COMPREHENSIVE ANALYSIS OF NON-CODING RNA IN...
(4*)
Su1232. COMPREHENSIVE ANALYSIS USING NEXT GENERATION SEQUENCING...
(5*)
Su1233. GASTRIC HYPERPLASTIC POLYPS IN PATIENTS WITH...
(5*)
Su1234. CHARACTERISTICS OF PATIENTS WITH ADVANCED GASTRIC...
(2*)
Su1235. WHAT IS APPROPRIATE UPPER ENDOSCOPY INTERVAL...
(5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1477. . . . INPATIENT HEALTHCARE UTILIZATION IN CIRRHOTIC PATIENTS... (5*)
Su1478. . . . VITAMIN D DEFICIENCY AND METABOLIC BONE... (2*)
Su1479. . . . CIRRHOTIC PATIENTS WITH AN INCREASED RISK... (5*)
Su1480. . . . FACTORS IMPACTING REBLEEDING REQUIRING READMISSION AMONG... (5*)
Su1481. . . . RISK OF POST-PROCEDURAL UNPLANNED HOSPITAL ENCOUNTERS...
Su1482. . . . RISK OF POST-OUTCOME OF ENCOUNTERS...
Su1483. . . . THE IMPACT OF A GI-REAL-WORLD INSIGHTS IN
Su1484. . . . GENETIC ANCESTRY AND EFFECT OF A NOVEL ECHOCARDIOGRAM IN PATIENTS...
Su1485. . . . ENCEPHALAPP STROOP HAS A HIGH SENSITIVITY...
Su1486. . . . BPC 157 THERAPY OF PORTAL HYPERTENSION... (2*)
Su1487. . . . LIVER STIFFNESS MEASUREMENT BY FIBROSCAN IN...
Su1503. . . . EFFICACY OF THE ASSOCIATION BETWEEN VITAMIN...
Su1505. . . . PREVALENCE AND DIAGNOSIS RATE OF IRRITABLE... (3*)
Su1506. . . . PREVALENCE OF ANTERIOR ABDOMINAL WALL PAIN... (5*)
Su1507. . . . REAL-WORLD INSIGHTS IN THE JOURNEY OF... (3*)
Su1508. . . . DIFFERENCES BETWEEN FUNCTIONAL CONSTIPATION AND CONSTIPATION... (3*) (EA Pharma Co.,Ltd)
Su1509. . . . ANTERIOR CUTANEOUS NERVE ENTRAPMENT SYNDROME: AN... (5*)
Su1510. . . . THE IMPACT OF A GIGENETICALLY-SPECIFIC BEHAVIORAL...
Su1512. . . . FUNCTIONAL DYSPEPSIA AND IRRITABLE BOWEL OVERLAP... (5*)
Su1513. . . . THERAPY OF GERD AND FD OVERLAP... (5*)
Su1514. . . . PROSPECTIVE EVALUATION OF GASTRIC EMPTYPING IN...
Su1515. . . . THE BACKGROUND FACTORS FOR FUNCTIONAL CONSTIPATION... (3* EA Pharma. Co.,Ltd)
Su1516. . . . CATEGORIZATION OF PATIENTS WITH DYSPSYPTIC SYMPTOMS... (2*)
Su1517. . . . TRANSILUMBAR AND TRANSSACRAL MAGNETIC STIMULATION THERAPY... (2*)
Su1518. . . . FECAL URGENCY IN A REPRESENTATIVE SAMPLE... (2*)
Su1519. . . . CLINICAL SYMPTOMS AND ANORECTAL MANOMETRY FINDINGS... (5*)
Su1520. . . . ASYMPTOMATIC PELVIC FLOOR DYSFUNCTION ... (2*)
Su1521. . . . THE EFFECT OF BIOFEEDBACK THERAPY (BFT)... (4*)
Su1522. . . . ENDORECTAL BALLOON (ERB) REDUCES RADIATION-INDUCED RECTAL... (4*)
Su1523. . . . MECHANISMS OF NORMAL AND DISORDERED DEFECATION... (2*)
Su1524. . . . BRAIN FUNCTIONAL MRI REVEALS ALTERATIONS IN... (1*)
Su1525. . . . OPTIMIZING ANORECTAL MANOMETRY AND BALLOON EXPULSION...
Su1526. . . . DIFFERENCES IN MANAGEMENT OF PATIENTS WITH...
Su1527. . . . DIFFERENCES IN THE IMPACT OF A GI-
Su1528. . . . THE IMPACT OF A GI-SPECIFIC BEHAVIORAL...
Su1529. . . . SELECTING SPINAL CORD INJURY PATIENTS FOR... (2*) (4)
Su1611. . . . CLINICAL AND PSYCHOLOGICAL CORRELATES OF SOILING... (5*)
Su1612. . . . A PROSPECTIVE STUDY OF LONG-TERM INTAKE... (7*) (2)
Su1613. . . . CLINICAL & QUALITY OF LIFE BENEFITS... (5*)
Su1614. . . . ENDOFLIP VS. HIGH-DEFINITION MANOMETRY IN FECAL...
Su1615. . . . HISTORY OF VAGINAL DELIVERY INDEPENDENTLY PREDICTS...
Su1616. . . . FUNCTIONAL LUMEN IMAGING PROBE (FLIP) TO...
Su1617. . . . 3D HIGH-RESOLUTION ANORECTAL MANOMETRY CORRELATES WITH...
Su1618. . . . WEIGHT-BASED VS. TIME-BASED BALLOON EXPULSION TEST...
Su1619. . . . GENDER DIFFERENCE IN PATIENTS WITH FECAL...
Su1620. . . . WHAT IS THE PREVALENCE OF DYSYNERGIC...
Su1621. . . . STOOL RETENTION SIMULATION EXERCISES DURING BIOFEEDBACK...
Su1622. . . . PHENOTYPIC IDENTIFICATION OF LARGE RECTOCELES USING...
Su1623. . . . ANATOMICAL AND FUNCTIONAL FEATURES OF THE...
Su1624. . . . GENDER DIFFERENCES IN THE EFFECT OF... (4*) (2)
Su1625. . . . INDIVIDUAL DIFFERENCES IN INTESTINAL PERMEABILITY: UTILITY...
Su1626. . . . A NOVEL NEUROMODULATION THERAPY FOR FUNCTIONAL...
Su1627. . . . CORTISOL AWAKENING RESPONSE IS REDUCED IN...
Su1628. . . . LONG-TERM SAFETY AND EFFICACY OF ACOTIAMIDE... (3*) (Zeria Pharmaceutical Co Ltd)
Su1629. . . . IMPAIRED AUTONOMIC RESPONSE TO MENTAL AND... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
**Abstract**

Su1630. ... EXPRESSION AND SIGNIFICANCE OF ENTERIC GLIAL... (2*)

Su1631. ... PROXIMAL GASTRIC EMPTYING ANALYSIS IN PATIENTS... (4)(5)

Su1632. ... SPINAL CORD STIMULATION IMPROVES GLUCAGON-INDUCED IMPAIRMENT... (2*)

Su1633. ... PATTERNS OF CANNABIS USE AND EFFECTS... (5*)

Su1634. ... AMELIORATING EFFECT AND MECHANISM OF VAGAL... (5*)

Su1635. ... NOT ONLY DUODENAL BUT ALSO JEJUNAL... (4*)

Su1636. ... USE OF PAGI-SYM AND ROME IV... (5*)

Su1637. ... EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS FOR ROME... (4*)[[This study was supported by the Rome Foundation, NIDDK (grant RO1 DK31369), the Swedish Medical Research Council (grants 13409, 21691 and 21692), AFA Insurance, an unrestricted grant from Ferring and 21692), AFA Insurance, an unrestricted grant from Ferring Insurance, and by the Faculty of Medicine, University)]

Su1638. ... NATIONAL ESTIMATES OF 30-DAY READMISSIONS AMONG... (5*)

Su1639. ... GASTRIC TRPA1 STIMULATION BY ALICIN-CONTAINING GARLIC... (5*)

Su1640. ... AGE AND MALE GENDER ARE ASSOCIATED... (4*)

Su1641. ... KETAMINE AS A NOVEL ABORTIVE THERAPY... (5*)

Su1642. ... VAGAL MATURATION AND STRESS ARE IMPORTANT... (2*){(4)}

Su1643. ... EFFICACY AND SAFETY OF LUBIPROSTONE IN... (3*)[[This study is supported by Takeda Development Center Americas, Inc., Deerfield, IL, USA, and Succupmo AG, Zug, Switzerland. Medical writing assistance was provided by InVention Medical Communications and supported by Takeda Development Center Americas, Inc.)]

Su1644. ... LONG-TERM OPEN-LABEL SAFETY EXTENSION STUDY ASSESSING... (3*)[[This study is supported by Takeda Development Center Americas, Inc., Deerfield, IL, USA, and Succupmo AG, Zug, Switzerland. Medical writing assistance was provided by InVention Medical Communications and supported by Takeda Development Center Americas, Inc.)]

Su1645. ... DUODENAL EXPRESSION OF BRAIN-DERIVED NEUROTROPHIC FACTOR... (4*)

Su1646. ... DUODENAL/ANTRAL EOSINOPHILIA DOES NOT DISTINGUISH FUNCTIONAL... (4*)

Su1647. ... SACRAL NERVE STIMULATION VERSUS ANTEGRADE CONTINENCE... (5*)

Su1648. ... CLINICAL MANAGEMENT OF PEDIATRIC ACHALASIA: A... (5*)

Su1649. ... SALIVARY PEPSIN MEASUREMENT CANNOT BE USED... (5*)

Su1650. ... DEVELOPMENT OF A CORE OUTCOME SET... (5*)

Su1651. ... THE INITIAL APPROACH TO PEDIATRIC PATIENTS... (5*)

Su1652. ... PAIN-PREDOMINANT FUNCTIONAL GI DISORDERS: IDENTIFYING VULNERABILITIES... (5*)

Su1653. ... FIRST EPIDEMIOLOGICAL EPIDEMIOLOGY OF FUNCTIONAL GASTROINTESTINAL... (5*)

Su1654. ... ABDOMINAL PAIN CHARACTERISTICS IN PEDIATRIC IRRITABLE... (5*)

Su1655. ... COMPARISON OF CLINICIAN DIAGNOSES AND QPGS-ROM... (7*)

Su1656. ... FAMILY HISTORY OF PAIN IS THE... (5*)

Su1657. ... PROBIOTICS FOR THE PREVENTION OF INFANTILE... (1*)

Su1658. ... GUT MICROBIOTA DEFINES HOST RESPONSES TO... (2*)

Su1659. ... A RANDOMIZED, CONTROLLED, SINGLE-BLIND, CROSS-OVER STUDY... (3*)[[ZESPRI International Ltd]

Su1660. ... THE FECAL MICROBIAL ECOSYSTEM IN IRRITABLE... (3*)[SOFA spa]

Su1661. ... TWO SIDES TO COLON CANCER: MICE... (2*)

Su1662. ... DISTAL VERSUS PROXIMAL SESSILE SERRATED ADENOMA/POLYPS... (1*)

Su1663. ... THE EXPRESSION AND CLINICAL SIGNIFICANCE OF... (1*)

Su1664. ... HISTONE DEACETYLASE 7 EXPRESSION IS UPREGULATED... (2*)

Su1665. ... MICRONA EXPRESSION PROFILE IN ESOPHAGUS OF... (2*)

Su1666. ... FECAL TRANSPLANTATION FROM OBESE, HIGH-FAT FED... (2*)

Su1667. ... EXPRESSION AND FUNCTION OF UMAMI (T1R1/T1R3)... (2*)

Su1727. ... COST-EFFECTIVENESS OF COLONOSCOPY COLORECTAL CANCER SCREENING... (5*)

Su1728. ... RISK FACTORS FOR EARLY ONSET COLORECTAL... (6*)

Su1729. ... 5-YEAR INTERVAL COLORECTAL CANCER INCIDENCE TRENDS... (5*)

Su1730. ... PARTICIPATION AND PRACTICAL USE OF FECAL... (2*)

Su1731. ... COMPARISON OF FIT-BASED COLORECTAL CANCER SCREENING... (5*)

Su1732. ... DIFFERENT SURVIVAL OF COLORECTAL CANCERS THAT... (2*)

Su1733. ... EVALUATING THE APPROPRIATENESS OF OPEN ACCESS... (5*)

Su1734. ... ESTABLISHING DIABETES AS A MAJOR RISK... (5*)

Su1735. ... SERRATED POLYP AND THE RISK OF... (2*)[[National Research Foundation (NRF) grant funded by the Korea government (NRF-2017R1A2B2009569)

Su1736. ... RESULTS OF THE DUTCH FIT-BASED COLORECTAL... (2*)

Su1737. ... NOVEL COMPUTER-AIDED RECOGNITION SYSTEM APPLYING DEEP... (5*)

Su1738. ... ACHIEVEMENT OF 80 X 18:00 A... (2*)

Su1739. ... POPULATION BASED COMPARATIVE STUDY OF POSTOPERATIVE... (5*)

Su1740. ... IMPACT OF A CLINICAL NURSE SPECIALIST... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1741. THE ASSOCIATION BETWEEN SESSILE SERRATED POLYPS/ADENOMAS... (2*)
Su1742. PERFORMANCE OF A POPULATION-BASED SCREENING PROGRAM... (4*)[3][LUHK Jockey Club Bowel Cancer Education Centre 2.Eiken Chemical Co. Ltd.)
Su1743. SEVERE COLONOSCOPY-RELATED COMPLICATION IN A FECAL... (2*)
Su1744. PREDICTORS OF COLON CANCER SCREENING AMONG... (5*)
Su1745. PREDICTIVE VALUE OF FECAL HEMOGLOBIN LEVELS... (5*)
Su1746. THE CLINICAL UTILITY OF INTERVAL FECAL... (3*)[FOBTs were provided by Eiken Chemical Company, Japan]
Su1747. COLORECTAL CANCER SCREENING COMPLETION AT A... (6*)
Su1748. LIMITED IMPACT OF SPECIFIC RECOMMENDATIONS ISSUED... (1*)
Su1749. FINDINGS AT INDEX COLONOSCOPY PREDICT THE... (5*)
Su1750. RELATIONSHIP BETWEEN TEAM FUNCTION AND FOLLOW-UP... (2*)
Su1751. COSTS AND BENEFITS OF IMPLEMENTING A... (5*)
Su1752. COMBINING WOMEN'S CANCER SCREENING EXAMINATIONS SHOWS... (5*)
Su1753. SELECT GROUP OF PATIENTS MIGHT BENEFIT... (5*)
Su1754. PRE-CLINICAL PERFORMANCE OF STOOL RNA FOR... (3*)[Geneoscopy LLC provided the funds used for this study]
Su1755. COMPARISON OF WATER INFUSION AND AIR... (5*)
Su1756. OVERWEIGHT AS ANOTHER RISK FACTOR FOR... (5*)
Su1757. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS... (5*)
Su1758. RAID-CRC: A NOVEL NON-INVASIVE TOOL FOR... (2*)
Su1759. INCREASED RISK OF ANY-TYPE COLORECTAL NEOPLASIA... (5*)

Su1760. RISK FACTORS FOR ADENOMATOUS POLYPS, HYPERPLASTIC... (2*)
Su1761. PREDICTION OF CONCURRENT CHEMORADIOLOGY RESPONSE... (2*)
Su1762. ESOPHAGEAL SUBMUCOSAL GLANDS AS A SOURCE... (4*)
Su1763. DIMINISHED GALLBLADDER FILLING, INCREASED FECAL BILE... (2*)
Su1764. THERAPEUTIC CORRELATION OF MULTI-DIMENSIONAL CULTURE SYSTEMS... (5*)
Su1765. PATIENT-DERIVED COLORECTAL CANCER EXPLANTS – ADEQUATE... (2*)[AbbVie]
Su1766. OGDHL INHIBITS HUMAN PANCREATIC DUCTAL ADENOCARCINOMA... (4*)
Su1767. HYPERBARIC OXYGEN THERAPY ENHANCES THE EFFECT... (5*)
Su1768. CHARACTERIZATION OF NOTCH ISOFORM VARIANTS IN... (2*)
Su1769. OVEREXPRESSION OF HACE1 IN GASTRIC CANCER... (2*)
Su1770. A POLY-ALANINE LENGTH POLYMORPHISM WITHIN MSH3... (2*)[4]
Su1771. CATHELICIDIN INHIBITS COLON CANCER METASTASIS WITH... (2*)
Su1772. THE RNA BINDING PROTEIN IMP1 ENHANCES... (2*)[6]
Su1773. THE EXPRESSION OF THE NUCLEAR HORMONE... (4*)
Su1774. SUPPRESSION OF TYROSINE PHOSPHATASE PTPRF INHIBITS... (5*)
Su1792. FECAL LACTOFERRIN IS A RELIABLE IBD... (6*)
Su1793. OUTCOMES OF MAINTENANCE USTEKINUMAB THERAPY FOR... (3*)[Janssen Scientific Affairs, LLC; Janssen Research & Development, LLC]

Su1794. DISCRIMINATION OF ENDOSCOPIC POSTOPERATIVE RECURRENT IN... (2*)
Su1795. DEVELOPING AN INDEX THAT PREDICTS ESCALATION... (6*)[AbbVie pharmaceuticals - through an unrestricted research grant, contributed to funding of the TrueColours pilot project]
Su1796. BIOMARKER CORRELATION WITH ENDOSCOPIC OUTCOMES IN... (3*) AbbVie Inc)
Su1797. ULTRASOUND FOR ASSESSING DISEASE ACTIVITY IN... (5*)
Su1798. COMPARISON BETWEEN FECAL CHITINASE 3-LIKE 1,... (3*)[The study was granted by LESPFR company]
Su1799. PREGNANCY OUTCOMES IN WOMEN EXPOSED TO... (3*)[Janssen Research & Development, LLC; Janssen Scientific Affairs, LLC]
Su1800. EOSINOPHILIC-PREDOMINANT COLONIC INFILTRATION CAN PREDICT STEROID-DEPENDENCY... (5*)
Su1801. DIFFERENT HISTOLOGICAL INDEXES FOR THE ASSESSMENT... (6*)
Su1802. HISTOLOGICAL DISEASE ACTIVITY DID NOT PREDICT... (5*)
Su1803. CORRELATION OF ENDOSCOPIC AND CLINICAL ENDPOINTS... (3*)[AbbVie Inc]
Su1804. LOWER PERIPOUCH FAT AREA IS RELATED... (5*)
Su1805. FECAL CALPROTECTIN IS HIGHLY EFFECTIVE TO... (5*)
Su1806. HISTOLOGICAL SEVERITY OF ULCERATIVE COLITIS CORRELATED... (6*)
Su1807. VEDOLIZUMAB TREATMENT IN CROHN'S DISEASE OF... (5*)
Su1808. MURAL STRATIFICATION ON CT SCAN INDEPENDENTLY... (5*)
Su1809. HISTOLOGICAL ACTIVITY IN CROHN'S DISEASE: RELATIONSHIP... (5*)
Su1810. FECAI CALPROTECTIN IS A VERY RELIABLE... (5*)
Su1811. . . HOME BASED FECAL CALPROTECTIN TESTING: A... [(5*)](BUHLMANN Laboratories AG)
Su1812. . . IS ENDOSCOPY NECESSARY TO MEASURE DISEASE... [(5*)]
Su1813. . . THE MOLECULAR LANDSCAPE IN ULCERATIVE COLITIS... [(2*)][(3*)](Roche Molecular Systems, Hoffman-La Roche Canada Ltd., Roche Organ Transplant Research Foundation, Astellas J & J)
Su1814. . . CLINICAL UTILITY OF ANTI-IFN116 SEROREACTIVITY IN... [(5*)]
Su1815. . . CHARACTERIZATION OF THE SILENT IBD PATIENT... [(6*)]
Su1816. . . AGREEMENT OF CT IMAGING FEATURES OF... [(2*)]
Su1817. . . MONITORING HISTOLOGICAL ACTIVITY IN ULCERATIVE COLITIS... [(3*)][(1*)](Enterosan Labor L+S AG 2) Techlab, inc.)
Su1818. . . RADIOLOGIC RESPONSE REDUCES THE RISK OF... [(5*)]
Su1819. . . TREATMENT NAIVE NEWLY DIAGNOSED PATIENTS WITH... [(6*)][(0*)](Funding support: This work was supported by the Leona M. and Harry B. Helmsley Charitable Trust.)
Su1820. . . ISOLATED ILEAL BLIND LOOP INFLAMMATION AFTER... [(5*)]
Su1821. . . MAGNETIC RESONANCE ENTEROGRAPHY AFTER COMPUTERIZED TOMOGRAPHY... [(5*)]
Su1822. . . RISK OF RELAPSE ACCORDING TO ENDOSCOPIC... [(4*)][(5*)]
Su1823. . . THE CLINICAL UTILITY OF A MULTI-MARKER... [(4*)]
Su1824. . . BIOMAKERS ASSOCIATED WITH EARLY ENDOSCOPIC RECURRENCE... [(2*)]
Su1825. . . THE ROLE OF BOWEL STIFFNESS MEASUREMENT... [(5*)]
Su1826. . . FECAL CALPROTECTIN AND PLASMA CYTOKINES IN... [(4*)]
Su1827. . . MARKERS OF SYSTEMIC INFLAMMATION IN MODERATE-SEVERE... [(5*)]
Su1828. . . RAID-CD MONITOR: A NEW NON-INVASIVE METHOD... [(2*)][(3*)]
Su1829. . . CONTRAST-ENHANCED ULTRASOUND IS HELPFUL IN THERAPEUTIC... [(5*)]
Su1830. . . FEASIBILITY OF AN ELECTRONIC NOSE FOR... [(5*)]
Su1831. . . EVALUATION OF SEGMENTAL ENDOSCOPIC DISEASE ACTIVITY... [(5*)]
Su1832. . . POTENTIAL ROLE OF SERUM 1,25-DIHYDROXY VITAMIN... [(5*)]
Su1833. . . HISTOLOGICAL AND ENDOSCOPIC HEALING AFTER QBECO... [(3*)][(2*)](Qu Biologics Inc.)
Su1834. . . SERUM MARKER PANEL FOR DETECTION OF... [(4*)]
Su1835. . . DISPARITIES IN THE CARE OF RURAL... [(3*)][(2*)][(Janssen Future Leaders in IBD Grant (independently administered by Mount Sinai Hospital, peer-reviewed)]
Su1836. . . LIFE EVENTS WITHIN THE FIRST YEAR... [(5*)]
Su1837. . . EPIDEMIOLOGY AND RISK FACTORS OF MALIGNANT... [(4*)][(5*)]
Su1838. . . THE EFFECTS OF DISEASE SEVERITY AND... [(7*)][(American College of Gastroenterology Canadian Gastrointestinal Epidemiologic consortium)]
Su1839. . . MEDIUM TO LONG-TERM MEDICAL AND SURGICAL... [(5*)]
Su1841. . . FRACTURE RISK IN PATIENTS WITH INFLAMMATORY... [(4*)][(6*)]
Su1842. . . EXAMINING THE ROLE OF AIR QUALITY... [(4*)][(5*)]
Su1843. . . RATES OF PREMATURITY AND LOW BIRTH... [(7*)][(American College of Gastroenterology Canadian Gastrointestinal Epidemiologic Consortium)]
Su1844. . . ADHERENCE TO MEDITERRANEAN DIET IS ASSOCIATED... [(6*)]
Su1845. . . THE EFFECT OF CHILDHOOD ANTIBIOTIC EXPOSURE... [(5*)]
Su1846. . . FIRST-ONSET PSYCHIATRIC DISORDERS IN PREGNANT AND... [(4*)]
Su1847. . . EPIDEMIOLOGY AND RISK FACTORS OF MALIGNANT... [(4*)]

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1866. . . PROTON PUMP INHIBITORS (PPI), H2 BLOCKER... (5*)
Su1867. . . A FOUR-FOLD INCREASE IN THE PREVALENCE... (2*)
Su1868. . . CLINICAL FACTORS RELATED TO LOW BONE... (5*)
Su1869. . . INCREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE... (2*)
Su1870. . . INCREASED RISK OF INFLAMMATORY BOWEL DISEASE... (5*)
Su1871. . . CLINICAL CHARACTERISTICS AND CURRENT MANAGEMENT OF... (3*) (Johnson & Johnson (China) Investment Ltd. Janssen China R&D Center)
Su1872. . . TRENDS IN THE PREVALENCE OF OVERWEIGHT... (4*)
Su1873. . . NON CELIAC WHEAT SENSITIVITY AND CELIAC... (3*) This study was supported by a grant from Frometheis laboratories.
Su1874. . . INCIDENCE AND SURVIVAL OF GASTROINTESTINAL CANCER... (5*)
Su1875. . . PREVALENCE AND PHENOTYPE OF INFLAMMATORY BOWEL... (5*)
Su1876. . . A COMBINATION OF CLINICAL, SEROLOGICAL AND... (4*)
Su1877. . . DISCORDANCE BETWEEN SYMPTOMS AND INFLAMMATION ACROSS... (2*)
Su1878. . . SERUM MARKERS CAN PREDICT FUTURE FIBROSTENOTIC... (2*) (6)
Su1879. . . HIGH BODY MASS INDEX IS ASSOCIATED... (7*)
Su1880. . . PREGNANT WOMEN WITH ULCERATIVE COLITIS ARE... (5*)
Su1881. . . BIOLOGIC DRUG DISCONTINUATION AND TOBACCO USE... (5*)
Su1882. . . POST-INFLAMMATORY POLYPS DO NOT PREDICT COLORECTAL... (5*)
Su1883. . . OLDER AGE AT THE TIME OF... (5*)
Su1884. . . COMBINATION THERAPY WITH ANTI-TNF AND IMMUNOSUPPRESSIVE... (5*)
Su1885. . . IMPACT OF OBESITY ON SHORT- AND... (7*)
Su1886. . . BURDEN OF HOSPITALIZATION AND PREDICTORS OF... (7*)
Su1887. . . IMPACT OF OBESITY ON FUTURE IBD-RELATED... (4*)
Su1888. . . INDEX SEVERITY SCORE AND EARLY READMISSION... (5*)
Su1889. . . RISK OF CANCER IN INFLAMMATORY DISEASE... (2*)
Su1890. . . FINDING THE SWEET SPOT: THE ASSOCIATION... (2*)
Su1891. . . LONG-TERM NATURAL HISTORY OF MICROSCOPIC COLITIS... (5*)
Su1892. . . FACTORS ASSOCIATED WITH INTESTINAL RESECTION IN... (5*)
Su1893. . . PATIENTS WITH PERSISTENTLY CLINICALLY SILENT CROHN'S... (5*)
Su1894. . . THERAPEUTIC GAIN OF CONTINUED, LONG-TERM INFLIXIMAB... (3*) This study was supported by a grant from Takeda)
Su1895. . . PREGNANCY OUTCOMES IN WOMEN WITH INFLAMMATORY... (2*) [This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science, ICT & Future Planning) (NRF-2016R1C1B2015185)
Su1896. . . CLOSTRIDIUM DIFFICILE DOES NOT CAUSE WORSE... (5*)
Su1897. . . AGGRESSIVE INFLAMMATORY BOWEL DISEASE PHENOTYPE IN... (5*)
Su1898. . . EMERGENT COLECTOMY RATES DECREASED WHILE ELECTIVE... (5*)
Su1899. . . VEDOLIZUMAB IS SAFE FOR USE IN... (3*) (Research grant from Takeda)
Su1900. . . AUTOMATED IMAGE ANALYSIS OF CT ENTEROGRAPHY... (2*)
Su1901. . . INDEFINITE Dysplasia CARRIES A HIGH RISK... (5*)
Su1902. . . CONGENITAL HYPOTHYROIDISM IS A RISK FACTOR... (5*)
Su1903. . . INDEX SEVERITY SCORE AND EARLY READMISSION... (5*)
Su1904. . . CLINICAL AND SURGICAL OUTCOMES POST FECAL... (5*)
Su1905. . . RISK AND PROTECTIVE FACTORS FOR NONALCOHOLIC... (5*)
Su1906. . . BRESTFEEDING INFANTS BORN TO MOTHERS WITH... (4*) [(CEGIIR, University of Alberta, WCHRI)
Su1907. . . WORSENING SEVERITY IN ULCERATIVE COLITIS IS... (5*)
Su1908. . . RECENT CORTICOSTEROID EXPOSURE AND ELEVATED C-REACTIVE... (5*)
Su1909. . . CROHN'S DISEASE PATIENTS WITH AT LEAST... (2*) [National Health and Medical Research Council (Australian Government)
Su1910. . . A COMPARISON OF THE RISK OF... (5*)
Su1911. . . CROHN'S DISEASE DECISION AID LEADS TO... (2*)
Su1912. . . EPIDURAL USE DURING VAGINAL DELIVERY WAS... (5*)
Su1913. . . CROHN'S DISEASE PATIENTS' PERSPECTIVES TOWARDS DE-ESCALATING... (2*)
Su1914. . . REAL WORLD USE OF ORAL CORTICOSTEROIDS... (3*) (This study was funded by Eli Lilly and Company.)
Su1915. . . REAL WORLD USE OF ORAL CORTICOSTEROIDS... (3*) (This study was funded by Eli Lilly and Company.)
Su1916. . . OUTCOMES OF TWIN PREGNANCIES IN MOTHERS... (5*)
Su1917. . . IMPROVING PATIENT OUTCOMES WITH PERSONALIZED INFLAMMATORY... (4*)
Su1918. . . CROHN'S DISEASE PATIENTS WITH MEDICARE OR... (5*)
Su1919. . . IMPACT OF EXTRA-INTESTINAL MANIFESTATIONS AT DIAGNOSIS... (4*)
Su1920. . . REAL-WORLD EVIDENCE COMPARISON OF THE EFFICACY... (3*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1977. . . . CHARACTERIZATION OF THE MUCOSAL- AND DEVICE-ASSOCIATED... (2*)[4]
Su1978. . . . DUODENO-JEJUNAL BYPASS LINER FOR THE TREATMENT... (2*)
Su1979. . . . ALTERED BODY COMPOSITION IN PATIENTS WITH... (2*)
Su1980. . . . AN ESTIMATE OF THE NEED FOR... (1*)
Su1981. . . . NEITHER SERUM VITAMIN B12 NOR M ETHYLMALONIC... (5*)
Su1982. . . . GLEPAGLUTIDE, A GLUCAGON-LIKE PEPTIDE-2 ANALOG, AMELIORATES... (3*)[(This trial was sponsored by Zealand Pharma.)
Su1983. . . . ALCOHOL UNIQUELY REGULATES SODIUM-GLUTAMINE CO-TRANSPORT IN... (2*)
Su1984. . . . ESCHERICHIA COLI IMPROVES THE INTESTINAL PERMEABILITY... (4*)
Su1985. . . . MICROBIOTA-RELATED CHANGES IN FECAL BILE ACID... (6*)
Su1986. . . . THE NON-ABSORBABLE ANTI BIBIOTIC RIFAXIMIN EXHIBITS WEIGHT... (3*)[Salix Pharmaceuticals]
Su1987. . . . EARLY LIFE STRESS INDUCES TYPE 2... (5*)
Su1988. . . . GASTROINTESTINAL TRACT LYMPHOMA RECEIVING CHEMOTHERAPY: DOES... (5*)
Su1989. . . . SEVERE GASTROINTESTINAL DYSMOTILITY RELATED INTESTINAL FAILURE... (5*)
Su1990. . . . FACTORS ASSOCIATED WITH A NEED FOR... (5*)
Su1991. . . . EFFECT OF PSYLLIUM FIBER SUPPLEMENTATION ON... (4*)[7]
Su1992. . . . VARIABILITY IN DEFINITIONS USED FOR ENTERAL... (3*)[Takeda Development Centre Europe Ltd]
Su1993. . . . THE USE OF ANTIMICROBIAL LOCKS FOR... (2*)[Fonds de recherches du Québec Santé (FRQS) Association des Gastro-entérologues du Québec (AGEQ)]
Su1996. . . . LOADING AND TRACKING INTESTINAL ORGANOIDS WITH... (4*)
Su1997. . . . GENERATION AND VALIDATION OF NEW CONFOCAL... (4*)
Su1998. . . . CONFOCAL LASER ENDOMICROSCOPY IN THE ASSESSMENT... (2*)
Su1999. . . . BARRETT'S ESOPHAGUS DYSPLASIA BURDEN MEASURED BY... (5*)
Su2000. . . . COMPARISON BETWEEN STANDARD ULTRASOUND AND POCKET... (5*)
Su2001. . . . EUS VERSUS MRI IN STAGING RECTAL... (5*)
Su2002. . . . GEMCITABINE-MEDIATED ANTITUMOR EFFECT FOR PANCREATIC DUCTAL... (5*)
Su2003. . . . INTRAVENOUS BEVACIZUMAB FOR THE TREATMENT OF... (5*)
Su2004. . . . EARLY COLONOSCOPY FOR DIVERTICULAR BLEEDING AND... (5*)
Su2005. . . . A RETROSPECTIVE ANALYSIS OF THE CLINICAL... (3*)[(Study funded by Index Pharmaceuticals)
Su2006. . . . HIGH PREVALENCE OF ELEVATED FECAL CALPROTECTIN... (3*)[Frost Diagnostika, Otterstadt, Germany]
Su2007. . . . IMAGE DIAGNOSIS OF MAGNETICALLY CONTROLLED ROBOTIC... (2*)
Su2008. . . . EVIDENCE OF MACROSCOPIC PERFORATION IN ACUTE... (5*)
Su2009. . . . SPECIFIC PREDICTION OF DUODENAL TUMOR USING... (4*)[2]
Su2010. . . . THE ANTI-MADCAM ANTIBODY SHP647 IN CROHN'S... (3*)[The OPERA I study was funded by Pfizer. Medical writing support was provided by Katie Pillidge PhD of PharmaGenesis London, London, UK, with funding from Shire.]
Su2011. . . . MINIMALLY INVASIVE GASTRIC STIMULATION USING NEWLY... (5*)
Su2012. . . . UTILITY OF SELF-EXPANDABLE METALLIC STENT IN... (5*)
Su2013. . . . EFFICACY OF CRYOTHERAPY IN ABLATION NAIVE... (5*)
Su2014. . . . EFFICACY OF OVER THE SCOPE CLIP... (5*)
Su2015. . . . EARLY 12 WEEK ULTRASOUND RESPONSE TO... (3*)[Abbvie]
Su2016. . . . UNEXPECTED BEHAVIOR OF HEMANGIOMAS ON CONTRAST... (5*)
Su2017. . . . PREDICTING RESPONSE TO STANDARDIZED PEDIATRIC COLITIS... (2*)
Su2018. . . . LONGITUDINAL ADHERENCE TO MESALAMINE IN PEDIATRIC... (2*)
Su2019. . . . A TREAT-TO TARGET STRATEGY GUIDED BY... (5*)
Su2020. . . . HIGHER POST-INDUCTION INFliximAb SERUM TROUGH LEVELS... (2*)[(5)]
Su2021. . . . MUCOSAL HEALING AND HISTOLOGICAL REMISSION IN... (5*)
Su2022. . . . EVALUATION OF ADAlimumAB EFFECTIVENESS IN PEDIATRIC... (3*)[(AbbVie)
Su2023. . . . UVEITIS IN A MULTICENTER PEDIATRIC INFLAMMATORY... (5*)
Su2024. . . . PATTERNS OF USE AND DURABILITY OF... (3*)[(Takeda Pharmaceuticals]
Su2025. . . . FACTORS ASSOCIATED WITH DISCONTINUATION OF INITIAL... (3*)[(Takeda Pharmaceuticals]
Su2026. . . . CONTINUED STATURAL GROWTH IN OLDER ADOLESCENTS... (3*)[(Celgene]
Su2027. . . . TEMPORAL PATTERNING OF INFLIXIMAB DURING... (5*)
Su2028. . . . PHENOTYPIC VARIATION IN PEDIATRIC IBD BY... (2*)
Su2029. . . . THERAPEUTIC DRUG MONITORING OF INFliximAB... (5*)
Su2030. . . . TEMPORAL PATTERNING OF PANCREATITIS AND INFLAMMATORY... (5*)
Su2041. . . . META-ANALYSIS OF RANDOMIZED AND NON-RANDOMIZED CONTROL... (5*)
Mo1002. . . . AXL RECEPTOR TYROSINE KINASE MEDIATES ESOPHAGEAL... (2*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1003. . . . RISK FACTORS LINKING ESOPHAGEAL SQUAMOUS-CELL CARCINOMA... (5*)
Mo1004. . . . COMPARISON OF ENDOSCOPIC SUBMUCOSAL DISSECTION AND... (2*)[(This paper was supported by the following grant(s): The National R & D Program for Cancer Control, Ministry of Health & Welfare, Korea (1720180)]
Mo1005. . . . THE CLOSING GENERATIONAL GAP OF ESOPHAGEAL... (5*)
Mo1006. . . . A DETAILED ANALYSIS OF THE CHARACTERISTICS... (5*)
Mo1007. . . . CLINICAL RELATIONSHIP BETWEEN THE CHANGES IN... (5*)
Mo1008. . . . WIDELY VIEWED YOUTUBE VIDEOS RELATED TO... (5*)
Mo1010. . . . MARKERS OF NON-CELIAC WHEAT SENSITIVITY IN... (2*)
Mo1011. . . . SIMVASTATIN AS A NOVEL TOOL TO ASSESS HISTOLOGIC, SEROLOGIC, AND SYMPTOMATIC... (3*)[(Alvine Pharmaceuticals ImmunogenX)]
Mo1012. . . . THE EFFECTS OF NORMAL, NEUTRAL DRIFT DYNAMICS OF INTESTINAL STEM... (2*)
Mo1013. . . . THE USE OF ABDOMINAL CT IMAGING... (5*)
Mo1014. . . . A NOVEL TOOL TO ASSESS SYMPTOMS... (3*)[(Ritter Pharmaceuticals, Inc.)]
Mo1015. . . . ANXIETY AND DEPRESSION IS NOT INCREASED... (4*)
Mo1016. . . . IMMUNOLOGICAL MEDIATORS ARE ASSOCIATED WITH... (1*)
Mo1017. . . . RELATIONSHIP BETWEEN NICKEL ALLERGIC CONTACT MUCOSITIS... (5*)
Mo1018. . . . MARKERS OF NON-CELIAC WHEAT SENSITIVITY IN... (2*)
Mo1019. . . . A NOVEL TOOL TO ASSESS SYMPTOMS... (3*)[(Ritter Pharmaceuticals, Inc.)]
Mo1020. . . . FORGOING THE DUODENAL BIOPSY FOR CELIAC... (5*)
Mo1021. . . . MICRONUTRIENT DEFICIENCY AT CELIAC DISEASE DIAGNOSIS... (4*)
Mo1022. . . . DIAGNOSTIC ACCURACY OF POINT OF CARE... (5*)
Mo1023. . . . FORGOING THE DUODENAL BIOPSY FOR CELIAC... (5*)
Mo1024. . . . LOW RATES OF SCREENING FOR CELIAC... (5*)
Mo1025. . . . EPIDEMIOLOGY OF ACUTE PANCREATITIS IN CELIAC... (5*)
Mo1026. . . . PREVALENCE OF TYPE 2 DIABETES IN... (2*)
Mo1027. . . . PATTERNS OF MARIJUANA USE AMONG CELIAC... (5*)
Mo1028. . . . PREVALENCE OF COLORECTAL ADENOMAS AMONG RECENTLY-DIAGNOSED... (5*)
Mo1029. . . . INFLAMMATORY BIOMARKERS AS PREDICTORS OF MUCOSAL... (5*)
Mo1030. . . . ANXIETY AND DEPRESSION IS NOT INCREASED... (4*)
Mo1031. . . . CLINICAL PROFILE OF CELIAC DISEASE: EPIDEMIOLOGICAL... (4*)
Mo1032. . . . PREVALENCE OF NUTRITIONAL DEFICIENCIES IN FOLLOW-UP... (2*)[4]
Mo1033. . . . THE USE OF ABDOMINAL CT IMAGING... (5*)
Mo1034. . . . UNDIAGNOSED CD IS ASSOCIATED WITH INCREASING... (5*)
Mo1035. . . . IRON-DEFICIENCY ANEMIA AND PREVALENCE OF CELIAC... (2*)
Mo1036. . . . PREVALENCE OF PRIMARY BILIARY CHOLANGITIS-RELATED AUTOANTIBODIES... (5*)
Mo1037. . . . PHYSICIAN DIAGNOSES AND SELF-DIAGNOSIS OF PATIENTS... (2*)[4]
Mo1038. . . . DIAGNOSTIC UTILITY OF ENDOSCOPIC DUODENAL BULB... (5*)
Mo1039. . . . THE PREVALENCE OF CELIAC DISEASE IS... (5*)
Mo1040. . . . SERUM IMMUNOLOGICAL MEDIATORS ARE ASSOCIATED WITH... (1*)
Mo1041. . . . ACCURACY OF SEROLOGIC MARKERS IN THE... (5*)
Mo1042. . . . CANADIANS WITH CELIAC DISEASE MAY INADVERTENTLY... (4*)[2]
Mo1043. . . . DETERMINATION OF GLUTEN CONSUMPTION BY CELIAC... (3*)[ImmunogenX]
Mo1044. . . . CORRELATION OF HISTOLOGIC, SEROLOGIC, AND SYMPTOMATIC... (3*)[(Alvine Pharmaceuticals ImmunogenX)]
Mo1045. . . . SIMVASTATIN AS A BIOMARKER FOR INTESTINAL... (3*)[ImmunogenX]
Mo1046. . . . ATOIMMUNE LIVER DISEASE IN ADULT CELIAC... (4*)
Mo1047. . . . RELATIONSHIP BETWEEN NICKEL ALLERGIC CONTACT MUCOSITIS... (5*)
Mo1048. . . . A NOVEL TOOL TO ASSESS SYMPTOMS... (3*)[(Ritter Pharmaceuticals, Inc.)]
Mo1049. . . . DETERMINATION OF GLUTEN CONSUMPTION BY CELIAC... (3*)[ImmunogenX]
Mo1050. . . . IBS PATIENTS WITH REACTION TO WHEAT... (4*)
Mo1051. . . . MARKERS OF NON-CELIAC WHEAT SENSITIVITY IN... (2*)
Mo1052. . . . CONFOCAL ENDOMICROSCOPY (CLE) BASED DOUBLE BLIND... (4*)
Mo1053. . . . EFFECT OF KIWIFRUIT ON GASTROINTESTINAL SYMPTOMS... (3*)[Study funded and kiwifruit supplied by Zespri International Limited]
Mo1054. . . . EOSINOPHILIC ESOPHAGITIS FOLLOWING EXPOSURE TO BURN... (5*)
Mo1055. . . . ASSESSMENT OF GASTROINTESTINAL TOLERABILITY AND Fermentation... (3*)[(Bustar Alimentos SAPI de CV)]
Mo1056. . . . DIAGNOSIS OF LACTOSE MALABSORPTION BY THIRD... (1*)
Mo1057. . . . MORPHO-BIOCHEMICAL ACTIONS OF CIGARETTE SMOKE ON... (4*)
Mo1058. . . . EFFECTS OF EGFR AND COX PATHWAY... (4*)
Mo1059. . . . COMPARISON OF ENDOSCOPICALLY (EGD/COLO) PROCURED ENTEROIDS... (4*)
Mo1060. . . . CHARACTERIZATION OF GLYCOLIPIDS AND GLYCOPROTEINS FROM... (2*)
Mo1061. . . . GATA4 IS REQUIRED FOR BUDDING MORPHOGENESIS... (2*)
Mo1062. . . . THE EFFECTS OF NORMAL, METAPLASTIC, AND... (4*)
Mo1063. . . . NEUTRAL DRIFT DYNAMICS OF INTESTINAL STEM... (2*)
Mo1064. . . . DIFFERENTIAL ORIGINS OF TUFT CELLS IN... (2*)
Mo1065. . . . P21WAF1/CIP1 AND RNA BINDING PROTEIN MUSASHI-1... (2*)
Mo1066. . . . REGULATION OF CANCER STEM CELL POPULATION... (5*)
Mo1067. . . . DEVELOPMENT OF A NOVEL HYBRID TREATMENT... (4*)
Mo1068. . . . CHARACTERISTIC MEAL PATTERNS IN AGED MICE... (5*)
Mo1069. . . . ENTRY AND SURVIVAL OF WESTERN TYPE... (4*)
Mo1070. . . . MELATONIN REGULATES GASTRIC ENDOTHELIAL CELL FUNCTION... (2*)
Mo1071. . . . BUTYRATE AND PROTEOLYTIC BIOACTIVE FORM OF... (5*)
Mo1072. . . . INDIVIDUAL AMINO ACIDS DIFFERENTIALLY MEDIATE INTESTINAL... (4*)[(3)][(Entrinsic Health Solutions)]

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA AASLD, etc.)
Mo1073. . . . THE NOVEL 5-HT4 RECEPTOR AGONIST, DSP-6952,... (5*)

Mo1074. . . . HEPATIC ELECTRICAL STIMULATION AMELIORATES DELAYED GASTRIC... (2*)

Mo1075. . . . MOLECULAR BASIS FOR THE HIGH AFFINITY... (2*)

Mo1076. . . . DECREASED LEVEL OF NEUROPEPTIDE Y IS... (5*)

Mo1077. . . . FOOD ADDITIVES, DYBSIOIS, MICROBIAL HORIZONTAL GENE... (4*)

Mo1158. . . . RISK FACTORS AND OUTCOMES OF PATIENTS... (5*)

Mo1159. . . . DIFFERENCE BETWEEN THE UPPER AND THE... (5*)

Mo1160. . . . NATIONAL TREND OF EMERGENCY DEPARTMENT VISITS... (5*)

Mo1161. . . . A NOVEL RISK SCORE FOR ASSESSING... (5*)

Mo1162. . . . CIRRHOTIC PATIENTS WITH HEPATIC C HAVE... (5*)

Mo1163. . . . GASTROINTESTINAL BLEEDING IN PATIENTS ON NOVEL... (5*)

Mo1164. . . . RISK FACTORS FOR RECURRENT BLEEDING FROM... (5*)

Mo1165. . . . ASSOCIATION BETWEEN LOWER GASTROINTESTINAL SYMPTOMS, BOWEL... (5*)

Mo1166. . . . RISK FACTORS FOR 30-DAY RE-BLEEDING IN... (5*)

Mo1167. . . . INCIDENCE OF DIVERTICULAR BLEEDING: A POPULATION-BASED... (5*)

Mo1168. . . . MIR-222 REPRESSIONS INTESTINAL EPITHELIAL RESTITUTION AFTER... (2*)

Mo1169. . . . ROLE OF CFTR AND CLC-2 IN... (2*) (4)

Mo1170. . . . ROLE OF VASOACTIVE RENIN-ANGIOTENSIN METABOLITE ANGIOTENSIN1-7... (5*)

Mo1171. . . . FUNCTIONAL LOCALIZATION OF FFA2 TO THE... (2*)

Mo1172. . . . EFFECTS OF SMOKING AND BILE ACID... (2*)

Mo1173. . . . THE IMPACT OF ESOPHAGEAL MUCOSAL BARRIER... (1*)

Mo1174. . . . THE PSYCHOTROPIC AGENT WAS ONE OF... (1*)

Mo1175. . . . TOPICAL PROTECTION OF ESOPHAGEAL MUCOSA: IN... (1*)

Mo1176. . . . EFFECTIVENESS OF MISOPROSTOL FOR SMALL BOWEL... (5*)

Mo1177. . . . WALNUT PHENOLIC EXTRACTS ALLEVIATES MSAD-INDUCED GI... (5*)

Mo1178. . . . LYMPHOCYTIC ESOPHAGITIS REVISITED: STILL A HISTOLOGIC... (5*)

Mo1179. . . . PREVENTION OF RECURRENT IDIOPATHIC GASTRODUODENAL ULCER... (2*)

Mo1180. . . . MACHINE LEARNING TO PREDICT OUTCOMES IN... (5*)

Mo1181. . . . ACUTE GASTROINTESTINAL BLEEDING AMONG PATIENTS ON... (5*)

Mo1182. . . . IMPACT OF HOSPITAL VOLUME ON MORTALITY,... (5*)

Mo1183. . . . EPIDEMIOLOGY AND RISK FACTORS OF UPPER... (5*)

Mo1184. . . . SIMILAR EFFICACY OF ACID SUPPRESSANTS AND... (3*) (The study was sponsored by Korea Otsuka Pharmaceutical Co., Ltd.)

Mo1185. . . . RECENT TRENDS IN PERFORMANCE OF EARLY... (5*)

Mo1186. . . . RISK FACTORS FOR GASTROINTESTINAL BLEEDING AMONG... (2*) (4)

Mo1187. . . . RESTRICTIVE VS. LIBERAL TRANSFUSIONS STRATEGY IN... (5*)

Mo1188. . . . REBLEEDING IN PEPTIC ULCER BLEEDING —... (4*)

Mo1189. . . . EXTERNAL VALIDATION OF THE INTERNATIONAL BLEEDING... (5*)

Mo1190. . . . PROTON PUMP INHIBITORS DECREASE UPPER GASTROINTESTINAL... (5*)

Mo1191. . . . BEVACIZUMAB AS TREATMENT OF BLEEDING IN... (5*)

Mo1192. . . . NO ADVANTAGE OF SCREENING WITH ROTEM®... (1*)

Mo1193. . . . SHOULD WE USE THE COMPOSITE SCORE... (5*)

Mo1194. . . . NATURAL HISTORY OF GASTRIC ULCER IN... (5*)

Mo1195. . . . EFFECT OF A NEW PPTENT ACID... (5*)

Mo1196. . . . HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH... (5*)

Mo1197. . . . ENDOSCOPIC EVALUATION OF UPPER GASTROINTESTINAL MUCOSAL... (4*)

Mo1198. . . . FRAILTY AND AIM65 SCORE PREDICT MORTALITY... (5*)

Mo1199. . . . TREATMENT OF ACUTE UPPER GASTROINTESTINAL BLEEDING:... (4*) (3) (PHARMACOSMOS)

Mo1200. . . . FACTORS IMPACTING 30 DAY REBLEEDING RATE... (5*)

Mo1201. . . . COMPARING MORTALITY RATE IN NON-VARICEAL UPPER... (5*)

Mo1202. . . . ONCE VERSUS TWICE DAILY ORAL PROTON... (5*)

Mo1203. . . . PREDICTORS OF INPATIENT HOSPITAL MORTALITY FOR... (5*)

Mo1204. . . . TREND OF MORTALITY IN NON-VARICEAL UPPER... (4*)

Mo1205. . . . GASTRIC ANTRAL VASCULAR ECTASIA WITH AND... (5*)

Mo1206. . . . ASSESSING THE PROGNOSTIC VALIDITY OF THE... (4*)

Mo1207. . . . CHALLENGING THE CURRENT CRITERIA FOR PROPHYLACTIC... (5*)

Mo1208. . . . EVEN IF SMALL SIZE LESS THAN... (5*)

Mo1209. . . . ANTIPROLIFERATIVE EFFECT OF ABOVE-LABEL DOSES OF... (5*)

Mo1210. . . . NCX PROMOTES GASTRIC CANCER PROLIFERATION VIA... (2*)

Mo1222. . . . FREQUENCY OF CARE FRAGMENTATION AND ITS... (5*)

Mo1223. . . . TRENDS OF POST-ENDOSCOPIC RETROGRADE

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
CHOLANGIOPANCREATOGRAPHY IN… (5*)
Mo1244. . . . EPIDEMIOLOGY OF DEEP VENOUS THROMBOSIS AFTER… (5*)
Mo1225. . . . IL-6 SIGNIFICANTLY IMPROVES PREDICTIVE VALUE OF… (4*)
Mo1226. . . . COMPARISON OF RISK FACTORS FOR POST-ERCP… (5*)
Mo1227. . . . SIRS IS A PROGNOSTIC INDICATOR FOR… (5*)
Mo1228. . . . IODINE MAPPING ON DUAL ENERGY CT… (5*)
Mo1229. . . . PORTOSPLENOBILARYVEINS: ARE THEY A CONTRIBUTOR TO… (5*)
Mo1230. . . . OPIATES IN ACUTE PANCREATITIS: MORE HARM… (4*)
Mo1231. . . . NORMAL SALINE VERSUS LACTATED RINGER’S SOLUTION… (5*)
Mo1232. . . . WHY ARE WE PERFORMING FEWER CHOLECYSTECTOMIES… (5*)
Mo1233. . . . UTILIZATION OF TUBE FEEDINGS IN ACUTE… (5*)
Mo1234. . . . RECENT TRENDS OF INCIDENCE AND HEALTH… (5*)
Mo1235. . . . ARE ACUTE PANCREATITIS SEVERITY OUTCOMES PREDESTINED… (5*)
Mo1236. . . . INCIDENCE OF ACUTE PANCREATITIS WITH THE… (5*)
Mo1237. . . . RAPID URINARY TRYPsinogen TEST IN EARLY… (5*)
Mo1238. . . . ENDOSCOPIC ULTRASOUND (EUS) AND SECRETIN ENDOSCOPY… (5*)
Mo1239. . . . RISK FACTOR FOR STEATORRHEA IN PEDIATRIC… (2*)
Mo1240. . . . SPATIAL DISTRIBUTION OF PANCREATIC STONES IN… (2*)
Mo1241. . . . DIABETES IN CHILDREN WITH ACUTE RECURRENT… (2*) [Supported by NIH R21DK096327, U01 DK108334, CTSA2UL1TR000442 and REDCap]
Mo1242. . . . LONG-TERM OUTCOME AND FACTORS OF RECURRENT… (5*)
Mo1243. . . . INCIDENCE AND PREDICTORS OF 30-DAY READMISSIONS… (5*)
Mo1244. . . . NUTRITIONAL STATUS ASSESSMENT BY BIOELECTRICAL IMPEDANCE… (2*)
Mo1245. . . . EFFECT OF CREON THERAPY ON EXOCRINE… (3*) AbbVie, Inc.)
Mo1246. . . . PERIOD PREVALENCE OF CHRONIC PANCREATITIS IN… (5*)
Mo1247. . . . INCIDENCE AND SIGNIFICANCE OF BILIARY STRICUTURE… (5*)
Mo1248. . . . ACUTE PANCREATITIS IN YOUNG POPULATION …(5*)
Mo1249. . . . PROFILES OF DISEASE IN CHRONIC PANCREATITIS… (2*) (NIH)
Mo1250. . . . RISK OF PANCREATIC CANCER IN PATIENTS… (2*)
Mo1251. . . . PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY IN… (3*) AbbVie, Inc.)
Mo1252. . . . NATIONAL TRENDS, RATE AND PREDICTORS OF… (5*)
Mo1253. . . . RISK FACTORS OF RECURRENT ACUTE PANCREATITIS… (5*)
Mo1254. . . . ANALYSIS OF CHRONIC PANCREATITIS IN A… (3*) (5*) (MYLAN through a educational non-restricted grant to develop the Project)
Mo1255. . . . CHRONIC PANCREATITIS QUALITY INDICATORS: IMPROVING QUALITY… (5*)
Mo1256. . . . THE ROLE OF EUS AND MRI… (5*)
Mo1257. . . . ANNUAL PANCREAS IS ASYMPOMATIC IN HALF… (5*)
Mo1258. . . . A META-ANALYSIS AND SYSTEMATIC REVIEW: EFFECT… (5*)
Mo1259. . . . DIAGNOSTIC ACCURACY OF MRI/MRCP IN DETECTING… (5*)
Mo1260. . . . THE RELATIONSHIP OF QUANTITATIVE HEPATITIS B… (2*) (3*) Roche supplies the laboratory kits.)
Mo1261. . . . SIGNIFICANT DECLINE IN HEPATITIS C VIRUS… (5*)
Mo1262. . . . AN ALGORITHMIC APPROACH TO DIAGNOSE CIRRHOSIS… (5*)
Mo1263. . . . SIGNIFICANTLY LOWER RATES OF HEPATITIS B… (3*) (Gilead Sciences FOCUS Grant)
Mo1264. . . . HIGHER ALT LEVELS AMONG PAKISTANI HCV… (5*)
Mo1265. . . . ACUTE LIVER FAILURE CAUSED BY HEPATITIS… (5*)
Mo1266. . . . ACUTE HEPATITIS E AND RIBAVIRIN TREATMENT… (5*)
Mo1267. . . . VITAMIN D DEFICIENCY IS NOT ASSOCIATED… (5*)
Mo1268. . . . COMPARATIVE ANALYSIS OF CLINICAL OUTCOMES FOR… (5*)
Mo1269. . . . USING LONGITUDINAL PREDICTION MODELS TO EVALUATE… (2*)
Mo1270. . . . A RETROSPECTIVE ANALYSIS OF PEGYLATED-INTERFERON (PEG-IFN)… (5*)
Mo1271. . . . IS TREATMENT OF HEPATITIS C WITH... (5*)
Mo1272. . . . AWARENESS RATE OF HEPATITIS C WITH… (5*)
Mo1273. . . . AWARENESS RATE OF CHRONIC VIRAL HEPATITIS… (5*)
Mo1274. . . . SIGNIFICANT REDUCTION OF MAC-2 BINDING PROTEIN… (5*)
Mo1275. . . . HOW OFTEN DOES HEPATIC DECOMPENSATION OR… (6*)
Mo1276. . . . DIAGNOSIS AND EVALUATION OF LIVER AMYLOIDOSIS… (5*)
Mo1277. . . . MITOPHAGY AND OXIDATIVE STRESS IN EARLY… (2*)
Mo1278. . . . MICRORNA-378 IS ASSOCIATED WITH HEDGEHOG-DEPENDENT EPITHELIAL-TO-MESENCHYMAL… (2*)
Mo1279. . . . SOX9EGFP EXPRESSION ASSESSMENT BY BIOELECTRICAL IMPEDANCE… (5*)
Mo1280. . . . A RETROSPECTIVE ANALYSIS OF PEGYLATED-INTERFERON (PEG-IFN)… (5*)
Mo1281. . . . USING LONGITUDINAL PREDICTION MODELS TO EVALUATE… (2*)
Mo1282. . . . AWARENESS RATE OF HEPATITIS C WITH… (5*)
Mo1283. . . . AWARENESS RATE OF CHRONIC VIRAL HEPATITIS… (5*)
Mo1284. . . . MITOPHAGY AND OXIDATIVE STRESS IN EARLY… (2*)
Mo1285. . . . DIAGNOSIS AND EVALUATION OF LIVER AMYLOIDOSIS… (5*)
Mo1286. . . . MITOPHAGY AND OXIDATIVE STRESS IN EARLY… (2*)
Mo1287. . . . MICRORNA-378 IS ASSOCIATED WITH HEDGEHOG-DEPENDENT EPITHELIAL-TO-MESENCHYMAL… (2*)
Mo1288. . . . SOX9EGFP EXPRESSION LEVELS MARK DISTINCT POPULATIONS… (7*) (2)
Mo1289. . . . EVALUATION OF PATIENTS HOSPITALIZED WITH HEPATIC… (5*)
Mo1290. . . . ESOPHAGEAL MOTILITY AND HIATUS FUNCTION IN… (2*)
Mo1291. . . . SIGNS AND SYMPTOMS OF PANCREATIC STONES IN… (2*)
Mo1292. . . . PERIOD PREVALENCE OF CHRONIC PANCREATITIS IN… (5*)
Mo1293. . . . INCIDENCE AND PREDICTORS OF 30-DAY READMISSIONS… (5*)
Mo1294. . . . NUTRITIONAL STATUS ASSESSMENT BY BIOELECTRICAL IMPEDANCE… (2*)
Mo1295. . . . CHRONIC PANCREATITIS QUALITY INDICATORS: IMPROVING QUALITY… (5*)
Mo1296. . . . THE ROLE OF EUS AND MRI… (5*)
Mo1297. . . . ANNUAL PANCREAS IS ASYMPOMATIC IN HALF… (5*)
Mo1298. . . . A META-ANALYSIS AND SYSTEMATIC REVIEW: EFFECT… (5*)
Mo1299. . . . DIAGNOSTIC ACCURACY OF MRI/MRCP IN DETECTING… (5*)
Mo1300. . . . THE RELATIONSHIP OF QUANTITATIVE HEPATITIS B… (2*) (3*) Roche supplies the laboratory kits.)
Mo1555. . . . THE VAGAL RESPONSE TO DOPAMINE IN... (2*)(4)
Mo1556. . . . THE IN VIVO AND IN VITRO... (2*)(4)
Mo1557. . . . CYCLICAL VOMITING SYNDROME: NATIONAL TRENDS AND... (5*)
Mo1558. . . . CHANGES IN PSYCHOLOGICAL PROCESSES THROUGHOUT ANORECTAL... (5*)
Mo1559. . . . CONDITIONED PAIN MODULATION IN PAINFUL FUNCTIONAL... (2*)(4)
Mo1560. . . . CENTRAL GLP-1 RECEPTORS ARE DIFFERENTIALLY INVOLVED... (2*)
Mo1561. . . . UNDERSTANDING THE INTERRELATIONSHIPS BETWEEN SLEEP DISTURBANCE,... (3*) Prometheus Laboratories]
Mo1562. . . . ATOPY AND AUTOIMMUNE DISEASES ARE LINKED... (3*) Prometheus Laboratories]
Mo1563. . . . TRANSCUTANEOUS NEUROMODULATION IMPROVES IMPAIRED RECTAL SENSATION... (5*)
Mo1564. . . . TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION ENHANCES POSTOPERATIVE RECOVERY... (5*)
Mo1565. . . . PREVENTIVE EFFECTS OF TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION... (5*)
Mo1566. . . . COLONIC STOOL BURDEN A USEFUL SURROGATE... (5*)
Mo1567. . . . OUTCOME RADAR PLOTS OF AGGREGATED DATA... (5*)
Mo1568. . . . THE NOVEL 5-HT4 RECEPTER AGONIST, DSP-6952,... (3*)
Mo1569. . . . CHRONIC CONSTIPATION PATIENTS WITH... (5*)
Mo1570. . . . METHANOGENESIS IS ASSOCIATED WITH DELAYED COLONIC... (5*)
Mo1571. . . . SAFETY OF NALDEMINE FOR THE TREATMENT... (3*) Shionogi, Inc.)
Mo1572. . . . ACTIVATION OF THE CYSTIC FIBROSIS TRANSMEMBRANE... (5*)
Mo1573. . . . PATTERNS OF PHARMACOTHERAPY IN PATIENTS WITH... (3*)(This study was funded by Shire Human Genetic Therapies, Inc. Medical writing support was provided by Laura Knapp Ph.D. of PharmaGenesis London, London, UK, with funding from Shire.)
Mo1574. . . . THE ECONOMIC BURDEN OF CHRONIC IDIOPATHIC... (3*) This study was funded by Shire Human Genetic Therapies, Inc. Medical writing support was provided by Laura Knapp Ph.D. of PharmaGenesis London, London, UK, with funding from Shire.)
Mo1575. . . . PHYSIOLOGIC MANIFESTATIONS OF ANXIETY IN PATIENTS... (5*)
Mo1576. . . . BILE ACID SEQUESTRANTS AS MAINTENANCE THERAPY... (5*)
Mo1577. . . . BREATH HYDROGEN SULFIDE DOES NOT CORRELATE... (6*)
Mo1578. . . . THE EFFECT OF A G-PROTEIN BIASED... (2*)
Mo1579. . . . INVESTIGATION OF SMALL BOWEL LUMINAL PH... (5*)
Mo1580. . . . REGULATION OF ENTERIC NERVOUS SYSTEM VIA... (2*)
Mo1581. . . . RELATIONSHIP BETWEEN AGE, BODY MASS INDEX,... (5*)
Mo1582. . . . CHRONIC CONSTIPATION RESPONDERS TO LUBIPROSTONE DEMONSTRATE... (5*)
Mo1583. . . . NON-INVASIVE MEDICAL DEVICE FOR THE TREATMENT... (3*) GI Therapies)
Mo1584. . . . PREDICTORS FOR COLONIC MANOMETRY OUTCOME RELATED... (4*)
Mo1585. . . . PERTURBING THE GUT MICROBIOTA IN MICE... (2*)
Mo1586. . . . PHOX2B-POSITIVE CELLS ARISE INDEPENDENTLY OF PRE-EXISTING... (2*)(4)
Mo1587. . . . CONDITIONAL ABLATION OF PTEN IN GLIA... (4*)
Mo1588. . . . ENTERIC GLIAL CELL PLASTICITY: ASTROCYTES, SCHWANN... (4*)
Mo1589. . . . CRE/loxP-MEDIATED INDUCIBLE ACTIVATION OF IKK2 IN... (2*)
Mo1590. . . . PURINERGIC SIGNALING IN ENTERIC GLIA CELLS... (2*)
Mo1591. . . . A NEW MOTILITY TOOL: HIGH CONCORDANCE... (3*)(G-Tech Medical Inc.)
Mo1592. . . . FREQUENCY SPECTRA FROM 72 HOUR EXTERNAL... (3*) G-Tech Medical, Inc)
Mo1593. . . . RECOGNITION OF THE DOMINANT ROLE... (5*)
Mo1594. . . . THE ROLE OF PIEZO2 MECHANOSENSITIVE ION... (2*)(7) (NIH K08 (DK106456) R01 (DK52766) P30 (DK094567) AGA Research Scholar Award (RSA)
Mo1595. . . . BASELINE NEUROMUSCULAR ASSESSMENT OF PATIENTS... (5*)
Mo1596. . . . EFFECT OF RESOLVIN D1, D2 AND... (4*)
Mo1597. . . . TARGETING THE SERINE PROTEASE PATHWAY IN... (4*)(2)
Mo1598. . . . UNCOMPlicated DIVERTICULAR DISEASE PATIENTS SHOW COLONIC... (4*)
Mo1599. . . . ABDOMINAL PAIN IN HYPERMOBILITY-TYPE EHLERS DANLOS... (2*)
Mo1600. . . . ENFB2 LIGAND AS KEY PLAYER IN... (2*)
Mo1601. . . . EXPRESSION OF PIEZO2 IN THE DISTAL... (2*)
Mo1602. . . . ROLE OF TRKB.T1 IN COLITIS-INDUCED REFERRED... (2*)
Mo1603. . . . DELTA OPIOID RECEPTOR ACTIVATION TRIGGERS BOTH... (6*)
Mo1604. . . . COLONIC PROTEASES EVOKE SUSTAINED PAIN SIGNALING... (2*)
Mo1605. . . . MULTIPLE TETRODOTOXIN-SENSITIVE VOLTAGE GATED NAV1 CHANNELS... (2*)
Mo1606. . . . INFLUENCE OF VARYING QUANTITATIVE FECAL IMMUNOCHEMICAL... (2*)
Mo1607. . . . ORGANIZATION OF COLONOSCOPY FOLLOW-UP OF POSITIVE... (2*)
Mo1608. . . . RE-THINKING THE RE-PREP: ATTITUDES TOWARDS NON-INVASIVE... (4*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Abstract Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>* = Primary Source</td>
</tr>
</tbody>
</table>

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCF, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1805. . . . IDENTIFYING UNMET NEEDS IN PATIENTS WITH... (6*)
Mo1806. . . . HEIGHTENED PSYCHOLOGICAL STRESS AND HYPOTHALAMIC-PITUITARY-ADRENAL AXIS... (4*)(2)
Mo1807. . . . THE SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE... (5*)
Mo1808. . . . IMPROVEMENTS IN SUBCOMPONENTS OF THE INFLAMMATORY... (3*)(Financing was provided by Takeda Pharmaceutical Company Ltd.)
Mo1809. . . . DISORDERED EATING, BODY DISSATISFACTION, AND PSYCHOLOGICAL... (4*)
Mo1810. . . . LOWER SOCIOECONOMIC STATUS IS ASSOCIATED WITH... (5*)
Mo1811. . . . POST HOC ANALYSIS OF THE IMPACT... (3*)(Janssen Scientific Affairs, LLC, Horsham, PA; US; Janssen Research & Development, LLC, Malvern, PA)
Mo1812. . . . PREVALENCE AND RISK FACTORS FOR MALE... (5*)
Mo1813. . . . HOW FOOD RELATED QUALITY OF LIFE... (5*)
Mo1814. . . . INCIDENCE OF SUICIDE IN INFLAMMATORY BOWEL... (5*)
Mo1815. . . . VALIDATION OF THE GAINING RESILIENCE THROUGH... (4*)
Mo1816. . . . THE USE OF SLEEP ACTIGRAPHY DIFFERENTIATES... (5*)
Mo1817. . . . THE PSYCHO-EMOTIONAL EXPERIENCE OF PREGNANCY IN... (6*)
Mo1818. . . . PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE... (3*)
Mo1819. . . . SPECIALIZED PRECONCEPTION AND PREGNANCY IBD CLINIC... (4*)
Mo1820. . . . THE ASSOCIATION OF JOINT EXTRA-INTESTINAL MANIFESTATIONS... (5*)
Mo1821. . . . POOR SLEEP QUALITY IS A RISK... (5*)
Mo1822. . . . INCREASED ANXIETY AND DEPRESSION IN PATIENTS... (4*)
Mo1823. . . . HIGH PATIENT ACTIVATION IS ASSOCIATED WITH... (6*)(2)
Mo1824. . . . SECULAR TRENDS IN PERCEPTIONS OF ANTI-TNF... (5*)
Mo1825. . . . PATTERNS OF USE OF PSYCHOTROPIC AND... (6*)(2)
Mo1826. . . . SUBSTANCE ABUSE IS ASSOCIATED WITH HIGH... (5*)
Mo1827. . . . FIRST STEP TOWARDS VALIDATION OF THE... (3*)
Mo1828. . . . SHARED DECISION MAKING AND HEALTH LOCUS... (5*)
Mo1829. . . . THE IMPACT OF SERUM CORTISOL ON... (2*)
Mo1830. . . . SLEEP FRAGMENTATION MEASURED BY WEARABLE DEVICE... (3*)
Mo1831. . . . CHRONIC FATIGUE IN PATIENTS WITH INFLAMMATORY... (5*)
Mo1832. . . . BASELINE LEVEL OF INTEGRIN A4B7 ON... (6*)
Mo1833. . . . THE INITIAL TROUGH CONCENTRATION AT 36... (5*)
Mo1834. . . . POSITIVE PHARMACOKINETIC EFFECT OF AZATHIOPRINE CO-MEDICATION... (4*)(5)
Mo1835. . . . SOLUBLE MADCAM-1 AND RETINOIC ACID ARE... (5*)
Mo1836. . . . VEDOLIZUMAB TROUGH LEVELS AT WEEK 6... (1*)
Mo1837. . . . ULTRASONOGRAPHIC RESPONSE TO ANTI-TNF AS POTENTIAL... (5*)
Mo1838. . . . PHARMACOKINETIC DASHBOARD-DRIVEN INFLIXIMAB DOSING IN IBD-A... (4*)(3)(Prometheus provided the therapeutic drug monitoring assays at no cost)
Mo1839. . . . LONG-TERM PREDICTION OF INFLIXIMAB RESPONSE USING... (4*)(6)
Mo1840. . . . BENEFIT OF COMBINATION THERAPY WITH INFLIXIMAB... (5*)
Mo1841. . . . INFLIXIMAB EXPOSURE PREDICTS SUPERIOR ENDOSCOPIC OUTCOMES... (3*)(5)(This investigator-funded study was financially supported by Merck Sharp & Dome and Janssen, which also provided IFX study drug. Buhlmann laboratories, Switzerland, kindly provided materials for Quantum Blue rapid measurements of fecal calprotectin.)
Mo1842. . . . CLINICAL EXPERIENCE WITH VEDOLIZUMAB TROUGH LEVELS... (5*)
Mo1843. . . . NON-MEDICAL MANDATORY REVERSED AND BACK AND... (2*)
Mo1844. . . . DRUG SURVIVAL AND IMMUNONGENICITY AFTER SWITCHING... (5*)
Mo1845. . . . HIGHER SERUM CONCENTRATIONS OF VEDOLIZUMAB ARE... (3*)(Financial support by Takeda)
Mo1846. . . . ADAPTIVE DOSING DURING INFLIXIMAB INDUCTION THERAPY... (5*)
Mo1847. . . . REACTIVE DOSE ESCALATION OF INFLIXIMAB IN... (3*)(5)(This investigator-initiated trial was financially supported by Merck Sharp Dome and Janssen, which also provided IFX study drug. Buhlmann laboratories, Switzerland, kindly provided materials for Quantum Blue rapid measurements of fecal calprotectin.)
Mo1848. . . . PROACTIVE INFLIXIMAB MONITORING FOLLOWING REACTIVE TESTING... (2*)
Mo1849. . . . INDUCTION TREATMENT WITH SUBCUTANEOUS RATHER THAN... (5*)
Mo1850. . . . LOWER NEED FOR ADALIMUMAB DOSE INTENSIFICATION... (5*)
Mo1851. . . . A MODEL UTILIZING WEEK 6 INFLIXIMAB... (3*)
Mo1852. . . . FECAL CALPROTECTIN AFTER 3 MONTHS OF... (5*)
Mo1853. . . . CHARACTERIZATION OF INFLAMMATORY PHENOTYPES IN PLASMA... (4*)(3)(Takeda Pharmaceutical)
Mo1854. . . . PHARMACIST-LED PROACTIVE THERAPEUTIC DRUG MONITORING WITH... (4*)(3)(Bühlmann Laboratories provided the rapid assay cassettes in kind.)
Mo1855. . . . CERTOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN... (5*)

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA AASLD, etc.)
# Abstracts

<table>
<thead>
<tr>
<th>Abstract Title</th>
<th>Authors and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mo1856. CLINICAL FEASIBILITY OF DRIED BLOOD SAMPLING...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1857. VEDOLIZUMAB LEVELS DURING INDUCTION ARE ASSOCIATED...</td>
<td>(3*) [(Prometheus Laboratories)]</td>
</tr>
<tr>
<td>Mo1858. CONTINUING USE OF COMBINATION THERAPY IS...</td>
<td>(6*) Crohn's and Colitis Canada</td>
</tr>
<tr>
<td>Mo1859. EARLY INITIATION OF ANTI-TNF IS ASSOCIATED...</td>
<td>(4*)</td>
</tr>
<tr>
<td>Mo1860. HIGH FECAL AND SERUM TUMOR NECROSIS...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1861. LONG-TERM SAFETY OF ADALIMUMAB IN PATIENTS...</td>
<td>(3*) [AbbVie Inc.]</td>
</tr>
<tr>
<td>Mo1862. OUTCOMES OF DOSE ESCALATION AND DRUG...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1863. MULTIPLE ASCENDING DOSE, OPEN-LABEL, PHASE 2-Jan...</td>
<td>(3*) [EA Pharma Co., Ltd.]</td>
</tr>
<tr>
<td>Mo1864. OBESITY AND RESPONSE TO INFlixIMAB IN...</td>
<td>(7*)</td>
</tr>
<tr>
<td>Mo1865. USTEKINUMAB INDUCES CLINICAL AND BIOLOGICAL REMISSION...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1866. IMMUNOSUPPRESSIVE AND ANTI-TNF TREATMENT IS ASSOCIATED...</td>
<td>(4*)</td>
</tr>
<tr>
<td>Mo1867. SHORTER DISEASE DURATION IS ASSOCIATED WITH...</td>
<td>(3*) [(Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals U.S.A, Inc.)</td>
</tr>
<tr>
<td>Mo1868. MEDIUM TO LONG TERM OUTCOMES IN...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1869. SWITCHING FROM INFlixIMAB ORIGINATOR TO A...</td>
<td>(6*)</td>
</tr>
<tr>
<td>Mo1870. RISK OF CMV REACTIVATION IN UC...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1871. DIRECT COSTS OF CARE AMONG PATIENTS...</td>
<td>(3*) [(6)] [Janssen Canada Crohn’s and Colitis Canada]</td>
</tr>
<tr>
<td>Mo1872. ADALIMUMAB PERSISTENCE AT 1 YEAR IS...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1873. EFFICACY OF INFlixIMAB AFTER FAILURE OF...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1874. LOSS OF RESPONSE TO ANTI-TUMOR NECROSIS...</td>
<td>(6*)</td>
</tr>
<tr>
<td>Mo1875. EFFICACY OF USTEKINUMAB IN PATIENTS WITH...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1876. COMBINATION THERAPY WITH INFlixIMAB AND AN...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1877. ADALIMUMAB SHORT TERM DOSE INTENSIFICATION WITH...</td>
<td>(3*) Abbvie</td>
</tr>
<tr>
<td>Mo1878. A ‘REAL WORLD’ RETROSPECTIVE MULTICENTRE STUDY...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1879. VEDOLIZUMAB[VDZ] REAL WORLD OUTCOMES IN ULCERATIVE...</td>
<td>(3*) [Takeda Pharmaceuticals Australia]</td>
</tr>
<tr>
<td>Mo1880. USTEKINUMAB INDUCES LIMITED MUCOSAL HEALING AFTER...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1881. VEDOLIZUMAB IS EFFECTIVE AND SAFE TO...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1882. VEDOLIZUMAB DOES NOT AFFECT INFLUENZA VACCINE...</td>
<td>(4*)</td>
</tr>
<tr>
<td>Mo1883. IS THERE A DIFFERENCE IN ADALIMUMAB...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1884. DRUG SURVIVAL OF VEDOLIZUMAB-TREATED INFLAMMATORY BOWEL...</td>
<td>(4*) [(3)] [Unrestricted grant from Takeda]</td>
</tr>
<tr>
<td>Mo1885. TREATMENT PATTERNS OF ANTI-TUMOR NECROSIS FACTOR...</td>
<td>(3*) Genentech</td>
</tr>
<tr>
<td>Mo1886. BEYOND THE BIG PICTURE: CAN MACRONUTRIENTS...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1887. SAFETY,EFFICACY AND PHARMACOKINETICS OF VEDOLIZUMAB IN...</td>
<td>(4*)</td>
</tr>
<tr>
<td>Mo1888. INFlixIMAB SALVAGE THERAPY IN ACUTE SEVERE...</td>
<td>(2*)</td>
</tr>
<tr>
<td>Mo1889. THE RESPONSE TO VEDOLIZUMAB IN CHRONIC...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1890. EFFECTS OF PRE-OPERATIVE USE OF BIOLOGIC...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1891. HYPOALBUMINEMIA AND BANDEMA PREDICT FAILURE OF...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1892. CLINICAL EFFECTIVENESS OF VEDOLIZUMAB: INTERIM ANALYSIS...</td>
<td>(3*) [The study was financially supported by Takeda.]</td>
</tr>
<tr>
<td>Mo1893. CLINICAL CHARACTERISTICS AND COMPLICATIONS IN HOSPITALISED...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1894. CLINICAL EFFECTIVENESS OF VEDOLIZUMAB: INTERIM ANALYSIS...</td>
<td>(3*) [The study was financially supported by Takeda.]</td>
</tr>
<tr>
<td>Mo1895. RATES OF RECURRENT ANTI-TNF TREATMENT INEFFECTIVENESS...</td>
<td>(6*) [Crohn’s and Colitis Canada Janssen Canada]</td>
</tr>
<tr>
<td>Mo1896. USTEKINUMAB FOR CROHN’S DISEASE: A NATIONWIDE...</td>
<td>(4*)</td>
</tr>
<tr>
<td>Mo1897. SAFETY AND EFFICACY OF BIOLOGIC THERAPIES...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1898. THE SAFETY OF BIOLOGIC THERAPY FOR...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1899. JOINT PAIN IN PATIENTS WITH INFLAMMATORY...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1900. VEDOLIZUMAB FOR THE TREATMENT OF POUCHITIS...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1901. REAL WORLD OUTCOMES OF VEDOLIZUMAB FOR...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1902. NON-ADHERENCE OF IBD MEDICATIONS AND DISEASE...</td>
<td>(2*)</td>
</tr>
<tr>
<td>Mo1903. PATERNAL DISEASE ACTIVITY IS ASSOCIATED WITH...</td>
<td>(6*)</td>
</tr>
<tr>
<td>Mo1904. LONG-TERM OUTCOMES OF IMMUNOSUPPRESSION-NAIVE STEROID RESPONDERS...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1905. DISCONTINUATION OF 5-AMINOSALICYLATES AFTER STARTING BIOLOGIC...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1906. THE EFFECTS OF VAGUS NERVE STIMULATION...</td>
<td>(3*) [SetPoint Medical l, Inc.]</td>
</tr>
<tr>
<td>Mo1907. 6-THIOGUANINE NUCLEOTIDE LEVELS ARE ASSOCIATED WITH...</td>
<td>(2*)</td>
</tr>
<tr>
<td>Mo1908. EARLY PREDICTION OF STEROID FAILURE IN...</td>
<td>(4*)</td>
</tr>
<tr>
<td>Mo1909. IS THERE STILL A ROLE FOR...</td>
<td>(6*) [Crohn’s and Colitis Canada]</td>
</tr>
<tr>
<td>Mo1910. GAINING RESILIENCE THROUGH TRANSITIONS IN IBD...</td>
<td>(4*)</td>
</tr>
<tr>
<td>Mo1911. HIGHER VITAMIN D LEVELS CORRELATE WITH...</td>
<td>(5*)</td>
</tr>
<tr>
<td>Mo1912. RESCUE TREATMENT WITH TACROLIMUS IN PATIENTS...</td>
<td>(5*)</td>
</tr>
</tbody>
</table>

---

Abstract Funding Source Key

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1971. . . . CROSSTALK BETWEEN
CEACAM AND TGF-β SIGNALLING... (2*)
Mo1972. . . . SERUM BIOMARKERS FOR
DETECTION OF GASTRIC... (2*)
Mo1973. . . . CIRCULATING TUMOR DNA
TO ASSESS CHARACTERISTICS... (3*)
Mo1974. . . . SUPERRENHANCERS IN
CHOLANGIOCARCINOMA ... (5*)
Mo1975. . . . TUBULAR ADENOMAS
HAVE GREATER GLOBAL DNA... (4*)
Mo1976. . . . TUMOR MUTATIONAL
BURDEN AS A NOVEL... (2*)
Mo1977. . . . LYMPHOCYTE-C-REACTIVE
PROTEIN RATIO AS A NEW... (5*)
Mo1978. . . . COMPREHENSIVE
ANALYSIS OF METHYLATION FIELD
DEFECT... (6*)|(2)
Mo1979. . . . TISSUE AND SERUM PD-L1
EXPRESSION AS... (5*)
Mo1980. . . . LOW-DOSE
ACETYLSALICYLIC ACID AND RISK OF...
(6*)[(This study was supported in part by
Fundación Instituto Teófilo Hernando
(Universidad Autónoma de Madrid).
BIFAP is funded and managed by the
AEMPS)]
Mo1981. . . . A NOMOGRAM TO
PREDICT LYMPH NODE... (2*)|(4)
Mo1982. . . . ASPIRIN EFFECT ON POLYP
RECURRENCE DEPENDS... (5*)
Mo1983. . . . THE EFFECT OF
HeliCOBacter PYlori ON...
(5*)
Mo1984. . . . A SCAVENGER OF
BIFUNCTIONAL ELECTROPHILES
REDUCES... (2*)|(4)
Mo1985. . . . EVALUATION OF THE
INHIBITORY EFFICACY AND...
(5*)
Mo1986. . . . CHEMOPREVENTION OF
AZOXYMETHANE-INDUCED COLON
CARCINOGENESIS BY... (2*)|(The study was supported in part by Florida Bank
Head Coley and DAVOS Life Sciences,
Singapore grants.)
Mo1987. . . . RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED
IMMUNOPREVENTION TRIAL WITH...
(2*)
Mo1988. . . . METFORMIN PREVENTS
KRAS-MUTANT PANCREATIC DUCTAL
ADENOCARCINOMA... (2*)|(6)
Mo1989. . . . γ-MANGOSTIN, A
NATURAL XANTHONE DERIVATIVE
TARGETS... (4*)
Mo1990. . . . IDO1 INHIBITOR
EPACODOSTAT PROMOTES ANTI-
TUMOR IMMUNITY... (2*)|(7)[(Incyte
Corp.)]
Mo1991. . . . PHARMACOLOGIC
INHIBITION OF INTEGRIN ανβ6
CAUSES... (2*)|(6)
Mo1992. . . . HDAC6 IS A NOVEL
REGULATOR OF... (2*)
Mo1993. . . . DEPTOR, A NOVEL TARGET
OF WNT/β-CATENIN/C-MYC,... (2*)
Mo1994. . . . EMU OIL IMPROVES
CLINICAL INDICATORS OF... (2*)|(4)
Mo1995. . . . CANCER PREVENTIVE
EFFECT OF TRAIL BY...
(5*)
Mo1996. . . . IDENTIFICATION OF 5-FU
RESISTANCE-RELATED MICRORNAs
IN... (4*)|(5)|(Grants-in-Aid for Scientific
Research from Japan Society for the
Promotion of Science)
Mo1997. . . . PER-PROCEDURE
TRIDIMENTIONAL HIGH RESOLUTION
ESOPHAGEAL MANOMETRY...
(5*)
Mo1998. . . . WATER EXCHANGE
COLONOSCOPY SIGNIFICANTLY
INCREASED,...
(5*)
Mo1999. . . . DEVELOPMENT OF AN
UPDATED SCORE CHART...
(5*)
Mo2000. . . . CHOOSING THE RIGHT
THROUGH-THE-SCOPE CLIP: A...
(5*)
Mo2001. . . . ENDOSCOPIC
ULTRASOUND VERSUS COMPUTED
IMPROVED SYMPTOMS AND...
(4*)|(2)
Mo2002. . . . AN ELECTRONIC-NOSE
DEVICE HAS FAIR ABILITY...
(1*)
Mo2003. . . . SAFETY OF
TRANSESOphAGEAL
ECHOCARDIOGRAPHY IN PATIENTS...
(5*)
Mo2004. . . . OUTCOME OF ENDOSCOPIC
MUCOSAL RESECTION OF...
(5*)
Mo2005. . . . COMPARISON OF EUS-
GUIDED FINE NEEDLE BIOPSY...
(5*)
Mo2006. . . . DEVELOPMENT AND
VALIDATION OF ENDOSCOPIC
PREDICTION...
(5*)
Mo2007. . . . A SINGLE CENTER
EXPERIENCE WITH MINIMALLY...
(5*)
Mo2008. . . . ENDOLUMINAL SURGERY
TRAINING FOR SENIOR
GASTROENTEROLOGY...
(5*)
Mo2009. . . . INPATIENT VIDEO
CAPSULE ENDOSCOPY FOR
SUSPECTED...
(5*)
Mo2010. . . . PROSPECTIVE STUDY
EVALUATING THE EFFECTS OF...
(5*)
Mo2011. . . . ASSOCIATION OF
ENDOTHELIAL DYSFUNCTION WITH
THE...
(5*)
Mo2012. . . . THE HIGHER ELASTIC
MODULUS USING SHEAR...
(5*)
Mo2013. . . . PERIAmpullary
DIVERTICULUM: DOES IT MATTER
DURING...
(5*)
Mo2014. . . . COST-EFFECTIVENESS
ANALYSIS OF TWO ENDOSCOPIC
BARIATRIC...
(5*)
Mo2015. . . . RECURRENT ABDOMINAL
PAIN AND PAINFUL FUNCTIONAL...
(4*)|(2)
Mo2016. . . . PSYCHOLOGICAL FACTORS
INFLUENCE SYMPTOMATOLOGY AND
QUALITY...
(5*)
Mo2017. . . . INFANTS ADMITTED
AFTER BRIEF RESOLVED
UNEXPLAINED...
(2*)|(4)
Mo2018. . . . PERCEPTIONS OF PAIN
TREATMENT IN PEDIATRIC...
(5*)
Mo2019. . . . GREEN BANANA BIOMASS
ELICITS A HIGH...
(5*)
Mo2020. . . . THICKENING LEADS TO
IMPROVED SYMPTOMS AND...
(2*)|(4)
Mo2021. . . . ESOPHAGOgastric
JUNCTION DISTENSIBILITY IN
PEDIATRIC ACHALASIA:...
(4*)
Mo2022. . . . FUNCTIONAL DYSBIOSIS
IN CHILDREN WITH IRITABLE...
(4*)
Mo2023. . . . NUTRIENT DEFICIENCIES
IN ADOLESCENTS WITH IRITABLE...
(2*)
Mo2024. . . . CHARACTERIZATION OF
GASTRIC EMPTYING SCINTIGRAPHY
PATTERNS...
(2*)
Mo2025. . . . MULTIDISCIPLINARY CARE
OF PATIENTS WITH
OROPHARYNGEAL...
(2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
EVALUATION OF CHILDREN WITH HYPERMOBILE... (5*)

Treating Functional Abdominal Pain Disorders In... (5*)

A Colonic Manometry Program... (5*)

Achievements in Colorectal Cancer Care During... (5*)

Significant Variation in the Detection Rates... (5*)

Administrative Billing Codes Do Not Accurately... (4*)

Can We Trust the Data at... (5*)

Automation and Process Redesign to Decrease... (5*)

Willingness to Stop Proton Pump Inhibitors... (4*)

Improvement in Colonoscopy Quality Metrics... (4*)

Elderly Patients May Not Receive Benefit... (5*)

Lactic Acid is an Independent Predictor... (5*)

A Pilot Study using Point of... (5*) [Assays were supplied by Buhlmann]

Does Calculation of a Buhlmann) Process Redesign to Decrease... (5*)

Independent Predictor... (5*)

Can We Trust the Data at... (5*)

A Retrospective Analysis of the Implementation... (5*)

Development of a Culinary Nutrition Education... (4*)

Preparing for the Move: Institutional Study... (5*)

Prevalence of Barrett's Esophagus in Esophageal... (5*)

Ongoing Development of a Screening Test... (4*)

What Makes an Expert Barrett's Pathologist?... (5*)

Use of the Electronic Health Record... (5*)

Abnormal PH-impedance is Associated with HistoLOGIC... (6*) [2]

The Impact of Optical Chromoendoscopy On... (5*)

Prior Diagnosis of Barrett's Esophagus in... (5*)

Using Natural Language Processing to Accurately... (2*)

Biomarkers Related to Methionine Metabolism and... (2*)

Efficacy of Cytosponge to Assess For... (2*)

Impact of Opioid Use in Patients... (4*) [AstraZeneca]

Impact of Implementation of the Anemia... (5*)

The Effect of Type of Inoculum... (5*)

Crohn's Colitis Care (CCCare) – Development... (6*) [This project (CCCare software – development and testing) was funded by Crohn's Colitis Cure charity www.c-c-cure.org Crohn's Colitis Cure has received support for the CMS from the following companies in the form of donation: o AbbVie o Takeda o Shi]

Analysis of the Implementation... (5*)

Voluntary Laser Endomicroscopy Determines Rate... (5*)

Differential Micron RNA Signatures in the Pathogenesis... (4*)

Gender Differences in Neoplastic Progression In... (5*)

Barrett's Esophagus Patients with Non-Dysplastic Visible... (5*)

Esophageal Adenocarcinoma Arising on the Background... (5*)

Barrett's Patients Overestimating Their Esophageal Cancer... (5*)

Ultrashort Segment Barrett's May Not Be... (5*)

Postreflux Swallow-Induced Peristaltic Wave Index and... (5*)

All Grades of Erosive Esophagitis Can... (5*)

Presence of a Nodule Independently Decreases... (5*)

Endosheath Ultrathin Transnasal Endoscopy as Cost-effective... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds

(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CFFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1274. . . . MITOCHONDRIAL SIGNALING AND REGULATION OF GASTRIC... (2*)

Tu1275. . . . CHROMOGRAFININ-A CONtributes to the INTESTINAL INFLAMMATION... (7*)|(4)

Tu1276. . . . LRp6 IS REQUIRED FOR CRYPTO REGENERATION... (2*)

Tu1277. . . . ACETATE PROMOTES THE WOUND HEALING OF... (5*)

Tu1278. . . . PUMA-MEDIATED GASTRIC EPITHELIAL CELL APOPTOSIS PROMOTES... (2*)

Tu1279. . . . YAP TRIGGERS THE WNT/β-CATENIN SIGNALING PATHWAY... (4*)

Tu1280. . . . GPR109A IS INVOLVED IN BUTYRATE-INDUCED HP25... (5*)

Tu1281. . . . THE PROTECTIVE ROLE OF NADPH OXIDASE... (5*)

Tu1282. . . . PLACENTA DERIVED MESENCHYMAL STEM CELLS AFFORDED... (5*)

Tu1283. . . . NADPH OXIDASE 2 IS A SOURCE... (2*)|(4)

Tu1284. . . . FUNCTIONAL ROLE OF HELICOBACTER PYLORI, CYTOTOXIN-ASSOCIATED... (2*)

Tu1285. . . . EFFECTS OF ALTERATIONS IN THE GASTRIC... (7*)|(3)|(Burroughs Wellcome Fund Post-Doctoral Enrichment Program)

Tu1286. . . . CRUCIAL ROLE OF AURKA IN H-PYLORI... (2*)|(4)

Tu1287. . . . DISCOVERY-DRIVEN METABOLICSTER IDENTIFIES NOVEL MICROBIAL METABOLITES... (2*)

Tu1288. . . . CO-ColONIZATION OF HELICOBACTER PYLORI WITH STAPHYLOCOCCUS... (2*)

Tu1289. . . . INDUCTION OF CELLULAR PLASTICITY THROUGH THE... (2*)

Tu1290. . . . REGULATION OF P14ARF TUMOR SUPPRESSOR BY... (2*)

Tu1291. . . . THE STEPWISE GASTRIC CARCINOGENESIS DURING HELICOBACTER... (2*)

Tu1292. . . . PLASMA GHRELIN IS A USEFUL MARKER... (1*)

Tu1293. . . . HUMAN METAGENOMIC DIVERSITY ASSOCIATED TO GASTRIC... (2*)

Tu1294. . . . HELICOBACTER PYLORI IMMUNOPROTEOMIC PROFILES IN PATIENTS... (2*)

Tu1295. . . . SYSTEMATIC REVIEW AND META-ANALYSIS: CONCOMITANT THERAPY... (4*)|(2)

Tu1296. . . . THE EFFECT OF HELICOBACTER PYLORI ERADICATION... (4*)

Tu1297. . . . HIGH DOSE CAM IS BETTER ON... (5*)

Tu1298. . . . VONOPRAZAN-BASED TRIPLE THERAPY IS EFFECTIVE FOR... (5*)

Tu1299. . . . VONOPRAZAN-BASED DUAL THERAPY WITH AMOXICILLIN IS... (4*)

Tu1300. . . . COMPARISON OF VONOPRAZAN AND HIGH DOSES... (4*)

Tu1301. . . . HELICOBACTER PYLORI ERADICATION IN OBESE PATIENTS... (5*)

Tu1302. . . . VONOPRAZAN-VERSUS PROTON-PUMP INHIBITOR-BASED THIRD-LINE 7-DAY... (5*)

Tu1303. . . . VONOPRAZAN, POTASSIUM COMPETITIVE ACID BLOCKER, IS... (5*)

Tu1304. . . . ONLINE REGISTRY FOR NATIONWIDE DATABASE OF... (7*)

Tu1305. . . . HIGH EFFECTIVENESS OF ONCE DAILY DOSING... (4*)

Tu1306. . . . ONCE-DAILY DOSE DEXLANSOPRAZOLE-LEVOFLOXACIN-BASED QUADRUPLE THERAPY FOR... (4*)

Tu1307. . . . A STRATEGIC THERAPY TO HP ERADICATION... (5*)

Tu1308. . . . ANTIBIOTIC ALLERGIES SIGNIFICANTLY DECREASE RATES OF... (2*)

Tu1309. . . . HELICOBACTER PYLORI ERADICATION RATE WAS NOT... (5*)

Tu1310. . . . TAILORED HELICOBACTER THERAPY... (5*)

Tu1311. . . . EFFECTIVENESS AND SAFETY OF PYLERA® IN... (5*)

Tu1312. . . . VONOPRAZAN SHOWS DIRECT ACTION TO THE... (2*)

Tu1313. . . . HELICOBACTER PYLORI ERADICATION RATE AND FACTORS... (5*)

Tu1314. . . . THE EFFICACY OF CULTURE-GUIDED THIRD-LINE ANTI-H... (5*)

Tu1315. . . . IS THE INTERVAL BETWEEN THE FIRST... (5*)

Tu1316. . . . ERADICATION THERAPY FOR HELICOBACTER PYLORI IS... (5*)

Tu1317. . . . COMPARISON OF THE COST AND EFFICACY... (2*)

Tu1318. . . . UPDATE ON NITAZOXANIDE AS A POTENTIAL... (5*)

Tu1319. . . . LACTOBACILLUS REUTERI AND A PPI ALONE... (3*) BioGaia

Tu1320. . . . THE PREVALENCE AND INCIDENCE OF NEOPLASIA... (5*)

Tu1321. . . . RACIAL AND GENDER DISPARITIES IN GASTROINTESTINAL... (5*)

Tu1322. . . . ACCELERATED DNA METHYLATION IN THE ADJACENT... (2*)

Tu1323. . . . HOW TO AVOID TOTAL GASTRECTOMY IN... (5*)

Tu1324. . . . PROTON PUMP INHIBITOR PANTOPRAZOLE ABROGATES GASTRIC... (2*)|(5)

Tu1325. . . . COMBINATION OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) AND... (5*)

Tu1326. . . . HELICOBACTER PYLORI INFECTION IS ASSOCIATED WITH... (2*)

Tu1327. . . . CLINICOPATHOLOGICAL FEATURES OF METASTATIC GASTRIC TUMORS... (5*)

Tu1328. . . . EFFECT OF METABOLIC COMPONENTS AND BODY... (2*)

Tu1329. . . . THE OVERVIEW OF THE H.PYLORI PREVALENCE... (4*)

Tu1330. . . . AGGRESSIVE TUMOR HISTOLOGY AND POOR PROGNOSIS... (5*)

Tu1331. . . . GASTRIC CANCER WITHOUT HELICOBACTER PYLORI INFECTION... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds    (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)    (3) = Industry or Commercial Entity    (4) = Institutional Funds

(5) = No Study Funding    (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)    (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1342. ... DEFINING PANCREATITIS AS A RISK FACTOR... (5*)
Tu1343. ... TP53 DETERMINES THE EFFECTS OF BECLIN1... (2*)
Tu1344. ... REG-4 EXPRESSION IN PANCREATIC DUCTAL ADENOCARCINOMA... (2*)
Tu1345. ... ALDH1A3-MEDIATED PANCREATIC CANCER METASTASIS IS ASSOCIATED... (2*)
Tu1346. ... USE OF BETA BLOCKERS HAS NO... (5*)
Tu1347. ... SURFACE PLASMON RESONANCE (SPR) AS A... (2*)
Tu1348. ... DIAGNOSTIC YIELD OF PANCREATIC CANCER SCREENING... (5*)
Tu1349. ... STENT PATENCY ACCORDING TO THE CHEMOTHERAPY... (5*)
Tu1350. ... SOJOURN TIME OF PANCREATIC CANCER ESTIMATED... (5*)
Tu1351. ... RISK FACTORS ASSOCIATED WITH PERITONEAL DISSEMINATION... (5*)
Tu1352. ... EFFECT ON SURVIVAL OF SKELETAL MUSCLE... (5*)
Tu1353. ... PREDICTORS OF PANCREATIC CANCER AMONG PATIENTS... (2*)
Tu1354. ... RADILOGICAL PREDICTORS OF INCREASED NUMBER OF... (5*)
Tu1355. ... QUANTITATIVE ANALYSIS OF CONTRAST-ENHANCED ENDOSCOPIC ULTRASOUND... (7*)
Tu1356. ... ENDOCOSCOPIC ULTRASOUND ASSESSMENT OF PANCREATIC DUCT... (5*)
Tu1357. ... ROLE OF 18F-FLUORODEOXY GLUCOSE POSITRON EMISSION... (5*)
Tu1358. ... KRÜPPEL-LIKE FACTOR 5 MEDIATES PANCREATITIS-INDUCED ADM... (2*) (4)
Tu1359. ... THE ROLE OF CANCER-ASSOCIATED ACINAR ATROPHY... (5*)
Tu1360. ... MULTIPLE GENETIC RISK HAPLOTYPES IN THE... (2*)
Tu1361. ... CLASSIFICATION OF PANCREATITIS SUBTYPES USING RNA-SEQ... (2*) (4)
Tu1362. ... CCK ACTIVATES PAK4 BY MULTIPLE SIGNALING... (2*)
Tu1363. ... QUANTITATION OF METHYLATION LOAD OF UCHL1... (2*)
Tu1364. ... STUDY ON THE CLINICOPATHOLOGY OF THE... (2*)
Tu1365. ... PANCREAS-SPECIFIC DELETION OF PROTEIN KINASE D... (2*)
Tu1366. ... NF-kB–NRF2 INTERPLAY REGULATES INFLAMMATION IN ALCOHOLIC... (2*)
Tu1367. ... LIPIOIC ACID INHIBITS THE ACTIVATION OF... (4*) (1)
Tu1368. ... RESOLVINS AMELIORATE FIBROSIS AND ALLEVIATE PAIN... (2*)
Tu1369. ... BLOCKAGE OF MORPHINE INDUCED INTESTINAL PERMIABILITY... (2*) (4)
Tu1370. ... RELATIVE RISE OF SERUM IGG4 LEVELS... (5*)
Tu1371. ... HYDROMORPHONE WORSENS THE SEVERITY OF ACUTE... (2*) (4)
Tu1372. ... DEVELOPING PATIENT-DERIVED PANCREAS-ON-A-CHIP TO STUDY CYSTIC... (2*)
Tu1373. ... THE EFFECT OF NAFAMOSTAT MESILATE INFUSION... (5*)
Tu1374. ... REDUCED LEFT VENTRICULAR END-DIASTOLIC VOLUME (LVEDV)... (2*)
Tu1375. ... DIFFERENTIAL REQUIREMENT OF IL-4RA FOR TUFT... (4*)
Tu1376. ... PEDIATRIC CHRONIC PANCREATITIS WITHOUT PRIOR ACUTE... (2*)
Tu1377. ... PANCREATIC STELLATE CELLS INCREASE INSULIN SECRETORY... (4*)
Tu1378. ... INCIDENCE OF PANCREATITIS AND GRAFT FAILURE... (5*)
Tu1379. ... OBESITY DAMAGES INTESTINAL MUCOSAL BARRIER AND... (2*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1532. NEUROENDOCRINE CARCINOMA OF THE GALLBLADDER: PROGNOSTIC... (5*)
Tu1533. SYNERGISTIC EFFECTS OF GEMCITABINE AND CISPLATIN... (5*)
Tu1534. COMPARABLE EFFECT OF RADIO FREQUENCY ABLATION... (5*)
Tu1535. GALL BLADDER STASIS IN PATIENTS WITH... (4*)
Tu1536. FINE MAPPING OF A CRITICAL GENETIC... (2*)
Tu1537. KML001, AN ARSENIC COMPOUND, AS A... (5*)
Tu1538. RADIOFREQUENCY ABLATION FOR LIVER METASTASIS... (5*)
Tu1539. GASTRIC CORTICOTROPIN-RELEASING FACTOR INFLUENCES MAST CELL... (2*)
Tu1540. SPINAL CORD STIMULATION IMPROVES GASTRIC ACCOMMODATION... (2*)
Tu1541. AMELIORATING EFFECTS OF TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION... (2*)
Tu1542. THE EFFECT OF BILE SALTS ON... (5*)
Tu1543. COMPARATIVE QUANTITATIVE ANALYSIS BETWEEN THE NORTH... (5*)
Tu1544. PREVALENCE OF FUNCTIONAL DYSPESIA, ANXIETY AND... (4*)
Tu1545. TRADITIONAL CHINESE MEDICINE ZHIZHU-KUANZHONG MODULATES THE... (3*) (This study was supported by a research grant from Beijing Lonch Pharmaceutical Co., Ltd.)
Tu1546. EFFICACY AND SAFETY OF YUKGUNJA-TANG FOR... (2*) (This study was supported by grants from the Korea Evaluation Institute of Industrial Technology [No.10060251, The project of 'Development of the diagnostic device for functional dyspepsia based on Korean-Western medicine fusion abdominal diagnosis'.)
Tu1547. EMPTY STOMACH AND BOTHERSOME HUNGER SENSATION... (5*)
Tu1548. FUNCTIONAL DYSPESIA IDENTIFIED BY ROME IV... (5*)
Tu1549. DIETARY INTAKE IN FUNCTIONAL DYSPESIA IS... (2*)
Tu1550. EPIDEMIOLOGICAL CHARACTERISTICS OF FUNCTIONAL GASTRODUODENAL DISORDERS... (2*)
Tu1551. GENESIS OF PRESSURIZATION AND BOLUS FLOW... (2*)
Tu1552. PHARMACOLOGIC INTERROGATION WITH CHOLECYSTOKININ DISTINGUISHES ACHALASIA... (5*) (1)
Tu1553. IDENTIFICATION OF EARLY ACHALASIA IN PATIENTS... (5*) (1)
Tu1554. CHRONIC OPIOID INTAKE IS ASSOCIATED WITH... (5*) (1)
Tu1555. THE INFLUENCE OF PRESSURE DRIFT AND... (4*)
Tu1556. CONTRIBUTION OF NON-TEMPERAL COMPONENTS TO PRESSURE... (4*)
Tu1557. FLIP 4D COLOR CONTOUR PLOTS TO... (5*)
Tu1558. STRAIGHT LEG RAISE PERFORMED DURING HIGH... (5*)
Tu1559. NICOTINE CAUSED THE DUAL REGULATION OF... (4*)
Tu1560. GABA-B AGONIST BACLOFEN INHIBITS ACID-INDUCED EXCITATION... (4*) (1) (This study was supported by the grant MOST 104-2314-B-303-006-MY2 from Ministry of Science and Technology, Taiwan.)
Tu1561. ACHALASIA IN PATIENTS... (4*) (5*)
Tu1562. THE INTEGRATED RELAXATION PRESSURE MAY NOT... (5*)
Tu1563. AN ESOPHAGEAL MANOBANK: FEASIBILITY AND TESTING... (2*)
Tu1564. AGGLOMERATIVE HIERARCHICAL CLUSTERING OF ESOPHAGEAL BODY... (2*)
Tu1565. INEFFECTIVE ESOPHAGEAL MOTILITY MANOMETRIC ISOCONTOUR ANALYSIS... (2*)
Tu1566. UPPER ESOPHAGEAL SPHINCTER METRICS ON HIGH-RESOLUTION... (5*)
Tu1567. OPIOID INTAKE IS ASSOCIATED WITH DISORDER... (5*)
Tu1568. PATIENTS WITH DYSPHAGIA AFTER WEIGHT-LOSS SURGERY... (5*)
Tu1569. WADING THROUGH THE TROUGH: AN EXAMINATION... (2*)
Tu1570. HOW THE CHANGE IN IBS CRITERIA... (4*) (This study was supported by the Swedish Medical Research Council [grants 13409, 21691

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds
   (5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
FICUS INDICA IMPROVES...

Tu1632. . . . SLEEP DISTURBANCE AND

Tu1629. . . . PICTOGRAMS ARE MORE

Tu1631. . . . NOPAL FIBER

META-ANALYSIS OF VSL#3...

Tu1630. . . . SYSTEMATIC REVIEW AND

EFFECTIVE THAN VERBAL...

Tu1640. . . . THE CLINICAL OUTCOME

OF SUDD: A...

Tu1641. . . . LOWER SOCIOECONOMIC

STATUS IS ASSOCIATED WITH...

Tu1642. . . . THE IMMUNE RESPONSE IS

MODULATED IN...

Tu1643. . . . THE EFFECT OF ENTERIC-

COATED PEPPERMINT OIL...

Tu1644. . . . GREEN KIWIFRUIT

COMpared to Psyllium For...

Tu1645. . . . Efficacy of

PlecAnATIDE For the Treatment...

Tu1646. . . . The diagnostic

Performance of peripheral

Blood...

Tu1647. . . . The Role of Dectin-1

and mast...

Tu1648. . . . Measuring sensitivity

with different Methods in...

Tu1649. . . . Effects of

Flatulogenic diets combined

with...

Tu1650. . . . Anti-Cdtb and anti-

Vinculin antibodies are specific...

Tu1651. . . . Evaluation of the Role

of Sample...

Tu1652. . . . Functional bowel

Disorders in a longitudinal...

Tu1653. . . . A standardized test

medium to detect...

Tu1654. . . . Reliability of an

Online analysis platform...

Tu1655. . . . Increase in duration of

deglutitive UES...

Tu1656. . . . Swallow strength

training by salr technique...

Tu1657. . . . Melanosis coli is not

Associated with...

Tu1658. . . . discovery and

assessment of senescence

associated...

Tu1659. . . . Development and

Evaluation of a Risk...

Tu1660. . . . The

Clinicopathological

characteristics of the lesions...

Tu1661. . . . Young adults with

Esophageal adenocarcinoma

Present...

Tu1662. . . . The global incidence of

Gastric cancer...

Abstract Funding Source Key

* = Primary Source

(1) = clinical practice funds  (2) = government (e.g. NIH, CDC, health ministry, etc.)  (3) = industry or commercial entity  (4) = institutional funds  (5) = no study funding  (6) = philanthropic organization (e.g. ALF, CCFA, etc.)  (7) = professional organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1753. **Type 1 Interferon Signaling in Intestinal... (2*)

Tu1754. **The Ubiquitin Editing Enzyme A20 Links... (2*) (4)

Tu1755. **Blockade of Lymphocyte Entrance to Peyers... (2*)

Tu1756. **A Novel 3D Bio-Printing Epithelial Model... (2*)

Tu1757. **The Role of Autophagy in Intestinal... (5*)

Tu1758. **Prolonged Exposure of Intestinal Epithelial Cells... (2*)

Tu1759. **Aryl Hydrocarbon Receptor Ameliorates Intestinal Barrier... (4*) [Supported by the National Natural Science Foundation of China, No. 81470827.]

Tu1760. **Identification of Lesion-Specific Epithelial Function of... (5*)

Tu1761. **Human Colonic Organoid Treated with Inflammatory... (2*)

Tu1762. **Inflammation-Activated Intestinal Muscularis Propria Muscle Cells... (2*)

Tu1763. **NLRP3-Dependent IL-1β Inhibits CD103+ Dendritic Cell... (2*) (6)

Tu1764. **TL1A Deficiency (but Not DR3-Deficiency) Protects... (2*)

Tu1765. **The TL9 Agonist Cobitolimod Modulates the... (3*) [(InDex Pharmaceuticals)]

Tu1766. **Macrophage Interleukin-10 (IL-10) Production Is Dependent... (2*) (6)

Tu1767. **Blockade of IL-1α Ameliorates Ileitis and... (2*) (6)

Tu1768. **Serum IL-10 Is the Best Inflammatory... (5*)

Tu1769. **Serum Cytokines and Chemokines in Newly... (4*)

Tu1770. **Role of TL1A and Its Receptor... (2*)

Tu1771. **Crohn’s Disease Patients Isolated Classical Monocytes... (2*)

Tu1772. **Epigenetic Silencing of Smad7 Contributes to... (2*)

Tu1773. **Exercise-Induced Myokines Mitigate Mucosal Permeability and... (4*)

Tu1774. **A Critical Role for the Sympathetic... (4*)

Tu1775. **A Novel OGR1 (GPR68) Inhibitor Attenuates... (2*)

Tu1776. **Modulation of Immune Cell Composition, Function... (6*) (7)

Tu1777. **Tissue Cytokine Profile Associated with Rapid... (6*)

Tu1778. **Zinc Finger Transcription Factor ZNF281: A... (4*)

Tu1779. **Oligosaccharide-Dependent Anti-Inflammatory Role of Galectin-1 in... (5*)

Tu1780. **Regulated Expression of Phosphatidylycerine-Specific Phospholipase A1... (5*)

Tu1781. **Stratification of Ulcerative Colitis Patients According... (2*)

Tu1782. **Tofacitinib Reduces Inflammatory Biomarkers in Ex... (3*) [Janssen R&D]

Tu1783. **Barrier Restitution Effects of EGCG Driven... (5*)

Tu1784. **The Severity of Murine Toxoplasma Gondii-Induced... (4*)

Tu1785. **The Anti-Inflammatory Effect of Adenosine A3... (2*) [Natural Science Foundation of Guangdong Province]

Tu1786. **Increased Degradation of Glucagon-Like Peptide 1... (2*)

Tu1787. **Human Beta-Defensin 2 Suppresses TNF-Alpha Secretion... (2*)

Tu1788. **Baff, April, Baff-R and Infliximab Therapy... (5*)

Tu1789. **Tofacitinib and Cytokines of the Jak... (3*) [Nordic Bioscience A/S]

Tu1790. **A Sub-Population of Crohn’s Disease (CD)... (2*) (4)

Tu1791. **An Expression-Based Risk Score for... (2*)

Tu1792. **Allele-Specific DNA Methylation of Disease Susceptibility... (2*) (4)

Tu1793. **Rapid and Automated Mapping of Genes... (2*) (4)

Tu1794. **Inhibition of PTProt Reduces Ulcerative Colitis... (5*)

Tu1795. **Integrating Clinical Factors and a Novel... (4*)

Tu1796. **Epigenome-Wide Association Study Identified Shared Methyloc... (7*)

Tu1797. **Multi-Center Cohort Analysis Identified a Genetic... (2*)

Tu1798. **Transcriptome Variation in Ileal and Rectal... (6*) (2)

Tu1799. **Serum Proteomic Profiling Reveals Changes in... (4*)

Tu1800. **Colonic Mucosal Transcriptomic Changes in Patients... (2*)

Tu1801. **Pro-Inflammatory Gene Network Regulated by Novel... (2*)

Tu1802. **Disease Demarcation in Ulcerative Colitis Is... (3*) (4) [Janssen Research & Development]

Tu1803. **The Gene Expression Landscape of Cobblestone... (2*) (6)

Tu1804. **Crohn’s Disease-Associated SNP, RS6651252, Demarcates A... (6*)

Tu1805. **Clinical and Genetic Risk Factors for... (4*)

Tu1806. **Genotype-Phenotype Association Analysis of Inflammatory Bowel... (5*)

Tu1807. **Genetically Distinct Signatures of Mild and... (2*) [National Health and Medical Research Council (Australian Government)]

Tu1808. **Colonic Inflammation Determines Ileal Gene Expression... (4*)

---

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1809. . . . NLRP3 INFLAMMASOME ACTIVATION DUE TO A... (2*)
Tu1810. . . . TRANSCRIPTOMIC PROFILE OF INFAMED COLONIC BIOPSIES... (4*)
Tu1811. . . . COLONIC GAMMA DELTA T CELLS RESPOND... (6*)
Tu1812. . . . IMBALANCE OF EFFECTOR AND SUPPRESSOR T... (2*)
Tu1813. . . . ANALYSIS OF ILEOCECAL IMMUNE RESPONSE IN... (2*)\(\{4\}\)
Tu1814. . . . LOSS OF PTPN2 IN DENDRITIC CELLS... (2*)\(\{4\}\)
Tu1815. . . . LEVELS OF THE CIRCULATING ANTICOAGULANT AND... (4*)
Tu1816. . . . POTENTIAL INVOLVEMENT OF STAT3 RS744166 IN... (7*)\(\{4\}\)
Tu1817. . . . FUSOBACTERIUM NUCLEATUM REGULATES MACROPHAGES REPOLARIZING AND... (2*)\(\{4\}\)
Tu1818. . . . VITAMIN A MODULATES MUCOSAL INFLAMMATION BY... (2*)
Tu1819. . . . DEEP IMMUNOPHENOTYPING REVEALS A ROLE FOR... (4*)
Tu1820. . . . FLAGELLIN-REACTIVE T CELL CLONOTYPES CONTRIBUTE DIFFERENTIALLY... (4*)
Tu1821. . . . MULTI-OMICS ANALYSES IN CROHN'S DISEASE DO... (2*)
Tu1822. . . . THE GUT MICROBIOTA OF PREGNANT WOMEN... (6*)
Tu1823. . . . DIFFERENTIAL RESPONSE TO BROAD-SPECTRUM ANTIBIOTICS BY... (2*)\(\{6\}\)
Tu1824. . . . THE CLINICAL DETERMINANTS AFFECT GUT MICROBIAL... (2*)\(\{4\}\)
Tu1825. . . . PRESCRIPTION OPIOIDS INDUCE GUT DYSBIOSIS AND... (2*)\(\{4\}\)
Tu1826. . . . PRESENCE OF AN AUTOIMMUNITY-ASSOCIATED VARIANT IN... (2*)
Tu1827. . . . FECAL CALPROTECTIN (FC) IN BABIES BORN... (6*)
Tu1828. . . . FECAL MICROBIOTA IN TREATMENT-NAIVE ULCERATIVE COLITIS... (2*)
Tu1829. . . . PERIPARTUM EXPOSURE TO ANTIBIOTICS INDUCES PERSISTENT... (2*)\(\{6\}\)
Tu1830. . . . DIFFERENCES IN THE MICROBIAL COMPOSITION IN... (6*)
Tu1831. . . . A NOVEL MODEL OF INTESTINAL FIBROSIS... (2*)
Tu1832. . . . ASSOCIATIONS OF MICROSCOPIC COLITIS WITH OTHER... (5*)
Tu1833. . . . THE MICRO-RNA MIR-223 REGULATES THE INFLAMMATORY... (6*)\(\{CCFA\}\)grant)
Tu1834. . . . THERAPEUTIC ROLE OF HYPERBARIC OXYGEN IN... (2*)
Tu1835. . . . ZIP7 INDUCES DISRUPTION OF THE INTESTINAL... (5*)
Tu1836. . . . CIRCULATING ELAFIN LEVELS ACCURATELY INDICATES PRESENCES... (2*)
Tu1837. . . . EFFICACY, SAFETY AND LONG-TERM OUTCOME OF... (5*)
Tu1838. . . . PLACENTA/CORD-DERIVED MESENCHYMAL STEM CELLS INHIBIT FIBROGENIC... (2*)\(\{This\}\) research was supported by a grant from Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (grant number: NRF-2015R1C1A1A02037048)
Tu1839. . . . THE HDAC INHIBITORS GIVINOSTAT AND VORINOSTAT... (2*)\(\{4\}\)
Tu1840. . . . SHORT-TERM AND LONG-TERM OUTCOME FOR DILATION... (2*)
Tu1841. . . . TGF-β1 SELECTIVELY INDUCES SEGMENTAL FIBROSIS UPON... (4*)
Tu1842. . . . MTOR-MEDIATED SUPPRESSION OF AUTOPHAGY ACTIVITY IN... (2*)\(\{4\}\)
Tu1843. . . . SECOND HARMONIC GENERATION IMAGING MICROSCOPY QUANTIFIES... (1*)\(\{3\}\)\(\{Genes\}\)is Imaging
Tu1844. . . . IL-10-INDEPENDENT PROTECTIVE ACTIVITIES OF HUMAN-DERIVED CLOSTRIDIUM... (3*)\(\{6\}\)\(\{Janssen Research & Development\}
Tu1845. . . . LOSS OF PTPN22 ABROGATES THE BENEFICIAL... (2*)\(\{4\}\)

Abstract Funding Source Key

\* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Tu1865 | HIGH DIMENSIONAL IMMUNE PHENOTYPING AND TRANSCRIPTIONAL... (2*)|[6]([PFIZER)] |
| Tu1866 | OUTCOMES WITH ADALIMUMAB THERAPY IN PEDIATRIC... (2*)|[6] |
| Tu1867 | CLINICAL USE OF INFlixIMAB TROUGH LEVELS... (5*) |
| Tu1868 | INFlixIMAB TROUGH LEVELS AFTER INDUCTION THERAPY... (5*) |
| Tu1869 | EFFICACY OF COMBINATION ANTIBIOTIC THERAPY FOR... (4*) |
| Tu1870 | COLECTOMY-FREE SURVIVAL AND FACTORS ASSOCIATED WITH... (5*) |
| Tu1871 | STANDARD VERSUS INTENSIFIED INFlixIMAB RESCUE THERAPY... (5*) |
| Tu1872 | PROTON PUMP INHIBITOR USE AND THE... (5*) |
| Tu1873 | LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS ALTERS GUT... (3*) |
| Tu1874 | COMPOSITION OF MUCOSA-ASSOCIATED MICROBIOME ALONG THE... (5*) |
| Tu1875 | FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT... (5*) |
| Tu1876 | THE EFFECT OF BOWEL PURGATIVE MEDICATION... (4*) |
| Tu1877 | HIGH RESOLUTION 16S RNA GENE PROFILES... (2*) |
| Tu1878 | GASTRIC MICROBIOTA ALTERNATION FOLLOWING ERADICATION OF... (4*) |
| Tu1879 | DEVELOPING MICROBIOME REHABILITATION BIOMARKERS FOR CLOSTRIDIUM... (3*)|[This analysis was funded by Rebiotix Inc., Roseville, MN.) |
| Tu1880 | ISOLATION OF STREPTOCOCCUS MOBILIS SP. NOV.... (5*) |
| Tu1881 | ASSOCIATION BETWEEN BODY MASS INDEX AND... (2*)|[6] |
| Tu1882 | FECAL MICROBIOTA TRANSPLANTATION IMPROVES GASTROINTESTINAL GRAFT-VERSUS-HOST... (5*) |
| Tu1883 | A LYOPHILIZED, NON-FROZEN, ORAL MICROBIOTA-BASED DRUG... (3*)|[Ritter Pharmaceuticals, Inc.) |
| Tu1884 | IMPROVEMENT OF CLINICAL SYMPTOMS OF LACTOSE... (3*)|[4](Ritter Pharmaceuticals, Inc.) |
| Tu1885 | MULTI-COHORT ANALYSIS OF COLORECTAL CANCER METAGENOME... (2*) |
| Tu1886 | METAGENOMIC ANALYSIS OF THE GUT MICROBIOME... (3*)|[CosmosID, Inc.] |
| Tu1887 | REAL WORLD EXPERIENCE OF BEZLOTOXUMAB FOR... (3*)|[Merck & Co.) |
| Tu1888 | CLINICAL AND DIAGNOSTIC SIGNIFICANCE OF ENTERIC... (2*)|[4] |
| Tu1889 | HELICOBACTER PYLORI ERADICATION THERAPY LEADS TO... (2*)|[4] |
| Tu1890 | INFECTIOUS AND GENETIC CHARACTERISTICS OF CLINICAL... (2*) |
| Tu1891 | FECAL MICROBIOTA TRANSPLANTATION CAPSULES WITH TARGETED... (5*) |
| Tu1892 | ABDOMINAL AND RECTAL REGIONS... (5*) |
| Tu1893 | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROL PILOT TRIAL... (4*)|[OpenBiome/Finch Therapeutics] |
| Tu1894 | POTENTIAL MOTIVATORS AND DETERENTS FOR STOOL... (4*)|[3](Alberta Innovates Health Solutions) |
| Tu1895 | DISTINCT MICROBIAL POPULATIONS EXIST IN THE... (2*) |
| Tu1896 | DIFFERENCES IN FECAL MICROBIOME OF PARENTERAL... (2*) |
| Tu1897 | VALIDATION OF A DIAGNOSTIC-CODE BASED CASE... (4*) |
| Tu1898 | UTILITY OF THE OFFICE-BASED GASTRIC EMPTYING... (5*) |
| Tu1899 | OPTIMIZED VAGAL NERVE STIMULATION FOR GLYCEMIC... (5*) |
| Tu1900 | COMPARISON OF EFFECT OF 16 WEEKS... (3*)|[2](NovoNordisk) |

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA AASLD, etc.)
Tu1943. . . . SERUM S100A6, S100A8, S100A9 AND S100A11... (4*)
Tu1944. . . . GRADING, BUDDING, TUMOR INFILTRATING LYMPHOCYTES... (5*)
Tu1945. . . . THE ROLE OF BROAD-COMPLEX, TRAMTRACK AND... (5*)
Tu1946. . . . CYCLOOXYGENASE-2 OVER-EXPRESSION IS ASSOCIATED WITH REDUCED... (5*)
Tu1947. . . . CLINICAL SIGNIFICANCE OF EGFR, ERBB2-4 AND... (5*)
Tu1948. . . . POORLY DIFFERENTIATED CLUSTERS HIGH GRADE IS... (5*)
Tu1949. . . . THE CHARACTERISTIC OF HMB1 EXPRESSION FOR... (Wuxi Municipal Bureau on Science and Technology(CSE01N1212)
Tu1950. . . . NOVEL BLOOD-BASED DETECTION OF COLORECTAL CANCER... (2*)[(4]
Tu1951. . . . EFFECTS OF ASPIRIN AND NON-STEROIDAL ANTI-INFLAMMATORY... (5*)
Tu1952. . . . PUBLIC AWARENESS OF COLORECTAL CANCER: ALARMING... (5*)
Tu1953. . . . PREDICTORS OF COLORECTAL ADENOMA IN A... (2*)[(6]
Tu1954. . . . CITROBACTER RODENTIUM-INDUCED AUTOPHAGY PROTECTS CANCER STEM... (2*)
Tu1955. . . . COMPARISON METFORMIN AND SULFONYLUREA WITH INSULIN... (5*)
Tu1956. . . . EXERCISE AND COLORECTAL CANCER: EXPLORING THE... (5*)
Tu1957. . . . ASPIRIN, NSAIDS, AND DYSPLASTIC COLONIC POLYPS... (4*)
Tu1958. . . . HELICOBACTER PYLORI ERADICATION THERAPY TO PREVENT... (5*)
Tu1959. . . . COX-2-REPORTER ACTIVITY AS SURROGATE MARKER FOR... (2*)
Tu1960. . . . VOLUMETRIC LASER ENDMICROSCOPY FINDS RESIDUAL OR... (3*)[(NinePoint Medical, Inc.)
Tu1961. . . . IMPROVED BARRETT'S NEOPLASIA DETECTION USING COMPUTER... (5*)
Tu1962. . . . FEASIBILITY, SAFETY, AND INITIAL EFFICACY OF... (2*)
Tu1963. . . . TETHERED CAPSULE IN-VIVO OPTICAL COHERENCE TOMOGRAPHY... (5*)
Tu1964. . . . HIGH DEFINITION TETHERED CAPSULE OPTICAL COHERENCE... (2*)
Tu1965. . . . OBSERVER RELIABILITY OF VISIBLE LIGHT SPECTROSCOPY... (5*)
Tu1966. . . . UNSEDATED TRANSNASAL OPTICAL COHERENCE TOMOGRAPHY (OCT)... (3*)[(Bill & Melinda Gates Foundation)
Tu1967. . . . SPECIFICITY OF PANCREATIC UPTAKE ON 18F-DOPA... (2*)
Tu1968. . . . ASSESSMENT OF COLONIC MOTILITY USING MAGNETIC... (2*)[(4]
Tu1969. . . . IMPACT OF SMALL BOWEL IMAGING ON... (5*)
Tu1970. . . . THE PEG CONTROVERSY: CAREGIVERS, DOCTORS AND... (5*)
Tu1971. . . . COMPARING COMBINATION THERAPY WITH PROTON PUMP... (5*)
Tu1972. . . . INTERNET DIETARY INFORMATION FOR CHILDHOOD IRRITABLE... (5*)
Tu1973. . . . PEDIATRIC INGESTIONS OF CHRISTMAS PAST, PRESENT... (5*)
Tu1974. . . . FOREIGN BODY INGESTIONS AMONG CHILDREN <... (5*)
Tu1975. . . . PREVALENCE OF LOW LUMBAR SPINE BONE... (5*)
Tu1976. . . . DIETARY INTAKE STUDY IN CHILDREN [DISH]... (5*)
Tu1977. . . . ESOPHAGEAL SQUAMOUS PAPILLOMA IN THE PEDIATRIC... (5*)
Tu1978. . . . EOSINOPHILIC ESOPHAGITIS: CORRELATION OF IMPROVEMENT IN... (5*)
Tu1979. . . . FIDGET SPINNER INGESTIONS IN CHILDREN- A... (5*)
Tu1980. . . . EVALUATION OF PH INTERERENCE AND ACCURACY... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA AASLD, etc.)